<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7ttitt6a1ng st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="Chapters_11-15.pdf">Chapters_11-15.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">19.1MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> Chapters_11-15.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>CHAPTER 11</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="infections">Infections<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Theresa Coyner • Katrina Nice Masterson</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Describe the cutaneous presentation of bacterial, viral, and fungal infections.</li>
<li>Discuss factors that may precipitate certain infections.</li>
<li>List appropriate treatment options.</li>
<li>Identify patient education to prevent cutaneous infections and restore skin integrity when infections occur.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Infection compromises the barrier function of the skin.</li>
<li>Immunocompromised patients are at higher risk for dissemination of cutaneous infections.</li>
<li>Cutaneous infections can be caused by both extrinsic and intrinsic factors.</li>
<li>Appropriate treatment of cutaneous infections depends upon accurate recognition and diagnosis.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="overview">OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Infections in the skin may range from superficial to deep and may be caused by bacteria, fungi, or viruses. These infections may occur in otherwise healthy individuals.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bacterial-infections">BACTERIAL INFECTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bacterial-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-impetigo">I. IMPETIGO<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-impetigo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. Definition: a common, contagious, superficial skin infection caused by streptococci, staphylococci, or both</p>
<ol>
<li>Bullous impetigo (Figure 11-1)</li>
</ol>
<p>a. Etiology</p>
<p>(1) Caused by group II Staphylococcus aureus.
(2) Usually not secondarily contaminated by streptococci.
(3) Colonization of the respiratory tract precedes colonization of the skin by days.</p>
<p>b. Pathophysiology</p>
<p>(1) Begins as small vesicles.
(2) Evolves into sharply demarcated bullae without erythematous halo, which eventually rupture.
(3) Nikolsky sign not present.
(4) Shallow erosions result within 1 to 2 days.
(5) Typically occurs on the face in infants and children but may infect any surface and any age group.
(6) Heals with hyperpigmentation with dark-skinned individuals.
(7) Characteristic honey-colored crust.</p>
<ol start="2">
<li>Nonbullous impetigo (Figure 11-2)</li>
</ol>
<p>a. Etiology</p>
<p>(1) Caused by beta-hemolytic streptococci.
(2) Begins with exposure to Streptococcus, which enters the skin via areas of minor trauma.
(3) Often becomes secondarily contaminated with staphylococcus.</p>
<p>b. Pathophysiology</p>
<p>(1) Begins as a small vesicle or pustule.
(2) After rupture, a moist, erythematous base is exposed.
(3) Characteristic honey-colored crust.
(4) Satellite lesions may appear beyond the periphery.
(5) Generally heals without scarring.</p>
<ol start="3">
<li>Ecthyma (Figure 11-3)</li>
</ol>
<p>a. Etiology</p>
<p>(1) Caused by Streptococcus pyogenes and rapidly contaminated with staphylococcus.
(2) Considered an ulcerated form of nonbullous impetigo.</p>
<p>b. Pathophysiology</p>
<p>(1) Begins like nonbullous impetigo but extends into the dermis.
(2) Shallow ulcer is formed. Generally, 1 to 10 lesions will be present.
(3) Lesion crusts over with a purulent, necrotic base.
(4) Most common on lower extremities in children, elderly, and patients with lymphedema.</p>
<p>B. Assessment</p>
<ol>
<li>
<p>History (Box 11-1)</p>
</li>
<li>
<p>Current health status</p>
</li>
<li>
<p>Physical examination
a. Clinical presentation
b. Evidence of trauma (bites, abrasions, lacerations)
c. Gram stain
d. Culture for causative organism(s)</p>
</li>
</ol>
<p>C. Treatment</p>
<ol>
<li>Topical
a. Mupirocin: apply to lesions tid for 7 to 10 days.
b. Retapamulin: apply to lesions bid for 5 days.</li>
<li>Oral antibiotics for widespread infections
a. Erythromycin 30 to 50 mg/kg/d every 6 to 8 hours
b. Cephalexin 25 to 50 mg/kg/d every 6 to 8 hours
c. Amoxicillin/clavulanate 25 to 45 mg/kg/d every 12 hours</li>
<li>Treatment of lesions
a. Wash with antibacterial soap.
b. Keep crusts moistened so they can gently be debrided by washing.</li>
</ol>
<p><img src="assets/images/image-20251225-ced5d68c.jpeg" alt="img-0.jpeg">
FIGURE 11-1. Bullous impetigo. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-04d5a749.jpeg" alt="img-1.jpeg">
FIGURE 11-2. Nonbullous impetigo. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-b57f9772.jpeg" alt="img-2.jpeg">
FIGURE 11-3. Ecthyma. (Courtesy of John K. Randall, MD.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-11-1-taking-the-history-in-the-patient-with-cutaneous-infection">BOX 11-1. Taking the History in the Patient with Cutaneous Infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-11-1-taking-the-history-in-the-patient-with-cutaneous-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In addition to a routine history and physical examination, the following issues must be explored:</p>
<ul>
<li>
<p>Time of onset of lesions (exacerbations, remission, and recurrences)</p>
</li>
<li>
<p>Site of onset (pattern of spread or dissemination is important to making correct diagnosis)</p>
</li>
<li>
<p>Change (evolution) in lesions (lesions seen on exam may not be the primary lesion)</p>
</li>
<li>
<p>Cutaneous symptoms (burning, pruritus, or other discomfort)</p>
</li>
<li>
<p>Precipitating factors</p>
</li>
<li>
<p>Previous treatment (self-treatment may alter presentation)</p>
</li>
<li>
<p>Occupation/hobbies: important to rule out exposure to specific infections</p>
</li>
<li>
<p>Family history or close contact exposure to similar symptoms or lesions</p>
</li>
</ul>
<p><img src="assets/images/image-20251225-2bb52e34.jpeg" alt="img-3.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bullous-impetigo">Bullous Impetigo<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bullous-impetigo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Infected children should be isolated briefly until treatment is under way.</li>
<li>Impetigo can spread via fingers, towels, and clothing.</li>
<li>Sodium hypochlorite (bleach) baths may be helpful.</li>
<li>¼ to ½ cup of household bleach added to tub of water.</li>
<li>Soak for 5 to 15 minutes at a frequency of two times weekly.</li>
<li>Mupirocin nasal ointment applied to the nares bid × 5 days to reduce colonization.</li>
<li>Poststreptococcal glomerulonephritis can develop 1 to 3 weeks following impetigo.</li>
<li>Incidence ranges from 2% to 5% of individuals with impetigo.</li>
<li>Children and at-risk adults for development of hematuria and edema should be monitored.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-cellulitis-figure-11-4">II. CELLULITIS (FIGURE 11-4)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-cellulitis-figure-11-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: a diffuse, acute bacterial infection of the skin and subcutaneous tissue
B. Etiology</p>
<ol>
<li>Group A beta-hemolytic streptococci (erysipelas) or staphylococci most common cause.</li>
<li>Non-group A streptococcus, Haemophilus influenzae type B, Pseudomonas aeruginosa, and Campylobacter fetus may be the etiology in patients with underlying abnormalities of lymphatics or venous drainage.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>
<p>Most commonly seen in lower extremities.</p>
</li>
<li>
<p>Infection spreads locally secondary to the release of enzymes.</p>
</li>
<li>
<p>Erythema and edema are present.</p>
</li>
<li>
<p>Skin will be hot and tender to the touch.</p>
</li>
<li>
<p>Lymphangitic streaks may develop specifically in erysipelas.</p>
</li>
<li>
<p>Typically occurs near surgical wounds and cutaneous ulcers or may occur in normal skin. It may occur anywhere in immunocompromised patients.</p>
</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1).</li>
<li>Evaluate patient's overall health status.</li>
<li>Physical examination.</li>
</ol>
<p>a. Pain
b. Erythema
c. Increased warmth to palpation
d. Edema
e. Fever
f. Assess for preexisting lesion
g. Lymphadenopathy</p>
<ol start="4">
<li>Diagnostic tests.</li>
</ol>
<p>a. CBC with differential</p>
<ol>
<li>Mild leukocytosis with increase in neutrophils</li>
<li>Mildly elevated sedimentation rate
b. Bacterial culture</li>
</ol>
<p>E. Treatment</p>
<ol>
<li>Staphylococcal or streptococcal organisms.</li>
</ol>
<p>a. Dicloxacillin 500 to 1,000 mg every 6 hours
b. Cephalexin 500 mg every 8 hours</p>
<ol start="2">
<li>Recurrent disease: prophylactic antibiotics.</li>
<li>Surgical debridement may be indicated if pockets of purulent material are present.</li>
</ol>
<p><img src="assets/images/image-20251225-a674e56f.jpeg" alt="img-4.jpeg"></p>
<p><img src="assets/images/image-20251225-117cc367.jpeg" alt="img-5.jpeg">
FIGURE 11-4. Cellulitis. (From Elder, D. E., et al. (2012). Atlas and synopsis of lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cellulitis">Cellulitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cellulitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Burow solution, comprised of an aqueous solution of aluminum acetate (available over the counter), compresses may help alleviate discomfort.</li>
<li>Leg elevation may hasten recovery.</li>
<li>Open wounds should be cleansed with a normal saline irrigation using a 30-gauge syringe attached to an 18-gauge angiocatheter.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-furuncle-carbuncle-figure-11-5">III. FURUNCLE/CARBUNCLE (FIGURE 11-5)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-furuncle-carbuncle-figure-11-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: Furuncle is a boil. Carbuncle is an aggregation of interconnected furuncles that drain through several openings in the skin.</p>
<p>B. Etiology</p>
<ol>
<li>Staphylococcal infection</li>
<li>May be secondary to ingrown hair or obstruction of sebaceous gland</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Abscess of the skin and subcutaneous tissue</li>
<li>Central necrosis and suppuration seen</li>
<li>Secondary factors that may induce infection</li>
</ol>
<p>a. Scratching
b. Friction
c. Infestation
d. Pressure from restrictive clothing
e. Chemical irritation
f. Hyperhidrosis
g. Occlusion of the follicle with ointments</p>
<ol start="4">
<li>Lesions</li>
</ol>
<p>a. Primary lesion: small, painful, indurated nodules.
b. Evolves to elevated, tender lesion with shiny erythema and intense pain.
c. Mature lesion.</p>
<p>(1) Fluctuant with yellow or creamy white discharge
(2) Central necrosis</p>
<p>d. May spontaneously rupture.
e. Single or multiple lesions may be present.</p>
<ol start="5">
<li>Systemic signs</li>
</ol>
<p>a. Fever
b. Malaise
c. Regional adenopathy</p>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Physical examination</li>
<li>Note location: lesions commonly seen on the back of the neck, face, buttocks, thighs, perineum, breasts, or axillae.</li>
<li>Evaluate the appearance of the lesion(s).</li>
<li>Distinguish between furuncle and ruptured epidermal cyst (cyst will have keratinous material).</li>
<li>Evaluate the presence of predisposing conditions.</li>
</ol>
<p>a. Occlusion, especially in hyperhidrosis
b. Follicular abnormalities
c. Colonized skin in patient with atopic dermatitis and scabies</p>
<ol start="7">
<li>Diagnostic tests</li>
</ol>
<p>a. Gram stain
b. Bacterial culture</p>
<p>E. Treatment</p>
<ol>
<li>Warm compresses</li>
<li>Incision, drainage, and packing to promote continuous drainage</li>
<li>Antibiotics appropriate for organism cultured</li>
</ol>
<p><img src="assets/images/image-20251225-d664a4c4.jpeg" alt="img-6.jpeg"></p>
<p><img src="assets/images/image-20251225-4e9ed416.jpeg" alt="img-7.jpeg"></p>
<p>FIGURE 11-5. Furunculosis/furuncle. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-60a0c4e5.jpeg" alt="img-8.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="furuncle-carbuncle">Furuncle/Carbuncle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#furuncle-carbuncle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Patients should avoid constrictive clothing.</li>
<li>Antibacterial soaps in patients with hyperhidrosis may be considered.</li>
<li>Bleach baths may help to prevent recurrence.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-erythrasma">IV. ERYTHRASMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-erythrasma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: superficial bacterial infection of skin in intertriginous areas</p>
<p>B. Etiology</p>
<ol>
<li>Corynebacterium minutissimum invades the stratum corneum.</li>
<li>Growth favored by warm, moist environment.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Lesions most common in the groin but may be seen in any intertriginous area.</li>
<li>Irregular erythematous plaque with well-defined borders.</li>
<li>Fine scale may cover the lesion.</li>
<li>Older lesions will fade to a brown color.</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Clinical examination.</li>
</ol>
<p>a. Assess for signs of hyperhidrosis.
b. Assess for signs of poor personal hygiene.</p>
<ol start="3">
<li>Assess for risk factors including diabetes mellitus, obesity, and exposure to humid climate conditions.</li>
<li>Diagnostic tests.</li>
</ol>
<p>a. Gram stain
b. Wood's lamp will fluorescence bright coral red.</p>
<p>E. Treatment</p>
<ol>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">11\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">11%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>  topical application of aluminum chloride</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>  clindamycin HCl topical solution</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>  erythromycin topical gel or solution</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="erythrasma">Erythrasma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#erythrasma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Erythrasma can be a chronic intermittent condition.</li>
<li>Weight loss is recommended for obese patients.</li>
<li>Cotton underwear is recommended, especially boxer shorts for men if erythrasma occurs in the groin area.</li>
<li>Daily washing includes antibacterial soap, pat dry, and use of a handheld hair dryer on cool setting to dry intertriginous areas thoroughly.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-pitted-keratolysis-figure-11-6">V. PITTED KERATOLYSIS (FIGURE 11-6)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-pitted-keratolysis-figure-11-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: noninflammatory bacterial infection on the soles of the feet and/or palms</p>
<p>B. Etiology</p>
<ol>
<li>Causative agent is either <em>Micrococcus sedentarius</em> or <em>Corynebacterium</em>.</li>
<li>Produce proteolytic enzymes that digest the stratum corneum.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Crater-like pits will occur on weight-bearing areas of the feet.</li>
<li>Pits are 1 to 7 mm in diameter.</li>
<li>Erosions may rarely occur.</li>
<li>No erythema will be present.</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Clinical examination
a. Assess for the characteristic craters.
b. Assess for the presence of hyperhidrosis and malodor.</li>
<li>Diagnostic tests
a. Generally, none are performed as this is a clinical diagnosis.
b. Wood’s lamp will not demonstrate fluorescence.</li>
</ol>
<p>E. Treatment</p>
<ol>
<li>10 to 25% aluminum chloride solution applied topically</li>
<li>2% clindamycin HCl topical solution</li>
<li>2% erythromycin topical solution</li>
</ol>
<p><img src="assets/images/image-20251225-ce3d41ec.jpeg" alt="img-9.jpeg">
FIGURE 11-6. Pitted keratolysis. (From Burkhart, C., Morell, D., Goldsmith, L. A., et al. (2009). VisualDx: Essential pediatric dermatology. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-7a36b3c4.jpeg" alt="img-10.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pitted-keratolysis">Pitted Keratolysis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pitted-keratolysis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Feet should be kept dry and clean by washing at least daily with antibacterial soap and drying thoroughly.</li>
<li>Cotton socks should be worn or socks specifically designed to wick moisture away from the skin; change socks daily or more frequently.</li>
<li>Shoes should be allowed to dry thoroughly prior to the next wear.</li>
</ul>
<p>VI. FOLLICULITIS (FIGURE 11-7)</p>
<p>A. Definition: inflammation of the hair follicle</p>
<p>B. Etiology</p>
<ol>
<li>Causative organisms include staphylococcus, dermatophytes, Klebsiella, Proteus, Enterobacter, and Pseudomonas.</li>
<li>Drug-induced folliculitis most commonly occurs with use of corticosteroids.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Organisms gain access to the hair follicle due to chemical irritation, physical injury, or occlusion: specifically with topical steroid.</li>
<li>Inflammation may be superficial to deep.</li>
<li>Pseudofolliculitis barbae caused by shaving.
a. More common in individuals with tightly curled spiral hair</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1).</li>
<li>Assess shaving practices.</li>
<li>Lesions (Table 11-1).</li>
<li>Diagnostic tests
a. Gram stain
b. Culture
c. Histologic analysis</li>
</ol>
<p>E. Treatment (Table 11-1)</p>
<p><img src="assets/images/image-20251225-48d6882b.jpeg" alt="img-11.jpeg">
FIGURE 11-7. Folliculitis. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>TABLE 11-1 Folliculitis Types, Clinical Presentation, and Treatment</p>
<table><thead><tr><th>Type</th><th>Clinical Presentation</th><th>Treatment</th></tr></thead><tbody><tr><td>Dermatophyte folliculitis</td><td>Erythematous papules and pustules in the beard area with crusting.</td><td>Itraconazole 200 mg bid for 1 wk/mo for 2 mo</td></tr><tr><td>Terbinafine 250 mg/d for 2–3 wk</td><td></td><td></td></tr><tr><td>Griseofulvin microsized 500–1,000 mg/d for 4–6 wk</td><td></td><td></td></tr><tr><td>Griseofulvin ultramicrosized 500–700 mg/d for 4–6 wk</td><td></td><td></td></tr><tr><td>Pityrosporum folliculitis</td><td>Follicular-based papules and pustules predominantly on the back, chest, and shoulders.</td><td></td></tr><tr><td>Very pruritic.</td><td>Topical antifungals</td><td></td></tr><tr><td>Fluconazole 100–200 mg/d for 3 wk</td><td></td><td></td></tr><tr><td>Itraconazole 200 mg/d for 1–3 wk</td><td></td><td></td></tr><tr><td>Drug-induced folliculitis</td><td>Erythematous follicular papules and pustules located on the trunk, shoulders, and upper arms.</td><td></td></tr><tr><td>Acute onset.</td><td>Stop the offending medication</td><td></td></tr><tr><td>Topical benzoyl peroxide or clindamycin</td><td></td><td></td></tr><tr><td>Gram-negative folliculitis</td><td>Hot tub folliculitis caused by Pseudomonas aeruginosa. Lesions will be pink to erythematous follicular papules and pustules that will appear edematous.</td><td>Ciprofloxacin 500 mg bid for 7 d</td></tr><tr><td>Bacterial folliculitis</td><td>Perifollicular papules and pustules on an erythematous base.</td><td>Treatment should be based upon culture results</td></tr><tr><td>Topical benzoyl peroxide</td><td></td><td></td></tr><tr><td>Topical clindamycin</td><td></td><td></td></tr><tr><td>Doxycycline 100 mg daily to bid for 2 wk</td><td></td><td></td></tr></tbody></table>
<p><img src="assets/images/image-20251225-a9b6ad16.jpeg" alt="img-12.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="folliculitis">Folliculitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#folliculitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Occlusive topical steroids should not be used when folliculitis is present.</p>
</li>
<li>
<p>Constrictive clothing is to be avoided.</p>
</li>
<li>
<p>Use of a chemical depilatory may be considered.</p>
</li>
<li>
<p>All shaving techniques must be done with care; an electric razor should be used if possible. Avoid twin, triple, and quadruple blades as these pull and cut the hair below the skin surface. Wet the area to be shaved with warm water and lather with a thick shaving gel. Shave with the grain of the hair. Replace shaving blades frequently as they dull quickly.</p>
</li>
<li>
<p>Cool compresses may be applied after shaving.</p>
</li>
<li>
<p>Glycolic acid lotion may be used to reduce hyperkeratosis (elevated bumps).</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vii-infections-with-potential-life-threatening-complications">VII. INFECTIONS WITH POTENTIAL LIFE-THREATENING COMPLICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vii-infections-with-potential-life-threatening-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Meningococcemia (Figure 11-8)</p>
<ol>
<li>Definition: gram-negative diplococcus skin infection</li>
<li>Etiology
a. Causative organism is Neisseria meningitides.
b. Transmitted by respiratory secretions.
c. Present in 10% to 20% of population.</li>
<li>Pathophysiology
a. Colonization occurs in nasopharyngeal area.
b. Systemic invasion causes bacteremia.
c. Organism invades endothelial cells of small vessels and releases endotoxin.
d. Cytokines are released causing hypotension, decreased cardiac output, and increased endothelial permeability.
e. Thirteen strains of N. meningitides and serotypes A, B, C, Y, and W-135 can cause meningococcemia.
f. Predominantly affects young adults and children.</li>
<li>Assessment
a. History (Box 11-1).
b. Assess for sudden onset of fever, headache, nausea, vomiting, and stiff neck.
c. Lesion assessment.
(1) Rash occurs in 70% of cases.
(2) Range from pink macules, erythematous papules, to purpuric lesions.
(3) Petechiae and ecchymosis may occur.
(4) Purpuric lesions will have central gunmetal gray discoloration.
d. Diagnostic tests
(1) Blood culture
(2) CSF culture
(3) Gram stain
(4) Histologic analysis: leukocytoclastic vasculitis and thrombi</li>
<li>Treatment
a. High-dose penicillin, chloramphenicol for penicillin allergic patients, or third-</li>
</ol>
<p>generation cephalosporin</p>
<p><img src="assets/images/image-20251225-17839c23.jpeg" alt="img-13.jpeg">
FIGURE 11-8. Meningococcemia. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-99402f33.jpeg" alt="img-14.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="meningococcemia">Meningococcemia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#meningococcemia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Triage nurses should have high degree of suspicion for patient calls with symptoms of rash, fever, headache, and stiff neck. Urgent visit or refer to emergency department.
Vaccine is available protecting against serotypes A, C, Y, and W-135.</li>
<li>Household members, day caregivers, and close personal contacts should be treated prophylactically with rifampin.</li>
</ul>
<p>A. Staphylococcal Scalded Skin Syndrome (SSSS) (Figure 11-9)</p>
<ol>
<li>
<p>Definition: staphylococcal epidermolytic toxic syndrome also known as Ritter disease</p>
</li>
<li>
<p>Etiology</p>
</li>
</ol>
<p>a. Epidermolytic toxin acts as a toxin and elicits an antibody reaction.
b. Antibody is present in 75% of people over age 10.
c. Affects young children, immunosuppressed individuals, and patients with chronic renal failure.</p>
<ol start="3">
<li>Pathophysiology</li>
</ol>
<p>a. Begins with a staphylococcal infection of the conjunctivae, throat, nares, or umbilicus.
b. Toxin is filtered through glomeruli.
c. Individuals with poor renal clearance or low glomeruli filtration rate may develop the toxin systemically.
d. Toxin acts in the epidermis affecting cell-to-cell adhesion.</p>
<ol start="4">
<li>Assessment</li>
</ol>
<p>a. History (Box 11-1)
b. Lesions</p>
<p>(1) Initially tender, erythematous skin with sandpaper-like appearance.
(2) Skin wrinkles and bullae occur, followed by peeling layers of the skin.
(3) Nikolsky sign will be present.
(4) Yellow crusting will occur followed by skin drying and cracking.
(5) Skin re-epithelializes in 7 to 10 days.</p>
<p>c. Diagnostic tests</p>
<p>(1) Culture of the conjunctivae, nose, throat, and bullae. Often negative in children.
(2) Histologic analysis: dermal–epidermal separation.</p>
<ol start="5">
<li>Treatment.</li>
</ol>
<p>a. Hospitalization and IV therapy may be needed.
b. Nafcillin 100 to 200 mg/kg/d IV.
c. Less severe cases managed at home with oral antibiotics: dicloxacillin 25 mg/kg/d or cephalosporin for 1 week.</p>
<p><img src="assets/images/image-20251225-fa894588.jpeg" alt="img-15.jpeg">
FIGURE 11-9. Staphylococcal scalded skin syndrome (SSSS). (From Burkhart, C., Morell, D., Goldsmith, L. A., et al. (2009). VisualDx: Essential pediatric dermatology. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-a18f26ab.jpeg" alt="img-16.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="staphylococcal-scalded-skin-syndrome">Staphylococcal Scalded Skin Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#staphylococcal-scalded-skin-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Signs of dehydration must be assessed.</p>
<ul>
<li>All medical and skin care needs individual recommendations.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-necrotizing-fasciitis-figure-11-10">I. Necrotizing Fasciitis (Figure 11-10)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-necrotizing-fasciitis-figure-11-10" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Definition: soft tissue infection causing local tissue necrosis and life-threatening sepsis</li>
<li>Etiology</li>
</ol>
<p>a. Type 1: polymicrobial infection including aerobic and anaerobic organisms
b. Type 2: Streptococcus pyogenes or staphylococcus
c. Vibrio vulnificus and Aeromonas hydrophila, both waterborne organisms, may rarely cause the condition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-pathophysiology">3. Pathophysiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-pathophysiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. Initially appears as a cellulitis.
b. Substances produced by the organism resist phagocytosis.
c. Pyogenic exostosis induces cytokines that mediate fever, shock, and tissue injury.
d. More common in elderly or individuals with chronic conditions. May occur in healthy individuals.
e. Extremities are most likely involved.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-assessment">4. Assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. History (Box 11-1).
b. Assess for the presence of chronic conditions, specifically diabetes, arterial disease, alcohol abuse, and malnutrition.
c. Assess vital signs: fever often absent initially, and tachycardia will be present.
d. Skin changes.
(1) Initially tender, erythematous, and swollen.
(2) Rapidly progresses from reddish purple appearing to gray-blue in poorly defined patches.
(3) Violaceous bullae may develop.
(4) Thin, malodorous fluid results from necrosis of fascia and fat.
(5) Subcutaneous tissue will feel hard and wooden.
e. Critical diagnostic signs.
(1) Severe pain out of proportion to the initial clinical signs
(2) Vital sign abnormalities
(3) Presence of hemorrhagic bullae indicating occlusion of deep vessels in the fascia
f. Diagnostic studies
(1) Coagulopathy, increased WBC with leukocytosis, and elevated creatinine kinase.
(2) Culture.
(3) MRI or CT scan may indicate depth of tissue involvement.
(4) Histologic analysis: frozen tissue will have massive polymorphonuclear infiltration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5-treatment">5. Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>a. Prompt and frequent surgical debridement
b. Broad-spectrum antibiotics
(1) Type 1: polymicrobial: combination of ampicillin/sulbactam or piperacillin plus clindamycin plus ciprofloxacin
(2) Type 2: streptococcal: penicillin plus clindamycin; staphylococcal: cefazolin plus vancomycin plus clindamycin</p>
<p><img src="assets/images/image-20251225-caf82aa3.jpeg" alt="img-17.jpeg">
FIGURE 11-10. Necrotizing fasciitis, postoperative. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-65cd3978.jpeg" alt="img-18.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="necrotizing-fasciitis">Necrotizing Fasciitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#necrotizing-fasciitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Prompt suspicion of pain that is out of proportion to initial clinical signs.</li>
<li>Nutritional support is required.</li>
<li>Scrupulous wound care is required.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="viral-infections">VIRAL INFECTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#viral-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-warts">I. WARTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-warts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: benign viral epidermal growths
B. Etiology/pathophysiology</p>
<ol>
<li>Human papillomavirus (HPV).</li>
<li>Infects the keratinocytes of the epidermis. Does not extend into the dermis.</li>
<li>Transmitted by touch.</li>
<li>Variable course. May resolve spontaneously or last a lifetime.</li>
<li>Regression of the virus dependent of the cell-mediated immune response.</li>
<li>Often occur at sites of prior trauma.</li>
<li>Most common in children and young adults but may occur at any age.</li>
<li>More severe in patients with impaired immunity.</li>
</ol>
<p>C. Common warts: verruca vulgaris (Figure 11-11)</p>
<ol>
<li>Elevated and well circumscribed.</li>
<li>Irregular shape with hyperkeratotic surface.</li>
<li>Minute papillary projections can be visualized.</li>
<li>Obscure normal skin lines.</li>
<li>Vary in size from 1 mm to over 10 mm.</li>
<li>May proliferate and coalesce (mosaic wart).</li>
<li>Color ranges from flesh toned, gray, and brown.</li>
<li>Black dots seen on the surface are not "seeds" but thrombosed small capillaries.</li>
<li>Common sites.
a. Hands: HPV types 2, 4, and 29
b. Periungual: often secondary to nail biting
c. Plantar surface: HPV type 1. Often secondary to communal moist environments</li>
</ol>
<p>D. Assessment (Box 11-1).</p>
<p>E. Treatment.</p>
<ol>
<li>
<p>Treatment ranges from attempting to activate an immune response to tissue destruction.</p>
</li>
<li>
<p>All treatments have the potential to cause some level of discomfort and scar.</p>
</li>
<li>
<p>Salicylic acid 17% to 40%. Creams, liquid, ointments, and plasters available.</p>
</li>
<li>
<p>Liquid nitrogen applied via spray or cotton applicator. One to three freeze-thaw cycles extending 2 mm beyond the wart diameter.</p>
</li>
<li>
<p>Laser therapy: various modalities can be used.</p>
</li>
<li>
<p>Bichloroacetic acid applied to plantar surface only. Protect surrounding skin with a light coat of petrolatum. Lightly curette the surface of wart prior to applying the acid. Cover with dry dressing.</p>
</li>
<li>
<p>Cantharidin—will create an allergic reaction with significant blistering. Apply to wart surface, allow to dry, and cover with occlusive dressing for 2 to 6 hours.</p>
</li>
<li>
<p>Imiquimod 5%—apply small amount nightly to wart surface and cover with Band-Aid.</p>
</li>
<li>
<p>Immunotherapy: squaric acid dibutylester (SADBE) or diphenylcyclopropenone (DCPC). Patient is sensitized with a 1% solution applied to the upper inner arm. When irritation occurs, a 0.1% solution is applied to the wart surface.</p>
</li>
<li>
<p>Candida albicans skin test antigen. 1:1 mixture combined with lidocaine. Injection of 0.1 mL of solution into the wart surface and the intradermal margins of the wart.</p>
</li>
<li>
<p>Duct tape. Apply to wart for 7 days. Remove the tape, soak, and gently pare the wart.</p>
</li>
<li>
<p>Electrocautery. Wart and surrounding skin anesthetized. Curette the wart and cauterize. A smoke evacuator should be used to reduce inhalation of viral particles.</p>
</li>
<li>
<p>Resistant warts.</p>
</li>
</ol>
<p>a. Blunt dissection
b. 5-Fluorouracil cream
c. Intralesional bleomycin:  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">3\mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span>  of normal saline mixed to 15-unit vial; additional  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">12\mathrm{mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm">mL</span></span></span></span></span></span>  of normal saline added. Inject a minute amount  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.1\mathrm{mL})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm">mL</span></span><span class="mclose">)</span></span></span></span></span>  into the wart surface.</p>
<p><img src="assets/images/image-20251225-3e3e3108.jpeg" alt="img-19.jpeg">
FIGURE 11-11. Common warts: verruca vulgaris. (Courtesy of John K. Randall, MD.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-verruca-plana-flat-warts-figure-11-12">II. VERRUCA PLANA (FLAT WARTS) (FIGURE 11-12)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-verruca-plana-flat-warts-figure-11-12" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. HPV types 3, 10, 28, and 49
B. Slightly raised, irregular, smooth, or slightly hyperkeratotic surface
C. Multiple lesions
D. Flesh colored to slightly pink
E. Prevalent in patients with compromised immunity
F. Common locations</p>
<ol>
<li>Dorsal hands</li>
<li>Face</li>
<li>Areas routinely shaved</li>
</ol>
<p>G. Treatment</p>
<ol>
<li>Topical retinoid cream applied nightly</li>
<li>Liquid nitrogen</li>
<li>Laser</li>
<li>Low levels of electrocautery</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  fluorouracil cream</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  imiquimod cream</li>
</ol>
<p><img src="assets/images/image-20251225-ec3a9efa.jpeg" alt="img-20.jpeg">
FIGURE 11-12. Flat warts: verruca plana. (From Elder, D. E., et al. (2012). Atlas and synopsis of lever's histopathology of the skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-18d6efbb.jpeg" alt="img-21.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="verruca">Verruca<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#verruca" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Treatments for verruca have the potential to scar the skin.</li>
<li>All treatments will have some level of discomfort.
Numerous treatments may be needed.</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  fluorouracil should be avoided in children.</li>
<li>Bichloroacetic acid should only be used on the plantar surface.</li>
<li>Topical retinoids, bleomycin, and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  fluorouracil should not be used in pregnancy.</li>
<li>Patients sensitized to SADBE or DCPC may have contact dermatitis to any area the chemical contacts. It should be applied during office visits, not at home.</li>
<li>Behavior changes to avoid nail biting with periungual lesions.</li>
<li>Shaving to be avoided in areas where warts are present. If patients refuse to stop shaving, they should use a disposable razor and shave the areas where warts are</li>
</ul>
<p>present last.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-molluscum-contagiosum-figure-11-13">III. MOLLUSCUM CONTAGIOSUM (FIGURE 11-13)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-molluscum-contagiosum-figure-11-13" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: benign tumor of the skin</p>
<p>B. Etiology/pathophysiology</p>
<ol>
<li>Double-stranded DNA cowpox virus.</li>
<li>Spread is by touch and autoinoculation by scratching.</li>
<li>In general, casual contact is a mode of transmission in children and sexual contact in adults.</li>
<li>Lesions are discrete ranging in size from 2 to 5 mm with central umbilication.</li>
<li>Core of the lesion (molluscum body) contains a white substance.</li>
<li>Lesions may be much larger in immunocompromised individuals.</li>
<li>Location: in children, on the face, trunk, extremities, and intertriginous areas. Lesions located in the genital area should arouse suspicion of sexual abuse. In adults, on the face, trunk, extremities, and genitalia.</li>
<li>Atopic individuals are at risk for dissemination of lesions.</li>
<li>Resolves spontaneously in 6 to 9 months, but lesions may remain up to 4 years.</li>
</ol>
<p>C. Treatment (see treatment options under verruca)</p>
<ol>
<li>Curettage: scraping individual lesions</li>
<li>Liquid nitrogen</li>
<li>Topical retinoid cream</li>
<li>Salicylic acid</li>
<li>Cantharidin</li>
<li>Laser</li>
<li>5% imiquimod cream</li>
</ol>
<p>D. Assessment (Box 11-1)</p>
<p><img src="assets/images/image-20251225-41d44158.jpeg" alt="img-22.jpeg">
FIGURE 11-13. Molluscum contagiosum: pubic. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-5ca1d369.jpeg" alt="img-23.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="molluscum-contagiosum">Molluscum Contagiosum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#molluscum-contagiosum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Teens and young adults with genitalia lesions should be screened for other sexually transmitted infections.</li>
<li>School policies may require lesions to be covered.</li>
<li>Close contacts and family members instructed to monitor for development of lesions.</li>
<li>All treatments may cause irritation, discomfort, and the potential to scar the skin.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-condyloma-acuminatum-figures-11">IV. CONDYLOMA ACUMINATUM (FIGURES 11-<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-condyloma-acuminatum-figures-11" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="14-and-11-15">14 AND 11-15)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#14-and-11-15" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: sexually transmitted HPV lesions</p>
<p>B. Etiology/pathophysiology</p>
<ol>
<li>Most common is HPV types 6 and 11. Other subtypes may occur. Types 16 and 18 are associated with neoplasms and dysplasia.</li>
<li>Generally asymptomatic, but pruritus may occur.</li>
<li>Minor trauma during sexual activity allows the virus entry into the skin.</li>
<li>Immunosuppressed and pregnant individuals are most susceptible.</li>
<li>Lesions range from single soft papules to multiple growths. They may coalesce and present as cauliflower-like masses.</li>
<li>Lesions present on the penis, scrotum, anus, and urethra in males.</li>
<li>Lesions present on the vulva, vagina, cervix, and perianal areas in females.</li>
<li>Virus can be transmitted to newborn during vaginal delivery.</li>
<li>Subclinical infections (no visible lesions) may be identified by application of 5% acetic acid. This will cause whitening of the lesions.</li>
<li>Association of HPV with subsequent head, neck, and throat cancers.</li>
</ol>
<p>C. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Diagnostic tests</li>
</ol>
<p>a. Serology tests
b. Cervical Pap smear in women. ViraPap for specific hybridization to determine specific subtypes
c. Anal smears in both men and women
d. Lesion biopsy</p>
<p>D. Treatment: often difficult to eradicate</p>
<ol>
<li>80% trichloroacetic acid or 90% bichloroacetic acid applied to the lesion. Surrounding skin should be protected by thin coating of petrolatum. After light frosting occurs, a baking soda paste is applied to neutralize.</li>
<li>5% imiquimod applied to the lesions two times weekly.</li>
<li>Sinecatechin 15% ointment. Apply topically tid for 2 to 4 months.</li>
<li>Podophyllin 10% to 25% compounded in tincture of benzoin, 0.5% solution, 0.15% cream. Podophyllin is a plant compound that halts cell mitosis leading to tissue destruction. Apply to lesion, allow to dry, and wash off in 1 hour.</li>
<li>Podofilox 0.5% gel or solution applied every 12 hours × 3 days then off 4 days.</li>
<li>5% fluorouracil cream.</li>
<li>Liquid nitrogen.</li>
<li>Light cautery.</li>
<li>Excision.</li>
<li>Ablative laser treatment.</li>
</ol>
<p><img src="assets/images/image-20251225-c4782dff.jpeg" alt="img-24.jpeg">
FIGURE 11-14. Condyloma acuminatum: penis. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-3d2b1975.jpeg" alt="img-25.jpeg"></p>
<p>FIGURE 11-15. Condyloma acuminatum: perianal. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-d85f39c0.jpeg" alt="img-26.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="condyloma-acuminatum">Condyloma Acuminatum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#condyloma-acuminatum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment irritation is expected.</li>
<li>Imiquimod, sinecatechin, and podophyllin must have irritation to provide any benefit. These medications should not be used in the urethra, vagina, cervix, and anal area.</li>
<li>Patients should have full sexually transmitted disease screenings including gonorrhea, syphilis, and chlamydia.</li>
<li>Podophyllin and 5% fluorouracil are contraindicated in pregnancy.</li>
<li>Condoms do not entirely prevent transmission of the virus.</li>
<li>HPV vaccination is recommended for all adolescents, male and female. Gardasil is protective against HPV types 6, 11, 16, and 18. Cervarix is protective for females against HPV types 16 and 18.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="v-human-herpesvirus-hhv-figures-11-16-and-11-17">V. HUMAN HERPESVIRUS (HHV) (FIGURES 11-16 AND 11-17)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-human-herpesvirus-hhv-figures-11-16-and-11-17" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: viral infection of the skin</p>
<ol>
<li>There are eight herpesviruses. Herpes simplex virus types 1 and 2 (HSV1 and HSV2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6, 7, and 8</li>
</ol>
<p>B. Etiology/pathophysiology</p>
<ol>
<li>HSV1 spreads by direct contact with contaminated secretions. HSV2 spread by secretions during sexual contact. HSV1 generally oral and HSV2 genital, but with oral/genital contact, HSV2 may be oral and vice versa.</li>
<li>Primary, latent, and recurrent infection types.</li>
</ol>
<p>C. Virus replicated at site of infection (primary) then travels retrograde to dorsal root ganglia (latent). Virus can be reactivated spontaneously or by a stimulus (recurrent).</p>
<p>D. Primary infection</p>
<ol>
<li>May be asymptomatic.</li>
<li>Elevated IgG antibody titer.</li>
<li>Severity will increase with advanced age and suppressed immune status.</li>
<li>Symptoms occur 3 to 7 days after contact.</li>
</ol>
<p>a. Tenderness, pain, mild paresthesias, and burning prior to appearance of lesions.</p>
<p>b. Localized pain, tender lymphadenopathy, and flu-like symptoms may occur.</p>
<p>E. Recurrent infection</p>
<ol>
<li>Exacerbating factors.</li>
</ol>
<p>a. Sunlight
b. Trauma
c. Stress
d. Menses
e. Systemic infection</p>
<ol start="2">
<li>
<p>Not all individuals will have recurrence.</p>
</li>
<li>
<p>Prodrome</p>
</li>
</ol>
<p>a. Duration 2 to 24 hours with symptoms similar to that of primary infection.
b. Recurrent lesions may occur within 12 hours of prodromal symptoms.
c. Increased frequency of recurrences with HSV2 infections.</p>
<p>F. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Assess overall health of patient.</li>
<li>Diagnosis is generally made on clinical presentation.</li>
</ol>
<p>a. Grouped vesicles on an erythematous base.
b. Vesicles quickly open leaving erosions.
c. Crusting may occur.
d. Lasts 2 to 6 weeks.
e. Heals without scarring.</p>
<ol start="4">
<li>Laboratory tests.</li>
</ol>
<p>a. Tzanck smear: multinucleated epithelial giant cells
b. Biopsy of intact lesion
c. Viral culture
d. Direct immunofluorescence
e. Serology: Western blot for HSV antibodies and other tests available for type-specific virus</p>
<p>G. Treatment</p>
<ol>
<li>Symptom control with cool moist compresses of water or Burow solution.</li>
<li>Topical antivirals less effective than oral medications. Applied every 2 hours.</li>
</ol>
<p>a. Acyclovir cream
b. Penciclovir cream
c. Docosanol cream (available OTC)
d. Acyclovir/hydrocortisone: applied five times daily for 5 days</p>
<ol start="3">
<li>L-Lysine has no research data demonstrating effectiveness.</li>
<li>Systemic antivirals.</li>
</ol>
<p>a. Acyclovir.
b. Valacyclovir.
c. Famciclovir.
d. See Table 11-2 for dosing regimens.</p>
<p>H. Other cutaneous types of herpetic infection (Figure 11-18)</p>
<ol>
<li>Herpes whitlow: infection of the fingertip, often common in health care providers.</li>
<li>Herpes gladiatorum: infection in athletes involved in direct skin-to-skin contact; common in wrestlers.</li>
<li>Eczema herpeticum: widespread HSV infection in atopic patients. Symptoms can range from mild to severe (Figure 11-19).</li>
</ol>
<p><img src="assets/images/image-20251225-d2e5df35.jpeg" alt="img-27.jpeg">
FIGURE 11-16. Human herpesvirus (HHV): lips. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-683b1e4d.jpeg" alt="img-28.jpeg">
FIGURE 11-17. Human herpesvirus (HHV): penis. (Courtesy of John K. Randall, MD.)</p>
<p>TABLE 11-2 Herpes Simplex Virus Treatment</p>
<table><thead><tr><th></th><th>Acyclovir</th><th>Valacyclovir</th><th>Famciclovir</th></tr></thead><tbody><tr><td>First episode</td><td>400 mg tid × 7–10 d</td><td></td><td></td></tr><tr><td>200 mg 5 times daily for 7–10 d</td><td>1 g bid × 7–10 d</td><td>250 mg tid × 7–10 d</td><td></td></tr><tr><td>Suppression</td><td>400 mg bid</td><td>500 mg bid</td><td>250 mg bid</td></tr><tr><td>Episodic</td><td>400 mg tid × 5 d</td><td></td><td></td></tr><tr><td>800 mg bid × 5 d</td><td></td><td></td><td></td></tr><tr><td>800 mg tid × 3 d</td><td>500 mg bid × 3 d</td><td></td><td></td></tr><tr><td>1 g daily × 5 d</td><td>125 mg bid × 5 d</td><td></td><td></td></tr><tr><td>1,000 mg bid × 1 d</td><td></td><td></td><td></td></tr><tr><td>500 mg × 1 d</td><td></td><td></td><td></td></tr><tr><td>then 250 mg bid × 2 d</td><td></td><td></td><td></td></tr></tbody></table>
<p><img src="assets/images/image-20251225-72419fb8.jpeg" alt="img-29.jpeg">
FIGURE 11-18. Herpes whitlow: index finger. (From Berg, D., &amp; Worzala, K. (2006). Atlas of adult physical diagnosis. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-d298b11d.jpeg" alt="img-30.jpeg">
FIGURE 11-19. Eczema herpeticum. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-f9f8cb05.jpeg" alt="img-31.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="herpes-viruses">Herpes Viruses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#herpes-viruses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>
<p>Herpes simplex virus is definitely transmitted during active infections and the prodrome period. There may be transmission during times there are no symptoms.</p>
</li>
<li>
<p>Condom use during sexual activity is highly recommended.</p>
</li>
<li>
<p>Individuals with frequent recurrence should be on suppressive therapy for at least 1 year.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vi-varicella-zoster-virus-vzv-figure-11-20">VI. VARICELLA-ZOSTER VIRUS (VZV) (FIGURE 11-20)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vi-varicella-zoster-virus-vzv-figure-11-20" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: an acute vesiculobullous eruption seen in a dermatomal distribution that rarely crosses the midline</p>
<p>B. Etiology</p>
<ol>
<li>Caused by reactivation of varicella virus acquired during an episode of (or exposure to) chickenpox.</li>
<li>Virus lies dormant in nerve root ganglion until reactivated.</li>
<li>Occurs in 10% to 20% of all persons and can occur in all ages with incidence increasing with age.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Factors that reactivate the virus</li>
</ol>
<p>a. Age
b. Immunosuppressive medications
c. Lymphoma and other cancers
d. Fatigue
e. Emotional upset
f. Radiation</p>
<ol start="2">
<li>Preeruptive symptoms (localized to dermatome): precede eruption 4 to 5 days</li>
</ol>
<p>a. Pain: may be severe simulating pleurisy, myocardial infarction, abdominal disease, or migraine headache.
b. Pruritus or burning.
c. Tenderness or hyperesthesia.
d. Urinary hesitancy or retention involves S2, S3, and S4 nerves.
e. Flu-like symptoms.
f. Regional lymphadenopathy may be present.</p>
<ol start="3">
<li>Eruptive phase</li>
</ol>
<p>a. Generally limited to a single dermatome
b. Rare bilateral symmetrical or asymmetrical dermatomes (may signal presence of underlying malignancy)
c. Viremia (appearance of 20 to 30 scattered vesicles, outside the dermatome); seen in approximately 50% of patients
d. Eruption</p>
<p>(1) Begins with erythematous, swollen plaques of various sizes
(2) Spreads to involve dermatome
(3) Vesicles with purulent fluid form 3 to 4 days after appearance of erythema</p>
<p>(4) Vesicular eruption may continue for up to 7 days.
(5) Rupture of vesicles leads to erosion and crusting.
(6) Elderly or debilitated patient may have a prolonged and difficult course of infection and may also have prolonged pain (postherpetic neuralgia) for several months.</p>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1)</li>
<li>Current health status of patient</li>
<li>Clinical presentation of lesions (particularly if atypical presentation)</li>
<li>Diagnostic tests for atypical presentation
a. Viral culture
b. Direct fluorescent antigen assay
c. Quantitative polymerase chain reaction for detection of VZV DNA</li>
</ol>
<p>E. Treatment</p>
<ol>
<li>Acyclovir 800 mg five times daily for 7 days</li>
<li>Valacyclovir 1,000 mg every 8 hours for 7 days</li>
<li>Famciclovir 500 mg every 8 hours for 7 days</li>
<li>Cool compresses</li>
<li>Burow compresses</li>
</ol>
<p>F. Postherpetic neuralgia treatment</p>
<ol>
<li>Topicals
a. Lidocaine 2% or 10% gel or 5% patch
b. Capsaicin 0.05% ointment, 0.075% cream, or 8% patch
c. Systemic agents
(1) Gabapentin 300 mg/day increasing 300 mg daily. Usual dose 1,800 to 3,600 mg/day
(2) Pregabalin 150 mg/day in divided dose increasing up to 30 mg/day within 1 week. Can be increased up to 600 mg/day after 2 to 4 weeks
(3) Tricyclic antidepressants
(a) Amitriptyline 10mg initially increased until desired effect up to 100mg nightly.
(b) Nortriptyline 10 to 25 mg nightly. May be increased up to 25 mg/week. The usual dose is 30 to 75 mg nightly
(c) Desipramine 10 to 25 mg/day. Dose may be increased every 3rd day. The usual dose is 50 to 150 mg/day.</li>
<li>Opioid analgesics
(a) Morphine: 10 mg at night or 10 to 30 mg every 12 hours; maximum dose 200 mg/day
(b) Tramadol: 100 to 400 mg/day in divided doses at least 4 hours apart
(c) Oxycodone: 10 mg bid; maximum dose 60 mg/day
(d) Methadone: 5 mg at night up to 15 mg/day</li>
</ol>
<p><img src="assets/images/image-20251225-ca8d2930.jpeg" alt="img-32.jpeg">
FIGURE 11-20. Varicella-zoster virus (VZV). (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-536d1535.jpeg" alt="img-33.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="varicella-zoster-virus">Varicella-Zoster Virus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#varicella-zoster-virus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Individuals with zoster are only contagious to individuals who have not had either the varicella virus or the vaccine.</li>
<li>Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends VZV vaccine given subcutaneously as a  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.65</mn><mrow><mo>−</mo><mi mathvariant="normal">m</mi><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">0.65\mathrm{-mL}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">0.65</span><span class="mord"><span class="mord">−</span><span class="mord mathrm">mL</span></span></span></span></span></span>  dose (Zostavax) in all immunocompetent adults aged 60 years and over, regardless of history of varicella infection.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fungal-infections">FUNGAL INFECTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fungal-infections" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-dermatophytes">I. DERMATOPHYTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-dermatophytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: known as tineas; superficial infections of the skin and responsible for the vast majority of skin, hair, and nail infections
B. Etiology</p>
<ol>
<li>Dermatophytes produce enzymes that break down keratin. Organism invades and survives</li>
</ol>
<p>on dead keratin (stratum corneum).</p>
<ol start="2">
<li>Dermatophytes cannot survive on mucosal surfaces, which are devoid of keratin.</li>
<li>Occasionally will undergo deep invasion, especially in immunocompromised individuals.</li>
<li>Some patients may have genetic predisposition to dermatophyte infections.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="c-pathophysiology">C. Pathophysiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-pathophysiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Lesions vary in presentation and may resemble other dermatoses, leading to misdiagnosis.</li>
<li>Classification</li>
</ol>
<p>a. Genera</p>
<p>(1) Trichophyton
(2) Microsporum
(3) Epidermophyton</p>
<p>b. Transmission modes</p>
<p>(1) Anthropophilic: human to human</p>
<p>(a) Mild inflammatory response</p>
<p>(2) Zoophilic: animal to human</p>
<p>(a) Intense inflammatory response</p>
<p>(3) Geophilic: soil to human or animal</p>
<p>(a) Moderate inflammatory response</p>
<p>c. Body region</p>
<p>(1) Tinea corporis: nonhairy parts of the body, face, neck, and extremities
(2) Tinea cruris: groin and inner thigh
(3) Tinea capitis: scalp
(4) Tinea manuum: hands
(5) Tinea pedis: feet
(6) Tinea unguium (onychomycosis): nails
(7) Tinea barbae (tinea sycosis): beard</p>
<p>d. Hair invasion types</p>
<p>(1) Endothrix pattern: fungal elements inside the hair follicle
(2) Ectothrix pattern: fungal elements inside and on the surface of the hair follicle</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="d-assessment">D. Assessment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>History (Box 11-1)</li>
<li>Inspect skin and mucous membranes</li>
<li>Assess for cervical lymphadenopathy with scalp involvement</li>
<li>Lesions</li>
</ol>
<p>a. Tinea corporis: annular lesion with central clearing and active leading edge of infection with scale. Lesions may also appear arcuate, circinate, and oval (Figure 11-21). Lesions treated with topical corticosteroids may have no scale (tinea incognito).</p>
<p>b. Tinea cruris: erythematous plaque in the groin with well-demarcated scaly border. Skin within the plaque may have a red-brown appearance. Vesicles may be present at the outer border (Figure 11-22).</p>
<p>c. Tinea manuum: lesions on the dorsal aspect will appear as tinea corporis. Lesions on the palm will be hyperkeratotic with scale (Figure 11-23).</p>
<p>d. Tinea pedis: lesions on the dorsal aspect will appear as tinea corporis. Lesions on the</p>
<p>sole will be hyperkeratotic with scale in moccasin-type distribution. Web spaces of the toes may have vesicles, fissures, and maceration (Figure 11-24).</p>
<p>e. Tinea barbae: lesions will be follicular-based pustules often eroded (Figure 11-25).</p>
<p>f. Tinea unguium: hyperkeratosis of the nail, separation of the distal plate (onycholysis), subungual white debris, and yellowing of the distal plate (Figure 11-26)</p>
<p>g. Tinea capitis (Figure 11-27)</p>
<p>(1) Most common organism in North America is Trichophyton tonsurans.</p>
<p>(2) Five patterns of presentation</p>
<p>(a) Noninflammatory black dot (the color of dot dependent upon hair color). Hair will be broken off at follicle, scalp scale will be present, and large areas of alopecia will be present.</p>
<p>(b) Kerion: areas of alopecia with boggy and purulent plaque. Abscess may be present (Figure 11-28).</p>
<p>(c) Seborrheic dermatitis type: fine white scale with tiny perifollicular pustules.</p>
<p>(d) Pustular: discrete pustules without scaling.</p>
<p>(e) Favus: thick yellow crusts composed of hyphae and skin debris. Scarring alopecia is common. The causative organism is T. schoenleinii.</p>
<p>h. Variants</p>
<p>(1) Tinea profunda: granulomatous or verrucal appearance</p>
<p>(2) "Two feet and one hand syndrome": diffuse hyperkeratosis of one palm and both soles</p>
<ol start="5">
<li>Diagnostic tests</li>
</ol>
<p>a. Potassium hydroxide wet mount (KOH); take specimen from active border of lesion.</p>
<p>b. Wood's lamp</p>
<p>(1) T. schoenleinii will fluoresce pale green.</p>
<p>(2) Microsporum audouinii will fluoresce yellow green.</p>
<p>c. Fungal culture</p>
<p>E. Treatment</p>
<ol>
<li>Topicals</li>
</ol>
<p>a. Allylamines</p>
<p>b. Azoles</p>
<p>c. CiclopiroxTavaborole 10% nail solution</p>
<ol start="2">
<li>Shampoos: may help to decrease the fungal load in tinea capitis but ineffective for cure</li>
</ol>
<p>a. Ketoconazole 2%</p>
<p>b. 1% to 2.5% selenium sulfide</p>
<p>c. 1% to 2% zinc pyrithione</p>
<ol start="3">
<li>Oral antifungals (Table 11-3)</li>
</ol>
<p><img src="assets/images/image-20251225-da157aef.jpeg" alt="img-34.jpeg"></p>
<p><img src="assets/images/image-20251225-121a5ace.jpeg" alt="img-35.jpeg">
FIGURE 11-21. Tinea corporis. (Courtesy of Charles E. Lewis, MD.)
FIGURE 11-22. Tinea cruris. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-bccf83e0.jpeg" alt="img-36.jpeg">
FIGURE 11-23. Tinea manuum. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-7d037b19.jpeg" alt="img-37.jpeg"></p>
<p><img src="assets/images/image-20251225-e2b5607b.jpeg" alt="img-38.jpeg">
FIGURE 11-24. Tinea pedis. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-c12076e0.jpeg" alt="img-39.jpeg">
FIGURE 11-25. Tinea barbae. (From Berg, D., &amp; Worzala, K. (2006). Atlas of adult physical diagnosis. Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-30ad42c3.jpeg" alt="img-40.jpeg">
FIGURE 11-26. Tinea unguium. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-8300b683.jpeg" alt="img-41.jpeg">
FIGURE 11-27. Tinea capitis. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-da77bff8.jpeg" alt="img-42.jpeg">
FIGURE 11-28. Kerion. (Courtesy of John K. Randall, MD.)</p>
<p>TABLE 11-3 Oral Antifungals to Treat Tinea Capitis</p>
<table><thead><tr><th>Medication</th><th>Dosage</th><th>Duration</th></tr></thead><tbody><tr><td>Griseofulvin microsize</td><td>Adults: 500 mg/d</td><td></td></tr><tr><td>PED: 10–20 mg/kg/d</td><td>6–8 wk</td><td></td></tr><tr><td>Or at least 2 wk after resolution of symptoms</td><td></td><td></td></tr><tr><td>Griseofulvin ultramicrosize</td><td>Adults: 375 mg/d</td><td></td></tr><tr><td>PED: 5–15 mg/kg/d</td><td>6–8 wk</td><td></td></tr><tr><td>Or at least 2 wk after resolution of symptoms</td><td></td><td></td></tr><tr><td>Terbinafine</td><td>&lt;20 kg: 62.5 mg/d</td><td></td></tr><tr><td>20–40 kg: 125 mg/d</td><td></td><td></td></tr><tr><td>Over 40 kg: 250 mg/d</td><td>2–4 wk</td><td></td></tr><tr><td>Or at least 2 wk after resolution of symptoms</td><td></td><td></td></tr><tr><td>Itraconazole</td><td>Oral suspension:</td><td></td></tr><tr><td>3–5 mg/kg/d</td><td></td><td></td></tr><tr><td>Oral capsules:</td><td></td><td></td></tr><tr><td>10–20 kg: 100 mg every other day</td><td></td><td></td></tr><tr><td>21–30 kg: 100 mg daily</td><td></td><td></td></tr><tr><td>31–40 kg: 100 mg and 200 mg on alternate days</td><td></td><td></td></tr><tr><td>41–50 kg: 200 mg daily</td><td></td><td></td></tr><tr><td>Over 50 kg: 200–300 mg daily</td><td>4–6 wk</td><td></td></tr><tr><td>Or at least 2 wk after resolution of symptoms</td><td></td><td></td></tr></tbody></table>
<p><img src="assets/images/image-20251225-ba5ff6be.jpeg" alt="img-43.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dermatophytes">Dermatophytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatophytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Topicals should be used for at least 2 to 4 weeks for cure.</li>
<li>Shampoos need at least 5-minute contact time on the scalp prior to rinsing.</li>
<li>Griseofulvin should be taken with a high-fat meal to facilitate absorption.</li>
<li>Itraconazole should be taken with a full meal. Grapefruit juice should be avoided.</li>
<li>T. tonsurans spores remain viable on inanimate objects, such as combs and brushes, and clothing, such as hats. All articles should be cleaned thoroughly and not shared with other family members.</li>
<li>Family members of patients with tinea capitis should be assessed for asymptomatic carriers.</li>
<li>Tinea pedis may have a high degree of recurrence. Inform patients to wear moisture-wicking socks and change them frequently. Wear well-ventilated shoes. Sandals should be worn in locker rooms and on pool decks.</li>
<li>Patients with tinea cruris should wear cotton underwear.</li>
</ul>
<p>II. TINEA VERSICOLOR (PITYRIASIS VERSICOLOR) (FIGURE 11-29)</p>
<p>A. Definition: superficial, chronic fungal infection seen on upper trunk, arms, or neck</p>
<p>B. Etiology</p>
<ol>
<li>
<p>Caused by <em>Pityrosporum orbiculare</em> or <em>Pityrosporum ovale</em> (Malassezia furfur)
a. Part of normal skin flora
b. Concentrated in areas with increased sebaceous activity</p>
</li>
<li>
<p>Factors contributing to fungal proliferation
a. Heat/humidity
b. Cushing disease
c. Pregnancy
d. Malnutrition
e. Burns
f. Corticosteroid therapy
g. Immunosuppression
h. Oral contraception</p>
</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Characteristic lesions and distribution. Generally on the trunk spreading to the neck, upper arms, and abdomen. Occasionally will involve the face, dorsal hands, and legs.</li>
<li>Postpubertal and mature individuals more susceptible.</li>
<li>Pruritus may be present, especially during sweating.</li>
<li>Lesions more prominent in summer due to tanning of noninvolved skin.</li>
</ol>
<p>D. Assessment</p>
<ol>
<li>History (Box 11-1).</li>
<li>Current health status.</li>
<li>Evaluate affected skin sites.</li>
<li>Clinical manifestations.
a. Multiple, small, circular macules of varying color
b. Lesions enlarge radially
c. Red to fawn-colored macules, patches, or follicular papules
d. Slightly scaly
e. Papular, nummular of confluent</li>
<li>Diagnostic tests
a. KOH: typical spaghetti-and-meatballs appearance of rod and spores.
b. Wood lamp: generally will fluoresce a pale, yellow-whitish appearance.</li>
</ol>
<p>E. Treatment</p>
<ol>
<li>
<p>Ketoconazole 2% shampoo: lather and leave on 5 minutes then rinse × 3 days.</p>
</li>
<li>
<p>Selenium sulfide shampoo: lather and leave on 5 minutes then rinse × 3 days.</p>
</li>
<li>
<p>Selenium sulfite 2.5% lotion: apply daily for 10 minutes then rinse off × 7 days. Alternative: apply at night and wash off in the AM, weekly × 4 weeks.</p>
</li>
<li>
<p>Terbinafine spray: apply bid × 1 week.</p>
</li>
<li>
<p>Topical antifungal cream: apply bid  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>×</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">\times 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">×</span><span class="mord">2</span></span></span></span></span>  to 4 weeks.</p>
</li>
<li>
<p>Itraconazole:  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">y</mi></mrow></mrow><annotation encoding="application/x-tex">200\mathrm{mg/day}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg/day</span></span></span></span></span></span>  for 7 days.</p>
</li>
<li>
<p>Fluconazole: 300 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400\mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>  for 1 day; repeat in 2 weeks.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-3739c0c5.jpeg" alt="img-44.jpeg">
FIGURE 11-29. Tinea versicolor. (Courtesy of John K. Randall, MD.)</p>
<p>PATIENT EDUCATION</p>
<p>Tinea Versicolor</p>
<ul>
<li>Tinea versicolor has a high degree of recurrence.</li>
<li>Hypopigmented lesions will take time to resolve, even when the organism has been eradicated.</li>
<li>Do not consume grapefruit juice with itraconazole.</li>
<li>Itraconazole should be taken with a full meal.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-candidiasis-moniliasis-thrush-figures-11-30-and-11-31">III. CANDIDIASIS (MONILIASIS, THRUSH) (FIGURES 11-30 AND 11-31)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-candidiasis-moniliasis-thrush-figures-11-30-and-11-31" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: skin, mucous membrane, and internal infection caused by proliferation of normal flora in the mouth, vaginal tract, and intestinal tract</p>
<p>B. Etiology</p>
<ol>
<li>C. albicans: yeast-like fungus; most common cause of superficial and systemic fungal infections</li>
<li>Factors predisposing to proliferation of organisms
a. Pregnancy
b. Oral contraceptives
c. Antibiotic therapy
d. Diabetes
e. Skin maceration
f. Topical steroids
g. Some endocrinopathies
h. Immunocompromised</li>
<li>Infects outer layers of epithelium of mucous membranes and stratum corneum of the skin</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Candidiasis of moist areas
a. Vulvovaginitis
(1) Heat/moisture increases the risk of infection.
(2) Menstruation may worsen symptoms.
(3) May coexist with Trichomonas.
b. Oral candidiasis
(1) Seen in infants and adults
(2) Causative factors: diabetes, depressed cell-mediated immunity, advanced age,</li>
</ol>
<p>cancer, prolonged steroid therapy, chemotherapy, broad-spectrum antibiotics, and AIDS</p>
<p>(3) Tongue involved in an acute infection: extending into the esophagus and trachea
(4) Localized, firmly adherent plaques characteristic of chronic infection</p>
<p>D. Intertrigo (Figure 11-32)</p>
<p>(1) Occurs in large skin folds.
(2) Heat and moisture provide environment for proliferation of organisms.
(3) Poor hygiene and inflammatory diseases also increase the risk of infection.</p>
<p>E. Assessment</p>
<ol>
<li>History (Box 11-1).</li>
<li>Current health status.</li>
<li>Evaluate skin and mucous membranes.</li>
<li>Clinical presentation.
a. Pustules (satellite lesions)
b. Erythematous, moist, glistening plaques extending beyond the limits of opposing skin folds
c. Painful fissuring</li>
<li>Pruritus and discharge are initial signs of infection.</li>
<li>Edema, erythema, and erosion of mucous membranes and external genitalia.</li>
<li>Satellite lesions may develop.</li>
<li>Diagnostic tests.
a. KOH
b. Wood lamp
c. Fungal culture</li>
</ol>
<p>F. Treatment</p>
<ol>
<li>Vulvovaginitis
a. Azole vaginal creams
b. Oral azoles: fluconazole 150 mg × 1
c. Nystatin vaginal tabs</li>
<li>Oral candidiasis
a. Nystatin oral suspension
b. Clotrimazole troche
c. Oral azoles: 200 mg/daily for 2 weeks</li>
<li>Intertrigo
a. Maintain dryness
b. Burow compresses
c. Antifungal creams
d. Oral azoles</li>
</ol>
<p><img src="assets/images/image-20251225-6244734d.jpeg" alt="img-45.jpeg">
FIGURE 11-30. Vulvovaginitis. (From Kroumpouzos, G. (2013). Text atlas of obstetric dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-fe4b5ad3.jpeg" alt="img-46.jpeg">
FIGURE 11-31. Oral candidiasis. (From Stedman's medical dictionary (2007). Stedman's medical dictionary for the health professions and nursing, illustrated. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-ac0b2393.jpeg" alt="img-47.jpeg">
FIGURE 11-32. Intertrigo. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-e52bfae9.jpeg" alt="img-48.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="intertrigo">Intertrigo<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#intertrigo" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Patients should wash the affected area daily with antibacterial soap or benzoyl peroxide wash. Pat dry and use handheld hair dryer on cool setting to thoroughly dry the area.</li>
<li>Cotton underwear should be worn.</li>
</ul>
<p>BIBLIOGRAPHY</p>
<p>Amagi, M., &amp; Stanley, J. R. (2012). Desmoglein as a target in skin disease and beyond. Journal of Investigative Dermatology, 132(3), 776–784.</p>
<p>Bader, M. (2013). Herpes zoster: Diagnostic, therapeutic, and preventive approaches. Postgraduate Medicine, 125(5), 78–91.</p>
<p>Bangert, S., Levy, M., &amp; Hebert, A. A. (2012). Bacterial resistance and impetigo treatment trends: A review. <em>Pediatric Dermatology</em>, 29(3), 243–248.</p>
<p>Bhanusali, D., Coley, M., Silverberg, J. I., Alexis, A., &amp; Silverberg, N. B. (2012). Treatment outcomes for tinea capitis in a skin of color population. Journal of Drugs in Dermatology, 11(7), 852–856.</p>
<p>Braunstein, I., Wanat, K. A., Abuaboura K., McGowan, K. L., Yan, A. C., &amp; Treat, J. R. (2013). Antibiotic sensitivity resistance patterns in pediatric staphylococcal scalded skin syndrome. <em>Pediatric Dermatology</em>, 31(3), 305–308.</p>
<p>Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practice. (2013). Recommended adult immunization schedule: United States. Annals of Internal Medicine, 158(3), 191–199.</p>
<p>Chen, N., Yang, M., He, L., Zhang, D., Zhou, M., &amp; Zhu, C. (2010). Corticosteroids for preventing post-herpetic neuralgia. Cochrane Database Systematic Reviews, (3), CD005582. doi: 10.1002/14651858/CD005582.pub4</p>
<p>de Sá, D. C., Lamas, A. P. B., &amp; Tosti, A. (2014). Oral therapy for onychomycosis: An evidence-based review. American Journal of Clinical Dermatology, 15(1), 17–36. doi: 10.1007/s40257-013-0056-2</p>
<p>Derry, S., Sven-Rice, A., Cole, P., Tan, T., &amp; Moore, R. A. (2009). Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Systematic Reviews, (4), CD007393. doi: 10.1002/14651858.CD007393.pub2</p>
<p>Dreyfus, D. H. (2013). Herpesvirus and the microbiome. Journal of Allergy and Clinical Immunology, 132(6), 1278–1286.</p>
<p>Elewski, B. E., Hughey, L. C., Sobena, J. O., &amp; Hay, R. (2012). Fungal diseases. In J. L. Bolgnia, J. L. Jorizzo, &amp; J. O. Schaffer (Eds.), Dermatology (3rd ed., pp. 1251–1284). New York, NY: Saunders/Elsevier.</p>
<p>Elewski, B., Parsier, D., Rich, P., &amp; Scher, R. K. (2013). Current and emerging options in the treatment of onychomycosis. Seminars in Cutaneous Medicine and Surgery, 32(2 suppl 1), s9–s12.</p>
<p>Elewski, B., Parsier, D., Rich, P., &amp; Scher, R. K. (2013). Onychomycosis: An overview. Journal of Drugs in Dermatology, 12(7), s96–s103.</p>
<p>Gan, E. Y., Tian, E. A. L., &amp; Tey, H. L. (2013). Management of herpes zoster and post-herpetic neuralgia. American Journal of Clinical Dermatology, 14(2), 77–85.</p>
<p>Gunderson, C. G., &amp; Martinello, R. A. (2012). A systematic review of bacteremias in cellulitis and erysipelas. Journal of Infection, 64(2), 148–155.</p>
<p>Gupta, A. (2013). Systemic antifungal agents. In S. Wolverton (Ed.), Comprehensive dermatologic drug therapy (3rd ed., pp. 98–120). New York, NY: Elsevier/Saunders.</p>
<p>Gupta, A. K., Cooper E. A., &amp; Paquet, M. (2013). Recurrence of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono and combined therapy of terbinafine and itraconazole. Journal of Cutaneous Medicine and Surgery, 17(3), 201–206.</p>
<p>Gupta, A. K., &amp; Drummond-Main, C. (2013). Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. <em>Pediatric Dermatology</em>, 30(1), 1–6.</p>
<p>Habif, T. (Ed.). (2010). Clinical dermatology (5th ed., pp. 355–381, 419–453, 454–490, 491–543). New York, NY: Mosby/Elsevier.</p>
<p>Hay, R. J., &amp; Adrians, B. M. (2010). Bacterial infections. In T. Burns, S. Breathnach, N. Cox, &amp; C. Griffiths (Eds.), <em>Rooks textbook of dermatology online</em> (8th ed., Chapter 30). West Sussex, UK: Wiley-Blackwell.</p>
<p>Idriss, M. H., Khalil, A., &amp; Elston, D. (2013). The diagnostic value of fungal fluorescence in onychomycosis. Journal of Cutaneous Pathology, 40(4), 385–390.</p>
<p>Kelly, B. P. (2012). Superficial fungal infections. <em>Pediatrics in Review</em>, 33(4), e22–e37.</p>
<p>Kilburn, S. A., Feathersone, P., Higgins, B., &amp; Brindle, R. (2010). Interventions for cellulitis and erysipelas. Cochrane Database of Systematic Reviews, (6), CD004299. doi: 10.1002/14651858.CD004299.pub2</p>
<p>Kimbauer, R., &amp; Lenz, P. (2012). Human papillomaviruses. In J. L. Bologna, J. L. Jorizzo, &amp; J. O. Schaffer (Eds.), Dermatology (3rd ed., pp. 1303–1320). New York, NY: Saunders/Elsevier.</p>
<p>Koning, S., van der Sande, R., van Suijlekom-Smit, L. W. A., Morris, A. D., Butler, C. G., Berger, M., &amp; van der Wouden, J. C. (2012). Interventions for impetigo. Cochrane Database of Systematic Reviews, (1), CD003261. doi: 10.1002/14651858.CD003261.pub3</p>
<p>Li, M. Y., Jua, Y., Wei, G. H., &amp; Qui, L. (2014). Staphylococcal scalded skin syndrome in neonates: An 8 year retrospective study in a single institution. <em>Pediatric Dermatology</em>, 31(1), 127–136.</p>
<p>Li, Q., Chen, N., Yang, J., Zhou, M., Zhou, D., Zhang, Q., &amp; He, L. (2009). Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Systematic Reviews, (2), CD006866. doi: 10.1002/14651858.CD006866.pub2</p>
<p>Magel, G. D., Haitz, K. A., Lapolla, W. J., DiGiorgio, C. M., Mendoza, N., &amp; Tyring, S. K. (2013). Systemic antiviral agents. In S. Wolverton (Ed.), Comprehensive dermatologic drug therapy (3rd ed., pp. 121–134). New York, NY:</p>
<p>Elsevier/Saunders.</p>
<p>Mendoza, N., Madkan, V., Sra, K., Willison, B., Morrison, L. K., &amp; Tyring, S. K. (2012). Human herpesvirus. In J. L. Bolognia, J. L. Jorizzo, &amp; J. O. Schaffer (Eds.), <em>Dermatology</em> (3rd ed., pp. 1321–1344). New York, NY: Saunders/Elsevier.</p>
<p>Millet, C. R., Halpern, A. O., Reboli, A. C., &amp; Heyman, W. R. (2012). Bacterial diseases. In J. L. Bolognia, J. L. Jorizzo, &amp; J. O. Schaffer (Eds.), <em>Dermatology</em> (3rd ed., pp. 1187–1220). New York, NY: Saunders/Elsevier.</p>
<p>Mirmirani, P., &amp; Tucker, L. Y. (2013). Epidemiologic trends in pediatric tinea capitis: A population based study from Kaiser Permanente northern California. <em>Journal of the American Academy of Dermatology</em>, 69(6), 916–921.</p>
<p>Motaparthi, K., &amp; Hsu, S. (2013). Topical antibacterial agents. In S. Wolverton (Ed.), <em>Comprehensive dermatologic drug therapy</em> (3rd ed., pp. 445–459). New York, NY: Elsevier/Saunders.</p>
<p>Phillips, R. M., &amp; Rosen, T. (2013). Topical antifungals. In S. Wolverton (Ed.), <em>Comprehensive dermatologic drug therapy</em> (3rd ed., pp. 460–472). New York, NY: Elsevier/Saunders.</p>
<p>Pride, H. B., Tollefson, M., &amp; Silerman, R. (2013). What’s new in pediatric dermatology. <em>Journal of the American Academy of Dermatology</em>, 68(6), 889 e1–889 e11.</p>
<p>Reglinski, M., &amp; Sriskandan, S. (2014). The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis. <em>Virulence</em>, 5(1), 127–136.</p>
<p>Rich, P., Elewski, B., Scher, R. K., &amp; Parsier, D. (2013). Diagnosis, clinical implications and complications of onychomycosis. <em>Seminars in Cutaneous Medicine and Surgery</em>, 32(2 suppl 1), s5–s8.</p>
<p>Scher, R., Rich, P., Parsier, D., &amp; Elewski, B. (2013). The epidemiology, etiology, and pathophysiology of onychomycosis. <em>Seminars in Cutaneous Medicine and Surgery</em>, 32(2 suppl 1), s2–s4.</p>
<p>Sheth, P. B., &amp; Landis, M. N. (2013). Topical and intralesional antiviral agents. In S. Wolverton (Ed.), <em>Comprehensive dermatologic drug therapy</em> (3rd ed., pp. 473–480). New York, NY: Elsevier/Saunders.</p>
<p>Shimizu, T., &amp; Tokuda, Y. (2010). Necrotizing fasciitis. <em>Internal Medicine</em>, 49(12), 1051–1057.</p>
<p>Sterlin, J. C. (2010). Virus infections. In T. Burns, S. Breathnach, N. Cox, &amp; C. Griffiths (Eds.), <em>Rooks textbook of dermatology online</em> (8th ed., Chapter 33). West Sussex, UK: Wiley-Blackwell.</p>
<p>Susun, K., Michaels, B. D., Kim, G. K., &amp; Del Rosso, J. Q. (2013). Systemic antibacterial agents. In S. Wolverton (Ed.), <em>Comprehensive dermatologic drug therapy</em> (3rd ed., pp. 61–97). New York, NY: Elsevier/Saunders.</p>
<p>Tiwan, A. K., &amp; Lal, R. (2014). Study to evaluate the role of severity stratification of skin and soft tissue infection (SSTIs) in formulating treatment strategies and predicting poor prognostic factors. <em>International Journal of Surgery</em>, 12(2), 125–133. doi: 10.1016/j.ijsu.2013.11.014</p>
<p>Vena, G. A., Chieco, P., Garafalo, A., Bosca, A., &amp; Cassano, N. (2012). Epidemiology of dermatophytoses: Retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. <em>New Microbiologica</em>, 35(2), 207–213.</p>
<p>Verrier, J., Krahenbuhl, L., Bontems, O., Fratti, M., Salaman, K., &amp; Monod, M. (2012). Dermatophyte identification in skin and hair samples using a simple and reliable nested polymerase chain reaction assay. <em>British Journal of Dermatology</em>, 168(2), 295–301.</p>
<p>Walker, D. H. (2012). Rickettsial diseases. In J. L. Bolognia, J. L. Jorizzzo, &amp; J. O. Schaffer (Eds.), <em>Dermatology</em> (3rd ed., pp. 1243–1250). New York, NY: Saunders Elsevier.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>The infectious organism that causes impetigo is:</li>
</ol>
<p>a. <em>Staphylococcus aureus</em>
b. <em>Streptococcus</em>
c. <em>Enterobacter</em>
d. Both a and b
e. None of the above</p>
<ol start="2">
<li>Impetigo can spread via:</li>
</ol>
<p>a. Fingers
b. Towels</p>
<p>c. Clothing
d. All of the above</p>
<ol start="3">
<li>
<p>Diagnostic tests for a patient with a suspected cellulitis include a complete blood count demonstrating increased:
a. Neutrophils
b. Monocytes
c. Lymphocytes
d. Eosinophils</p>
</li>
<li>
<p>A superficial bacterial infection of the skin in an intertriginous area describes:
a. Ecthyma
b. Erythrasma
c. Erysipelas</p>
</li>
<li>
<p>Drug-induced folliculitis most commonly occurs with
a. Long-term use of oral cephalosporins
b. Use of phenytoin
c. Topical use of mupirocin
d. Topical use of corticosteroids</p>
</li>
<li>
<p>Which one of the following is the causative organism of meningococcemia?
a. Neisseria
b. Rickettsia
c. Spirochete
d. Streptococcus
e. None of the above</p>
</li>
<li>
<p>In staphylococcal scalded skin syndrome, Nikolsky sign will be:
a. Absent
b. Present</p>
</li>
<li>
<p>The most critical diagnostic sign for necrotizing fasciitis is:
a. Fever
b. Bradycardia
c. Presence of hemorrhagic bullae
d. Severe pain out of proportion to initial skin findings</p>
</li>
<li>
<p>Warts extend into the dermis.
a. True</p>
</li>
</ol>
<p>b. False</p>
<ol start="10">
<li>
<p>HPV subtypes associated with neoplasms include:
a. 3 and 10
b. 6 and 11
c. 16 and 18
d. 28 and 49</p>
</li>
<li>
<p>Appropriate treatment of varicella-zoster virus includes acyclovir:
a. 200 mg tid for 5 days
b. 400 mg tid for 5 days
c. 800 mg five times daily for 3 days
d. 800 mg five times daily for 7 days</p>
</li>
<li>
<p>Tinea manuum describes a tinea infection of the:
a. Groin
b. Feet
c. Hands
d. Nails</p>
</li>
<li>
<p>The most common organism causing tinea capitis in North America is:
a. Trichophyton tonsurans
b. Trichophyton schoenleinii
c. Microsporum canis</p>
</li>
<li>
<p>Prodromal symptoms of HSV infection include all of the following except:
a. Flu-like symptoms
b. Nausea
c. Paresthesias
d. Burning sensation</p>
</li>
<li>
<p>Factors that may reactivate herpes zoster include:
a. Immunosuppressive drugs
b. Fatigue
c. Stress
d. Smoking
e. a, b, and c
f. a, c, and d</p>
</li>
<li>
<p>All of the following are characteristics of dermatophyte infections except:</p>
</li>
</ol>
<p>a. Invades the skin and survives on dead keratin
b. Undergoes deep invasion
c. Cannot survive on mucosal surfaces</p>
<ol start="17">
<li>Factors contributing to fungal proliferation include all of the following except:</li>
</ol>
<p>a. Heat and humidity
b. Pregnancy
c. Corticosteroid therapy
d. Age
e. Malnutrition</p>
<ol start="18">
<li>Factors contributing to the formation of a furuncle include all of the following except:</li>
</ol>
<p>a. Friction
b. Hyperhidrosis
c. Nutritional status
d. Scratching
e. Pressure from restrictive clothing</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.d
2.d
3.a
4.b
5.d
6.a
7.b
8.d
9.b
10.c
11.d
12.c
13.a
14.b
15.e
16.b
17.d
18.c</p>
<p>CHAPTER 12</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bites-stings-and-infestations">Bites, Stings, and Infestations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bites-stings-and-infestations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Theresa Coyner • Katrina Nice Masterson</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="part-i-bites-and-stings">Part I: BITES AND STINGS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#part-i-bites-and-stings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>After studying Part I of this chapter, the reader will be able to:</p>
<ul>
<li>Identify the common manifestations of biting and stinging insects.</li>
<li>List appropriate avoidance behaviors that may reduce exposure to biting and stinging insects.</li>
<li>Describe common therapeutic interventions used to return the skin and tissues to preexposure condition.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Incidence of bites and stings can be greatly reduced by avoiding or utilizing protective behaviors when encountering the insects natural habitat.</li>
<li>Topical application of over-the-counter and household therapies will reduce much of the pain and discomfort of many bites and stings.</li>
<li>Careful hand washing and reduction of scratching will greatly lessen the chance of secondary infections after insect bites.</li>
<li>Prompt emergency treatment is indicated for some bites or stings and any anaphylactic reactions.</li>
<li>Patient and family education must include precautions to be used when sensitivity reactions are identified.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="phylum-arthropoda">PHYLUM ARTHROPODA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#phylum-arthropoda" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Humans come in frequent contact with varying numbers of more than one million varieties of insects that inhabit the planet. A limited number of these cause more than a fleeting annoyance or discomfort. Some insects inject venom into humans as a means of self-protection. Others use the human for a blood meal. Although almost everyone has experienced a bite or sting, only about  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>  of pediatric and  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span>  of adult population experiences an allergic reaction. Insects also transmit some diseases (Table 12-1).</p>
<p>TABLE 12-1 Potential Vector Diseases from Blood-Sucking Insects</p>
<table><thead><tr><th>Insect</th><th>Vector Diseases</th></tr></thead><tbody><tr><td>Flea</td><td>Plaque, typhus, tapeworms, filariasis, brucellosis, and melioidosis</td></tr><tr><td>Mosquito</td><td>Malaria, encephalitis, dengue, and yellow fever</td></tr><tr><td>Chigger</td><td>Rickettsial typhus, viral encephalitis, and pasteur- rella plaque</td></tr><tr><td>Bedbug</td><td>Oriental sore, Chagas disease, Kala-azar, relapsing fever, and perhaps hepatitis B. Note all of which are rare occurrences</td></tr><tr><td>Tick—specifically deer tick</td><td>Rocky Mountain spotted fever, Lyme disease, and relapsing fever</td></tr></tbody></table>
<p>A. Arachnida: a class of eight-legged insects that includes scorpions, spiders, ticks, and mites.</p>
<ol>
<li>Scorpion: Centruroides sculpturatus (Figure 12-1)</li>
</ol>
<p>a. Found in all continents except Antarctica. In North America, the scorpion is found in Mexico and southwestern states of the United States.
b. Obtaining a length of  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>9</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">9\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">9</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mtext>&nbsp;</mtext><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">20~\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span><span class="mspace nobreak">&nbsp;</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span> , it has a forebody, six projecting legs, large anterior claws (pedipolyps), and a hind body with a hooked caudal stinger which it uses to inject venom into its prey.
c. Major function is control of insect population.
d. Stings occur most frequently on the legs, thighs, and buttocks of its human victims, often the result of sitting or walking in the scorpion's territory.
e. Sting produces an immediate sharp burning sensation. Local edema soon surrounds the small puncture wound often followed by skin discoloration. Numbness may extend beyond the puncture site.
f. The only scorpion in the United States with enough venom to cause serious side effects is the bark scorpion found in the southwest desert. Its bite may produce hypersalivation, tachycardia, decreased blood pressure, peripheral motor symptoms, and severe agitation.
g. Children due to their size may have a more severe reaction. Debilitated or immunocompromised adults have increased risks of complications of bites. Scorpion bites in the United States rarely are associated with death.</p>
<ol start="2">
<li>Black widow spider: Latrodectus mactans (Figure 12-2)</li>
</ol>
<p>a. Found in the entire continental United States except Alaska.
b. The female is  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1.5\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span> , glossy black with the characteristic red hourglass on the underside of the abdomen. The male of the species is smaller with four pairs of red markings on the abdomen.
c. Diet consists of insects, centipedes, and other spiders. After mating, the female often ensnares and devours her mate from which she derives the name, black widow.
d. Often resides in yard debris and wood piles. The spider can also be found inside of homes. It is generally not aggressive. It will bite when threatened or when guarding an egg sac.</p>
<p>e. The bite feels like a pinprick and leaves a mildly erythematous 3- to 4-mm papule with a central punctum.</p>
<p>(1) The injected venom contains α-latrotoxin, which is a neurotoxin that produces massive presynaptic release of acetylcholine.</p>
<p>(2) Diaphoresis and hypertension may occur.</p>
<p>(3) Severe muscle spasms occur within 1 hour of the bite and may mimic myocardial infarction or an acute abdomen.</p>
<ol start="3">
<li>Brown recluse spider: <em>Loxosceles reclusa</em> (Figure 12-3)</li>
</ol>
<p>a. The highest concentration of spider population is found in Midwest and southern states of the United States.</p>
<p>b. The spider has a cephalothorax with a characteristic violin-shaped marking, joined to abdomen, and is light to medium brown in color. This violin-shaped marking is not unique to the brown recluse spider. The spider can be identified due to its six eyes as compared to other spiders having eight eyes (two eyes in front and two sets of eyes on the cephalothorax).</p>
<p>c. Spider prefers an insect diet.</p>
<p>d. Bites occur most frequently on the extremities of its victim (Figure 12-4).</p>
<p>(1) Bite may feel like a pinprick or not even noticed by the victim.</p>
<p>(2) A coagulotoxin is injected at the time of the bite.</p>
<p>(3) Pain develops 2 to 8 hours after the initial bite.</p>
<p>(4) Presentation is very unpredictable often with the presence of a gray-blue halo surrounding the puncture site within 24 hours.</p>
<p>(5) Early signs of necrosis include hyperesthesia, bullae, cyanosis, red-blue ulcer, and/or painful eschar.</p>
<p>(6) Systemic reactions (loxoscelism) can occur in some victims. This may vary from a mild flu-like presentation to anaphylactic shock. Symptoms caused by coagulotoxin may include deep vein thrombosis, pyoderma gangrenosum, intravascular hemolysis, renal failure, pulmonary edema, and cardiac arrhythmias.</p>
<ol start="4">
<li>Chigger (Figure 12-5)</li>
</ol>
<p>a. Present in most grain-growing regions of the United States. They are most prevalent in the south during the summer and fall. They may be known by many other names such as red bugs, jiggers, harvest mites, harvest lice, and harvest bugs.</p>
<p>b. A barely visible reddish colored mite, the larval stage of the chigger attaches to the skin of the host by means of a hooked mouthpart.</p>
<p>c. It ingests a blood meal while attached to the human host. The mite does not burrow and releases after engorgement.</p>
<p>d. Lesions occur most frequently after contact with infested hay or grains. The mite prefers an area where it can feed undisturbed, especially under constrictive clothing.</p>
<p>e. Pruritic macules or papules up to 5 mm in size are very common after the mite bite. If the individual is sensitized, the eruption may vary from urticarial to a more severe granulomatous reaction. Lesions slowly regress over 1 to 2 months.</p>
<ol start="5">
<li>Tick (Figures 12-6 and 12-7)</li>
</ol>
<p>a. Classification: Ixodidae—“hard tick” with hard-like shield with the head visible.</p>
<p>Argasidae—"soft tick" with leathery skin and the head hidden by the body of the tick.</p>
<p>b. This parasite is widespread, preferring thick vegetation or grasses on which to cling when not in contact with an animal or human host.</p>
<p>c. Most species have three stages in their 2-year life cycle. Larva stage usually hatches in the early spring. The nymph stage in which the tick is about the size of a poppy seed. The adult tick is about the size of an apple seed. Ticks only require one blood meal for each stage of its life cycle. Diseases can be transmitted from tick bites during any of their three life cycle stages.</p>
<p>d. The tick has four pairs of clawed legs and a specialized mouthpart used for grasping and slicing a hole in its victim to enable the tick to suck blood. Blood meals are generally provided by small rodents (mice) in the larva stage. Larger mammals (deer and humans) provide the blood meals for the nymph and adult ticks.</p>
<p>e. Ticks will attach to any exposed skin and often travels under clothing or around body parts until they reach a constricted area. When the tick attaches to the victim, it emits a cement-like substance to help keep the tick adhered to the host.</p>
<p>f. Rocky Mountain spotted fever (RMSF; Figure 12-8) is a rickettsia disease transmitted to humans after the bite of a deer or dog tick (Box 12-1).</p>
<p>g. Lyme disease (Figure 12-9) is a spirochete Borrelia burgdorferi infection transmitted to humans generally by the bite of a deer tick (Box 12-2).</p>
<p>B. Insecta: class of six-legged insects, many with wings, which includes bees, wasps, and ants. Hymenoptera is a superorder of the class of insects containing wings. Hymenoptera can cause severe hypersensitivity reactions (Box 12-3).</p>
<ol>
<li>Bumblebee</li>
</ol>
<p>a. Largest of the Hymenoptera, the bumblebee is found throughout the United States and is better adapted to cold regions than other bees.</p>
<p>b. The bumblebee is hairy and usually a black and yellow coloration.</p>
<p>c. The bee is responsible for pollination of a wide variety of plants.</p>
<p>d. Generally not aggressive, often stings when its victim disturbs it while walking in patches of clover.</p>
<p>e. The bee produces one painful, stabbing defensive sting into its victim that may leave behind a barbed stinger. The sting injects formic acid and proteins into its victim. The venom sac is attached to the stinger and will continue to contract and inject additional venom if it is not removed.</p>
<p>f. The skin lesion is an erythematous papule, which becomes urticarial and edematous. It may remain painful for hours.</p>
<ol start="2">
<li>Honeybee</li>
</ol>
<p>a. Found in all of the United States, the honeybee is found in any area with flowers and fruit.</p>
<p>b. Smaller and somewhat similar in appearance to the bumblebee. It is generally yellow, brown, or gray in color. It measures 1 to 1.5 cm in length.</p>
<p>c. Very important to pollination, the honeybee is generally not aggressive, unless it perceives a threat.</p>
<p>(1) Since experiments in Brazil sought to cross the native honeybee with an African</p>
<p>cousin, a much more aggressive bee has developed.</p>
<p>(2) The Africanized honeybee migrated into the United States in the early 1990s.
(3) This aggressive bee is capable of chasing a fleeing victim for up to one quarter of a mile.
(4) The sting of this bee is no more venomous than the native honeybee.</p>
<p>d. If the entire hive is disturbed, a swarm of insects may attack, stinging any body surface. The honeybee may leave a barbed stinger with a venom sac that may continue to inject venom.</p>
<p>e. The sting produces an edematous erythematous papule.</p>
<ol start="3">
<li>Wasp</li>
</ol>
<p>a. The paper wasp lives in communities, while the mud dauber, potter wasp, and digger wasp are solitary.
b. The wasp has a smooth body that ranges in color from mahogany to black. It ranges from 2 to 5 cm in length. The wasp legs hang down from the body when it flies.
c. The diet consists of other insects and vegetable matter. Some species are pollinators of crops.
d. Like other members of Hymenoptera, wasps sting when disturbed or threatened.
e. Produces a similar lesion to other stings, the venom of all wasps contains histamines and a factor that dissolves red blood cells.</p>
<ol start="4">
<li>Yellow jacket</li>
</ol>
<p>a. A member of the wasp family, closely related to the hornet, and widely distributed throughout the United States.
b. Named for its characteristic yellow markings, it is hairless and has three sets of legs and two sets of wings. It measures 1 to 1.5 cm in length.
c. The diet consists chiefly of insects and rotting fruit.
d. Stings may be inflicted on any body part when the nest or individual yellow jacket is disturbed.
e. Sting is similar to that of the honeybee.
f. Nests are generally underground or close to the ground and may contain thousands of yellow jackets.</p>
<ol start="5">
<li>Hornet (Figure 12-10)</li>
</ol>
<p>a. A member of the wasp family, the hornet, may be found in unique football-shaped nests made of papery material comprising of masticated plant foliage and wood suspended from a tree limb. The hornet's habitat is more evident in the northern United States.
b. The hornet is about 3 cm in length and is generally white faced with black and white markings on its segments.
c. The diet consists largely of other insects and ripe fruit.
d. The hornet stings to protect its environment and is likely to swarm if the nest is disturbed, whether by accident or intentionally.
e. The sting produces a painful, edematous papule.</p>
<ol start="6">
<li>Ant (Figure 12-11)</li>
</ol>
<p>a. The wingless member of the order Hymenoptera; the imported fire ant (IFA) is the species most frequently involved in painful stings and allergic reactions. Introduced</p>
<p>into the United States from South America; it is prevalent in most of the south.</p>
<p>b. Ants are generally 2 to 5 mm in length, colors varying from tan, red to black. The IFAs live in large colonies, often producing large mounds of dirt or sand especially noticeable after rains.</p>
<p>c. The ant serves a useful purpose as an aerator and mixer of soil. Most species are omnivorous. The IFA can be dangerous to young or injured livestock as well as humans.</p>
<p>d. Walking, gardening, and sitting in the habitat of the ant may result in one or more stings. Multiple stings, with the increased venom load, increase the risk of systemic reaction for small children and debilitated adults.</p>
<p>e. IFA stings create erythematous sterile pustules with high levels of neutrophils. The sterile pustules result from piperidine venom alkaloids.</p>
<ol start="7">
<li>Flea (Figure 12-12)</li>
</ol>
<p>a. A member of the order of Siphonaptera, fleas can be found all over the world with cat and dog fleas causing the highest proportion of infestation in households. Human fleas are rare in the United States.</p>
<p>b. Wingless, and with three pairs of legs, fleas can jump distances out of proportion to their size.</p>
<p>c. Fleas require a blood meal for survival. However, they can live up to a year without contact with humans or pets.</p>
<p>d. Bites occur most frequently about the ankle of the human but may be scattered in any area as the flea attempts to hide from lights.</p>
<p>e. The bite produces an erythematous papule that may progress to a wheal or blister. Bites may be intensely itchy.</p>
<ol start="8">
<li>Sandfly</li>
</ol>
<p>a. Sandfly is a colloquial name for the genus of flying biting dipteran. There are many types of dipterans that may be extremely small to as large as a horsefly. The female bites to obtain a blood meal of which the protein is necessary to form her eggs. The sandfly discussed in this section is the type responsible for development of leishmaniasis.</p>
<p>b. The sandfly consists of four legs and two wings with a proboscis.</p>
<p>c. The organism that causes leishmaniasis is a protozoa. It exists in two forms: the promastigote and the amastigote. The organism multiplies in the promastigote form in the gut of the sandfly. It then migrates to the proboscis. When the sandfly bites a mammal host, it transforms to the amastigote form.</p>
<p>d. Types of leishmaniasis include the cutaneous form restricted to the skin, the mucocutaneous form that affects both skin and mucosal surfaces, and visceral leishmaniasis that affects organs of the reticuloendothelial system.</p>
<p>e. Cutaneous leishmaniasis occurs primarily in the Mediterranean basin, Middle Eastern countries, North Africa, India, and parts of Central and Southern Americas. In the United States, cutaneous forms of leishmaniasis are found in individuals who have traveled to countries where leishmaniasis is endemic or in military personnel who have served terms of duty in the Middle East.</p>
<p>f. Cutaneous leishmaniasis starts as a small papule that may enlarge into a nodule or plaque. The area further develops into an ulcerated or verrucous lesion with rolled borders. Lesions may be solitary or multiple on exposed skin sites (Figure 12-13).</p>
<ol start="9">
<li>Mosquito</li>
</ol>
<p>a. A member of the order Diptera, the mosquito inhabits most of the world where there is sufficient water to permit the hatching phase.
b. A two-winged, narrow insect with long, slender legs.
c. The male feeds on nectar, but the female uses her specialized mouthparts to pierce the skin and inject saliva, which inhibits clotting, permitting her to ingest blood. Infectious organisms may be transferred during feeding.
d. The mosquito will attack any uncovered skin and is able to pierce lightweight clothing.
e. The bite forms an urticarial papule with intense itching that may begin within 10 minutes and last for days.</p>
<ol start="10">
<li>Bedbug</li>
</ol>
<p>a. A member of the order Hemiptera, the bedbug (Figure 12-14) is often far less common than most other insects in the United States. There has been a recent insurgence of bedbugs thought to be due to increase in international travel. Cimex lectularius is the bedbug found in tropical climates. Cimex hemipterus is the bedbug found in temperate climates.
b. The bedbug is 2 to 5 mm in length, slightly ovoid and flattened, and brown in color. It resembles an apple seed in appearance.
c. Blood meals are required every 3 to 5 days as the bug progresses through its multistage development. The adult bedbug can live up to 1 year without a blood meal.
d. The bedbug pierces the skin with specialized stylets, ingesting blood and dissolved epidermal tissue before releasing. They only feed at night as they hide from bright lights. The victim is rarely aware of the initial bite as the bedbug releases a local anesthetic when biting.
e. Lesions may occur on any exposed body surface. There is generally a pattern of three linear bites often labeled as "breakfast, lunch, and dinner." The stylets leave behind two red marks that become pruritic papules several minutes after the bite. Depending on the sensitivity of the victim, wheals, vesicles, or hemorrhagic bullae may develop. More severe symptoms including anaphylactic reactions may occur.</p>
<p><img src="assets/images/image-20251225-3255beca.jpeg" alt="img-49.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="chiggers-mosquitoes-and-sandflies">Chiggers, Mosquitoes, and Sandflies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#chiggers-mosquitoes-and-sandflies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>The addition of 1 to 2 teaspoons of chlorine bleach to bathwater before possible exposure may reduce natural body odors that attract the female mosquito.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-12-1-rocky-mountain-spotted-fever-rmsf">BOX 12-1. Rocky Mountain Spotted Fever (RMSF)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-12-1-rocky-mountain-spotted-fever-rmsf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RMSF (Figure 12-8) is an infectious disease spread to humans by the bite of a deer or dog tick. Severe headache and fever generally appears after a 2- to 16-day incubation period following transfer of the organism <em>Rickettsia rickettsii</em> from the tick. Generally, a tick must be attached to the human host over 24 hours to transmit the infection. However, there are rare cases where the organism can be transmitted in as little as 6 to 8 hours of tick attachment.</p>
<p>The rickettsia are intracellular gram-negative rods that invade endothelial cells. Eighty percentage of victims will have severe headache and fever. A morbilliform rash will start on palms and soles and progresses to a petechial rash on extremities that spreads to the trunk. Myalgias and nausea and vomiting may occur. Children are more commonly affected but fatalities more likely in the elderly.</p>
<p>Diagnosis is made upon clinical presentation, and appropriate antibiotic therapy should be started immediately. Doxycycline is the medication of choice for all nonpregnant individuals despite age. Chloramphenicol is the drug of choice during pregnancy. Use of antibiotic other than doxycycline has an increased risk of death.</p>
<p>Diagnostic tests with highest degree of sensitivity are the indirect immunofluorescence assay (IFA) with rickettsia antigen. An initial serum sample is obtained immediately upon suspicion of RMSF and repeated in 2 to 4 weeks. A fourfold increase is a definitive diagnosis. IgG is negative initially and then will raise in 2 to 4 weeks. IgM starts to elevate in 2 to 4 weeks and may stay elevated for months to years after the tick bite.</p>
<p>RMSF was originally identified in the early 1900s in the Copper Mountain valley in Montana. RMSF cases have occurred throughout the United States with majority of cases occurring in Arkansas, Oklahoma, Tennessee, North Carolina, and South Carolina. Most cases occur during the months of April through September. Prevention is aimed at control of tick populations, avoidance behaviors, and early tick removal.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-12-2-lyme-disease">BOX 12-2. Lyme Disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-12-2-lyme-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Lyme disease (Figure 12-9) is caused by the transfer of the spirochete <em>Borrelia burgdorferi</em> to humans by feeding of the deer tick, <em>Ixodes dammini</em>, and certain other tick species. The tick is capable of transmitting the disease during any of its stages of development when it varies from poppy seed to sesame seed size. The risk of transmission from an infected attached tick is 0% if less than 24 hours, 12% if 48 hours, 79% in 72 hours, and 94% at 96 hours. The characteristic rash, erythema migrans (EM), occurs in about 60% of patients within 3 days to 4 weeks of the tick bite. The classical presentation is a large circular to oval rash with central clearing (bull’s eye). The lesion may enlarge up to 5 cm in size with</p>
<p>an irregular margin of erythema surrounding the bite. Satellite lesions may occur with the spread of the lesion. Flu-like symptoms, fever, chills, and myalgias may be present. Administration of doxycycline or amoxicillin at this stage is over 90% effective in curing the condition.</p>
<p>Borrelial lymphocytosis, a bluish-red nodule appearing on either a nipple or an earlobe, is another type of Lyme disease lesion that may rarely occur.</p>
<p>Untreated Lyme disease may eventually develop to chronic or late-stage disease. This condition is characterized by musculoskeletal arthritic changes. Usually, this will be effusion of a large joint. Central nervous symptoms such as lymphocytic meningitis and cranial nerve palsies may also occur. Heart symptoms may include conductive problems such as AV blocks.</p>
<p>Atrophic chronic acrodermatitis (ACA) is a late cutaneous finding in chronic Lyme disease. It is characterized by erythematous to bluish-red discoloration with hyperpigmentation on the lower extremities. Untreated ACA can progress to the atrophic phase where the lower extremity skin is thin with dilated veins.</p>
<p>High-dose penicillin or cephalosporins may be required for treating arthritis or meningitis.</p>
<p>Lyme disease is primarily a clinical diagnosis. If symptoms present less than 30 days, an IgG and Western blot is recommended. If symptoms present greater than 30 days, perform the IgM and the Western blot.</p>
<p>Prevention is aimed at control of tick populations, avoidance behaviors, and early tick removal.</p>
<p><img src="assets/images/image-20251225-f56476f3.jpeg" alt="img-50.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ticks">Ticks<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ticks" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Meticulous search should be done for ticks on the skin after seeing a tick anywhere.</p>
</li>
<li>
<p>Light-colored clothing increases the visibility of ticks upon clothing.</p>
</li>
<li>
<p>Clothing sprayed with permethrin may be helpful.</p>
</li>
<li>
<p>Tick removal.</p>
</li>
<li>
<p>Do not use petroleum jelly, nail polish, and a burnt match as these methods will cause more harm.</p>
</li>
<li>
<p>Do not use bare hands to remove ticks.</p>
</li>
<li>
<p>Do not compress the body of the tick as it may increase secretion of potentially infectious material.</p>
</li>
<li>
<p>Use tweezers to grasp the tick as close to the skin as possible and pull steadily away from the skin. Avoid a twisting motion.</p>
</li>
<li>
<p>An alternative technique is to tie a thread tightly around the tick’s head as close to the skin as possible and use steady traction to pull away from the skin.</p>
</li>
<li>
<p>Another technique is use of a plastic spoon or a plastic card with a “V” cut out of the center. Slide the “V” under the tick and use steady traction to lift the tick away from the skin.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="box-12-3-hypersensitivity-reactions-to-hymenoptera-venom">BOX 12-3. Hypersensitivity Reactions to Hymenoptera Venom<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-12-3-hypersensitivity-reactions-to-hymenoptera-venom" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypersensitivity reactions affect about 5% of the population. Hymenoptera venom from insect stings can cause an immediate type 1 hypersensitivity reaction. This is allergy mediated where a free antigen cross-links to the IgE on mast cells and basophils, which cause release of vasoactive biomolecules. The reaction can be mild causing a localized erythematous wheal at the site of the sting, which may have symptoms of pruritus to pain and localized edema.</p>
<p>IgE will be elevated for several weeks in 20% of adults after following a sting, but generally, this will be asymptomatic.</p>
<p>Type IV hypersensitivity reactions may occur, which is a cell-mediated immune memory response. At least one prior sting is necessary to develop this sensitivity reaction. Sensitivity is more likely to occur with multiple, simultaneous stings. With subsequent stings, mast cell and basophil degranulation occurs resulting in histamine release and inflammatory mediators. Antihistamines may be effective in mild cases. Severe reactions may range from pruritus, flushing, urticaria, and angioedema. Respiratory involvement can include cough and shortness of breath. Cardiovascular involvement may include dizziness, hypotension, decreased consciousness, bradycardia, and arrhythmias. Epinephrine will be needed to treat severe reactions.</p>
<p>The single best predictor of the outcome of a future sting is still the history of reaction to a prior sting. Individuals with an elevated baseline tryptase level above 11.4 ng/mL have a higher incidence of underlying mast cell disorder and may be at higher risk for severe reactions. Individuals with prior severe reactions should be prescribed an epinephrine autoinjector to have available for the possibility of reactions to future stings. They also should be referred to allergy/immunology for evaluation of possible venom immunotherapy (VIT).</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bees-wasps-and-hornets">Bees, Wasps, and Hornets<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bees-wasps-and-hornets" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Perfumes and bright-colored and rough-textured clothing are attractive to bees.</li>
<li>Beehives and hornets' nests should not be disturbed. Professional exterminators should be contacted for removal.</li>
</ul>
<p><img src="assets/images/image-20251225-dfe72c52.jpeg" alt="img-51.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ants">Ants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>One can observe for characteristic mounds of sand or soil.</li>
<li>Sandboxes should be checked prior to play sessions for presence of ants.</li>
<li>Closed-toe footwear will decrease the incidence of ant bites.</li>
<li>Brushing away ants from the skin with a firm article, such as a credit card, will reduce the likelihood of retaining the ant's head in the skin.</li>
</ul>
<p><img src="assets/images/image-20251225-977ff092.jpeg" alt="img-52.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fleas">Fleas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fleas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Treatment of pets and other animals will decrease and possibly eliminate fleas and their eggs.</li>
</ul>
<p><img src="assets/images/image-20251225-5f23cc1a.jpeg" alt="img-53.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="bedbugs">Bedbugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bedbugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>When bedbugs are seen, thorough vacuuming behind baseboards, in cracks and crevices, and behind peeling wallpaper may be helpful.</li>
<li>Bedbugs can be transported in luggage and clothing.</li>
<li>Professional exterminators will be needed to eradicate bedbugs.</li>
<li>Infested mattresses should be disposed.</li>
</ul>
<p><img src="assets/images/image-20251225-03c33ef8.jpeg" alt="img-54.jpeg">
FIGURE 12-1. Scorpion: <em>Centruroides sculpturatus</em>. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-c4fc4163.jpeg" alt="img-55.jpeg">
FIGURE 12-2. Black widow spiders: Latrodectus mactans. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-c8e8da91.jpeg" alt="img-56.jpeg"></p>
<p><img src="assets/images/image-20251225-e01ae86a.jpeg" alt="img-57.jpeg">
FIGURE 12-3. Brown recluse spider: Loxosceles reclusa. (Courtesy of John K. Randall, MD.)
FIGURE 12-4. Brown recluse spider bite on the left lateral thigh. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-9c368bfc.jpeg" alt="img-58.jpeg">
FIGURE 12-5. Chigger bites on the lower legs and ankles. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-acd329b2.jpeg" alt="img-59.jpeg">
FIGURE 12-6. Tick: Ixodidae on the plantar surface toe. (Courtesy of John K. Randall, MD.)</p>
<p><img src="assets/images/image-20251225-b39389b3.jpeg" alt="img-60.jpeg">
FIGURE 12-7. Tick bite with inflammation. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-96b1159a.jpeg" alt="img-61.jpeg">
FIGURE 12-8. Rocky Mountain spotted fever rash on the hand and arm. (From Harvey, R. A., &amp; Cornelissen, C. N. (2012). Microbiology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-06be1e6b.jpeg" alt="img-62.jpeg">
FIGURE 12-9. Lyme disease; erythema migrans. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-451b734f.jpeg" alt="img-63.jpeg">
FIGURE 12-10. Hornet. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-3a0af08a.jpeg" alt="img-64.jpeg">
FIGURE 12-11. Fire ant bite on the thumb. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-df1a4bd2.jpeg" alt="img-65.jpeg">
FIGURE 12-12. Flea bites on freckled skin. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-0fea5915.jpeg" alt="img-66.jpeg">
FIGURE 12-13. Cutaneous leishmaniasis. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-c59ace4b.jpeg" alt="img-67.jpeg">
FIGURE 12-14. Bedbugs: Cimex hemipterus. (Image provided by Stedman's.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History and physical examination</p>
<ol>
<li>History of exposure or potential exposure to insect.</li>
<li>Presence of one or more lesions with characteristic appearance.</li>
<li>Distribution of lesions consistent with biting or stinging habits of insects.</li>
<li>Hypertension, tachycardia, and respiratory distress noted with scorpion sting, especially with the presence of hypersalivation.</li>
<li>Presence of severe muscle pain or spasms associated with black widow spider bite.</li>
<li>Presence of necrosis with brown recluse spider bite.</li>
<li>Presence of headache and fever after tick bite.</li>
<li>Arthralgia, weakness, and confusion may indicate delayed hypersensitivity reaction.</li>
<li>Expressions of feeling of doom may indicate onset of anaphylaxis.</li>
</ol>
<p>B. Diagnostic tests</p>
<ol>
<li>Generally not indicated unless required to follow course of disease or with specific envenomation.</li>
<li>Oxygen saturation may be required with anaphylaxis.</li>
<li>Leukocytosis and elevated creatine phosphokinase may be present with the bite of a black widow spider.</li>
<li>Hemoglobinemia, thrombocytopenia, and hemoglobinuria may result with envenomation of the brown recluse spider.</li>
<li>Positive blood cultures may indicate secondary bacterial infection from any bite, often present with deep tissue necrosis of brown recluse spider bite.</li>
<li>About 4 to 6 weeks after the bite of a tick, the ELISA test can be performed. If ELISA is positive or equivocal, the more sensitive Western blot should be performed. IgM will be elevated in 2 to 4 weeks after infectious tick bite. IgG will be elevated in 6 weeks.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-treatment-modalities">III. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-local-treatment">A. Local treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-local-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>The bites of many insects can be rendered less painful and itching reduced by applying cold compresses.</li>
<li>Applying topical antihistamine lotions or systemic antihistamines may reduce the urge to scratch.</li>
<li>Topical 1% hydrocortisone may reduce inflammation and pruritus. It is contraindicated with any open areas of skin.</li>
<li>Elevation of the affected extremity may reduce edema.</li>
<li>Anti-infective topical may reduce incidence of secondary infections when the skin is broken.</li>
<li>Keeping the hands and skin clean and trimming nails reduces the risk of secondary infections when the skin integrity is lost.</li>
<li>Crotamiton may be helpful in reducing the itch as it has antipruritic properties.</li>
<li>Application of a counter irritant such as dilute ammonium solution may decrease itching.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-treatments-specific-to-envenomation">B. Treatments specific to envenomation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-treatments-specific-to-envenomation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>Scorpion
a. Treat symptoms of severe agitation, peripheral motor jerking, and hypersalivation as needed.
b. Be prepared to support respiration.
c. Anascorp, an antivenom, may be used to reduce symptoms.</li>
<li>Black widow spider
a. Intravenous benzodiazepines to reduce muscle spasms.
b. Narcotics for pain.
c. Equine antivenom may be considered up to 48 hours after the bite. Use only if severe pain persists after standard treatment. One ampule diluted in 100 mL of normal saline infused 1 mL/minute over first 15 minutes. Then remainder is infused over 2 to 3 hours. Serum sickness can be a complication.</li>
<li>Brown recluse spider</li>
</ol>
<p>a. Overaggressive bite management may cause more harm than good.
b. Tissue necrosis may be treated with dapsone 100 mg/day for 14 days. A G6PD level should be checked prior to administration.
c. Surgical intervention should be avoided for the first 21 days as toxin remains biologically active in tissues during this time. Generally, surgical intervention should be delayed for 6 to 8 weeks allowing the lesion to stabilize.
d. After tissue destruction has stopped, skin flaps may be required to repair the defect.</p>
<ol start="4">
<li>
<p>Leishmaniasis
a. Pentavalent antimalarials should be used. Sodium stibogluconate 20 mg/kg/d for 20 days. Meglumine antimoniate 20 mg/kg/d for 20 days.</p>
</li>
<li>
<p>Rocky Mountain spotted fever
a. Adults and children over 45 kg: doxycycline 100 mg bid for 7 to 14 days or at least 3 days after fever subsides.
b. Children under 45 kg: doxycycline 2.2 mg/kg/d given bid for 7 to 14 days or at least 3 days after fever subsides.
c. Doxycycline should be given despite concern about staining of teeth in children. Use of alternate antibiotics may result in an increased risk of death from the condition.
d. Pregnant women should receive intravenous chloramphenicol sodium succinate 50 to 75 mg/kg/d divided into qid dosing.</p>
</li>
<li>
<p>Lyme disease
a. Adults: doxycycline 100 mg bid × 21 days, amoxicillin 500 mg tid × 21 days, and cefuroxime 500 mg bid × 21 days.
b. Children: amoxicillin 50 mg/kg/d × 14 to 21 days and cefuroxime 30 mg/kg/d × 14 to 21 days.</p>
</li>
</ol>
<p><img src="assets/images/image-20251225-dccfb75c.jpeg" alt="img-68.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general-information-about-bites-and-stings">General Information about Bites and Stings<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-information-about-bites-and-stings" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Bites and stings are avoided by being aware of their natural habitat and use precaution.</p>
</li>
<li>
<p>Food and drinks should be covered when eating outdoors.</p>
</li>
<li>
<p>Hats and long pants are to be worn and long pants are tucked into socks.</p>
</li>
<li>
<p>Application of diethyltoluamide (DEET) to exposed skin may provide protection against mosquitoes, ticks, fleas, chiggers, leeches, and many other biting insects. Concentrations of 10% up to 50% are recommended.</p>
</li>
<li>
<p>DEET in concentration of 10% may be applied to children older than 2 months of age, taking caution to avoid the lips and the hands. One must not use DEET in areas that may cause inadvertent introduction into the mouth. DEET is safe to use in pregnancy during the second and third trimesters.</p>
</li>
<li>
<p>Concentrations greater than 50% have minimal additional benefit and have a higher probability of increased skin absorption. Regular use should be discussed with the patient's health care providers.</p>
</li>
</ul>
<p>PART II: INFESTATION WITH ECTOPARASITES, SCABIES AND LICE</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>After studying Part II of this chapter, the reader will be able to:</p>
<ul>
<li>Identify the causative ectoparasite in scabies and lice infestations.</li>
<li>List the most common treatments and cautions for treating infestations.</li>
<li>List environmental and fomite treatments, which prevent reinfestation.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>All cases of very pruritic rashes with intense nighttime itching should raise the suspicion of scabies infestation. Calm acceptance of the patient diagnosed with scabies or lice will help the family deal with the social stigma and promote attention to treatment plans. Schools and institutions often require complete nit removal before child can reenter the school even when pediculicides are effective. Parent education should include methods of eradicating scabies and lice from the home environment to prevent reinfestation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="scabies">SCABIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scabies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The common itch mite, Sarcoptes scabiei (Figure 12-15), is responsible for a great deal of misery in every inhabited area of the globe. It is no respecter of social or economic class, sex, gender, age, or standard of personal hygiene.</p>
<p><img src="assets/images/image-20251225-c0fb6eb4.jpeg" alt="img-69.jpeg">
FIGURE 12-15. Scabies mite: Sarcoptes scabiei. (Courtesy of John K. Randall, MD.)</p>
<p>A. Ectoparasite: Sarcoptes scabiei</p>
<ol>
<li>The mature female mite is about  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">0.5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span>  in diameter.</li>
<li>Only the female mite burrows into the skin.</li>
<li>Mites from animals can feed on humans but do not burrow or reproduce in humans.</li>
</ol>
<p>B. Reproduction</p>
<ol>
<li>Reproduction takes place on the skin of the host.</li>
<li>The female is impregnated by the male who then dies.</li>
<li>The impregnated female penetrates the skin by producing a secretion that lyses the stratum corneum. This process takes about 45 minutes.</li>
<li>The mature female mite lays up to 4 eggs each day during her 30-day life span. Less than  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>  of the eggs develop into mature mites.</li>
<li>The embryo hatches in 3 to 10 days producing a six-legged larva.</li>
<li>The larva goes through two additional shedding stages, finally producing an eight-legged nymph that matures into the adult mite.</li>
<li>Both the larva and the nymph can survive and mature outside of the host.</li>
</ol>
<p>C. Infestation</p>
<ol>
<li>Occurs only in close physical contact with a host already infested with the mite or may be</li>
</ol>
<p>transmitted by fomites such as clothing and bed linen.</p>
<ol start="2">
<li>The mite pushes through the corneocytes into the stratum granulosum.</li>
<li>The motion of the mite is always forward at a rate of 0.5 to 5 mm/day producing an externally visible burrow on the skin of the host.</li>
<li>The burrow may be 5 to 20 mm long, straight, or serpentine in appearance.</li>
</ol>
<p>D. Immune response (Box 12-4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-12-4-immune-response">BOX 12-4. Immune Response<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-12-4-immune-response" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Immune response is caused by soluble antigen produced when the saliva, body secretions, and feces of the mite come in contact with cellular fluid.</p>
<p>Immune response develops over 4 to 6 weeks with first infestation of the mite.</p>
<p>During the latent period, the mite multiplies.</p>
<p>When the normal allergic response begins, many mites die.</p>
<p>Inflammatory response develops.</p>
<p>In the immunocompromised individual, the mite continues to multiply unchecked. This superinfestation is commonly called Norwegian or crusted scabies. Up to a million mites may be present with crusted scabies. Nails may become thickened with white scaly subungual debris.</p>
<p>With the presence of the antigen, future infestations result in pruritus within 24 hours to several days. Past infestation does not confer future immunity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination (Figure 12-16)</p>
<ol>
<li>Very pruritic eruption with increased intensity or symptoms at night.</li>
<li>Family members and household contacts with similar rash and itching.</li>
<li>Presence of papules, pustules, and vesicles.</li>
<li>Presence of a thread-like linear or serpentine-shaped gray-brown or pearly burrow less than 1 mm in width.</li>
<li>Lesions tend to be concentrated in the web spaces of the fingers around the wrists, axillae, breasts, areolae, waist, thighs, lower buttocks, and genitalia.</li>
<li>In infants and children, the lesion may be nodular and present over the back and on the head.</li>
<li>Nodular lesions may be present in the groin or axillae in adults.</li>
<li>Lesions in the immunocompromised patient may present with disseminated papular eruption and extensive hyperkeratotic lesions and fissuring, especially on flexor surfaces.</li>
</ol>
<p>B. Diagnostic tests</p>
<ol>
<li>Mineral oil prep.</li>
</ol>
<p>a. Scabies prep using a scalpel blade (premoistened with mineral oil) to scrape a</p>
<p>suspected burrow and placing the material on a slide with mineral oil.</p>
<p>b. Examining the material under the microscope with low magnification.
c. Presence of the scabies mite, ova, or fecal pellets (scybala) is diagnostic of scabies.</p>
<ol start="2">
<li>Burrow ink test (BIT).</li>
</ol>
<p>a. Use of a pen or nonpermanent marker to identify a suspected burrow.
b. After penetration, the excess ink is removed with an alcohol wipe.
c. A mineral oil prep is performed as above.</p>
<ol start="3">
<li>
<p>Potassium hydroxide (KOH) is generally not used. It will dissolve the keratin but may also dissolve mite pellets.</p>
</li>
<li>
<p>Failure to find mites with scraping can be common and does not rule out a scabies diagnosis.</p>
</li>
<li>
<p>Biopsy.</p>
</li>
</ol>
<p>a. Seldom used except when lesions are atypical. Scabies mineral oil prep is much more reliable diagnostic test.
b. Biopsy will demonstrate the presence of eosinophils.</p>
<ol start="6">
<li>Blood tests.</li>
</ol>
<p>a. IgE elevated, IgA decreased in crusted scabies.
b. IgE antibody against recombinant scabies antigen has 100% sensitivity and 93.75% specificity.
c. Eosinophilia in crusted scabies.</p>
<p>C. Differential diagnosis</p>
<ol>
<li>Unless proven otherwise, all pruritic rashes should raise the suspicion of scabies.</li>
<li>Atopic, contact dermatitis, dermatitis herpetiformis, and neurodermatitis may have similar excoriated lesions.</li>
</ol>
<p><img src="assets/images/image-20251225-e7505585.jpeg" alt="img-70.jpeg">
FIGURE 12-16. Scabies rash on the palm. (From Werner, R. (2012). Massage therapist's guide to pathology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-treatment-modalities">III. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-medication">A. Medication<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-medication" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Permethrin  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  cream. Acts upon the cell membrane by disabling the sodium transport and decreases polarization of cell membrane. This causes paralysis of the mite.</li>
<li>Applied at night massaged into the skin of adults and children from the neck down and washed off in the morning. Generally recommended to repeat in 1 week.</li>
<li>Permethrin  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  cream applied from head to toe in infants over 2 months of age and washed off in the morning.</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span>  to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span>  sulfur for pregnant or lactating females and infants under 2 months. Applied nightly for 3 nights and washed off in the morning.</li>
<li>Gamma benzene hexachlorine. This is an organochlorine insecticide that inhibits neurotransmission, which induces respiratory and muscular paralysis in mites.</li>
</ol>
<p>a. When used properly, it has minimal toxicity but has been associated with seizures and death of an infant.
b. Distributed throughout the body, slowly metabolized, and stored in fatty tissues and in</p>
<p>the brain.</p>
<p>c. Carries black box warning. It is contraindicated in pregnancy and lactation, and in infants.
d. 30 mL is the adequate treatment amount for an adult. Apply to the skin at night and wash off in the morning. Second applications should be avoided to reduce chance of neurotoxicity.</p>
<ol start="6">
<li>Crotamiton 10% cream or lotion. This is used to apply to the skin from the neck down at night for 2 to 5 consecutive nights then washed off each AM. Crotamiton is one of the least effective of the current scabies medications. It does though have antipruritic properties and is helpful in some people for this action. Pregnancy category C.</li>
<li>Ivermectin. This is available in 3-mg tablets. It acts by binding glutamate-gated chloride ion channels. This creates increased permeability of chloride ions causing hyperpolarization of nerve cells causing death of the mite. It is frequently used to treat scabies, but this use is an off-label indication.</li>
</ol>
<p>a. Dose is 200 µg/kg in a single dose repeated in 7 to 10 days.
b. Pregnancy category C. Manufacturer states that it is not recommended in pregnancy and in children less than 15 kg of weight.</p>
<ol start="8">
<li>Low-dose topical or systemic steroids or oral antihistamines may be needed for treating continued pruritus even after mites have been eradicated.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iv-complications">IV. COMPLICATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Intense scratching in response to pruritus may result in secondary bacterial infections.</p>
<ol>
<li>
<p>Antibiotics may be necessary to treat bacterial infections.
B. In the immunocompromised host, the lack of cell-mediated response permits the mite to multiply unchecked.</p>
</li>
<li>
<p>Hyperkeratotic plaques may form with fissuring.</p>
</li>
<li>
<p>Normal skin flora then has a portal of entry into the bloodstream.</p>
</li>
<li>
<p>Once in the bloodstream, normal skin flora may develop into bacteremia, sepsis, and potentially death.</p>
</li>
<li>
<p>If the normal cell-mediated response does not limit the number of mites, huge numbers may tunnel in and around the fingernails promoting the spread of the mite to other body areas or caretakers.</p>
</li>
<li>
<p>The hyperkeratosis, fissuring, and numbers of mites make eradication difficult. Appropriate treatment may include alternating permethrin 5% cream and oral ivermectin.</p>
</li>
</ol>
<p>PATIENT EDUCATION</p>
<p>Scabies</p>
<ul>
<li>The itching caused by the mite will persist for weeks even after eradication of the mites.</li>
<li>Fingernails should be kept short to avoid traumatizing the skin when scratching.</li>
<li>All household contacts and sexual contacts should be treated at the same time.</li>
<li>Clothing and linen should be changed after overnight or recommended treatment time.</li>
<li>Clothing is to be washed with hot water wash and dried in hot dryers.</li>
<li>All nonwashable surfaces are to be vacuumed and then seal and dispose of vacuum bag.</li>
<li>Fabric articles that cannot be washed or dry cleaned may be encased in plastic for several weeks to avoid reinfestation.</li>
<li>Medications: topicals should be thoroughly massaged into body crevices (axillae and groin) as well as under fingernails.</li>
<li>Ivermectin is better absorbed with high-fat meal.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pediculosis">PEDICULOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pediculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Two species of the order Anoplura (Figures 12-17 and 12-18) infest human beings. The louse, which is visible to the naked eye, is endemic to all areas of the globe and is likely responsible or well over 10 million cases of infestation in the United States each year. Although the head louse may be found in all social and economic levels, the body louse and pubic louse are far more prevalent in those with crowded living conditions and uncertain hygiene.</p>
<p><img src="assets/images/image-20251225-8ef2f886.jpeg" alt="img-71.jpeg">
FIGURE 12-17. Pediculosis nit on hair. (Courtesy of Charles E. Lewis, MD.)</p>
<p><img src="assets/images/image-20251225-2736dd29.jpeg" alt="img-72.jpeg">
FIGURE 12-18. Pediculosis louse. (Courtesy of John K. Randall, MD.)</p>
<p>A. Ectoparasite: Pediculus humanus</p>
<ol>
<li>Subspecies Pediculus humanus corporis or body louse</li>
<li>Subspecies Pediculus humanus capitis or head louse</li>
</ol>
<p>B. Ectoparasite: Phthirus pubis</p>
<ol>
<li>Commonly called the crab louse</li>
<li>Infests predominately the pubic hairs and other body hair with similar diameter</li>
</ol>
<p>C. Reproduction</p>
<ol>
<li>All three types of lice undergo five developmental stages.</li>
</ol>
<p>a. The egg or oviposit, which hatches in 5 to 10 days in response to body heat.
b. Three nymphal stages, which depend on blood meal for survival, develop over the next 8 or 9 days.
c. The adult louse is capable of mating within hours of reaching the adult stage.</p>
<ol start="2">
<li>
<p>The adult louse produces 6 to 10 eggs a day and may lay up to 300 eggs during its life span.</p>
</li>
<li>
<p>All require blood meals for survival although they may live off a host for a period of 10 to 30 days if conditions of temperature and humidity are met.</p>
</li>
</ol>
<p>D. Infestation</p>
<ol>
<li>
<p>P. humanus capitis attaches its oviposit or nit on scalp hair close to the skin.</p>
</li>
<li>
<p>P. humanus corporis attaches its oviposit on fabric fibers, particularly the seams of clothing.</p>
</li>
<li>
<p>Phthirus pubis attaches its oviposit on hairs at the skin line of the pubic region, the beard, the eyebrows, the eyelashes, and the axillae.</p>
</li>
</ol>
<p>E. Lesions</p>
<ol>
<li>
<p>The head louse produces pruritic red papules above the shoulders, often with dark red spots visible on the neck and shoulders from fecal droppings.</p>
</li>
<li>
<p>The body louse produces an urticarial papule. With extensive infestation, the skin may become dry and scaly with the development of hyperpigmented areas.</p>
</li>
<li>
<p>Pubic lice often produce gray-blue areas called macula cerulea over the trunk and thighs.</p>
</li>
</ol>
<p>F. Immune response (Box 12-4)</p>
<ol>
<li>
<p>Develops from saliva injected into the skin when the louse prepares to feed.</p>
</li>
<li>
<p>The saliva prevents blood from clotting while feeding occurs.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and physical examination</p>
<ol>
<li>
<p>Presence of pruritus, often worse at night</p>
</li>
<li>
<p>Lackluster hair and presence of cervical adenopathy and purulent dermatitis with heavy or prolonged infestation by the head louse</p>
</li>
<li>
<p>Presence of urticarial papules, dry and scaly skin with body louse infestation</p>
</li>
<li>
<p>Presence of macules over the thighs and trunk with infestation by the pubic louse</p>
</li>
<li>
<p>Evidence of louse on the body or in the clothing on close inspection</p>
</li>
</ol>
<p>a. Presence of fecal droppings in the seams of clothing</p>
<ol start="6">
<li>Presence of the nit on the hair shaft with head and pubic lice</li>
</ol>
<p>a. The position of the nit from the skin surface is indicative of the time since attachment, moving with the growing hair.</p>
<p>b. Nits spread at multiple intervals along the hair shaft indicate prolonged or repeated infestations.</p>
<p>c. Egg casing distant from the scalp is empty or contains killed ova.</p>
<p>B. Diagnostic tests</p>
<ol>
<li>
<p>Visualization of the louse on the skin or clothing, presence of oviposits.</p>
</li>
<li>
<p>Wood light will cause fluorescence of hair infested with head lice.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-treatment-modalities">III. TREATMENT MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-treatment-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Medication for head lice</p>
<ol>
<li>1% permethrin lotion and 5% permethrin cream.</li>
</ol>
<p>a. Lotion is allowed to remain on the hair for 10 minutes followed by rinse and towel drying with a clean towel.
b. Cream is allowed to remain on hair overnight followed by rinse and towel drying with a clean towel. Provides protection from reinfestation for 2 weeks.</p>
<ol start="2">
<li>Malathion 0.5% lotion compounded in isopropyl alcohol 78% and terpineol 12%.</li>
</ol>
<p>a. Weak organophosphate that inhibits acetylcholinesterase resulting in neuromuscular paralysis. The alcohol and terpineol have ovidical and pediculicidal actions to help increase effectiveness.
b. Similar products were brought to the market prior to 1999 and were removed due to concerns about prolonged application times and flammability issues. They were later reintroduced into the market due to concerns about increases of resistance to other products.
c. Application to dry hair. Wait 8 to 12 hours and then shampoo. Note—postmarketing studies have demonstrated that 20-minute application time is effective.
d. Pregnancy category B.</p>
<ol start="3">
<li>Spinosad 0.9% topical.</li>
</ol>
<p>a. Action is by excitation of motor neurons resulting in muscle contractions, paralysis, and eventual death of the louse.
b. Applied to dry hair for 10 minutes. Rinse out and towel dry.
c. Pregnancy category B.</p>
<ol start="4">
<li>Benzyl benzoate 5% lotion.</li>
</ol>
<p>a. Dosage varies according to the length of hair. Ranges from 4 to 6 ounces for hair less than 2 inches in length and up to 32 to 48 ounces for hair longer than 22 inches.
b. May be used in children over 6 months of age.
c. Applied to dry hair every 7 days × 2 doses.
d. Pregnancy category B.</p>
<ol start="5">
<li>Gamma benzene hexachloride 1% shampoo may be used for treatment. 1% lotion may be used for body lice.</li>
</ol>
<p>a. Treatment is often less effective than with permethrin.
b. Apply to wet hair, 15 to 30 mL for short hair, 45 mL for medium length, and up to 60 mL for very long hair.
c. Allow to remain on the hair for 4 minutes before adding water to work up a lather.
d. Thoroughly rinse and towel dry.
e. To reduce chance of excess absorption, wear gloves while applying, avoid getting shampoo on other body parts, and do not apply any occlusive cover.
f. May require one repeat treatment in 7 to 10 days.</p>
<ol start="6">
<li>Pyrethrin may be used for any type of pediculosis infestation.</li>
</ol>
<p>a. Available over the counter, this product is less effective than other pediculicides.
b. Apply and wash off after 10 minutes.
c. High potential for misuse due to lack of understanding of the treatment schedule.
d. Chemically related to chrysanthemums and may cause hypersensitivity reactions in some individuals.</p>
<p>e. Pregnancy category C.</p>
<ol start="7">
<li>Ivermectin 0.5% lotion. May be used in adults and children over 6 months of age.
a. Apply to dry hair for 10 minutes, then rinse.</li>
<li>Permethrin 5% cream may be used on the body. Apply at night and wash off in the morning. May also be used on the scalp if prior treatment to 1% permethrin has been ineffective.</li>
<li>Petrolatum may be applied to eyelashes 2 to 3 times a day to aid in removing lice and nits.</li>
</ol>
<p>B. Removal of nits</p>
<ol>
<li>Meticulous combing of hair with a special nit comb to remove all nits. Hair should be separated into sections and combed repetitively with nit comb to remove the nits.</li>
<li>Shaving the hair will also remove the nits, but this is generally not acceptable to most individuals.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-complications">IV. Complications<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-complications" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Complications are rare except in debilitated individuals with secondary infections.
B. Potential for some vector diseases.</p>
<p><img src="assets/images/image-20251225-8db37a6e.jpeg" alt="img-73.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="pediculosis">Pediculosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pediculosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>All head coverings such as scarves and caps must be dry cleaned or washed in hot water.</li>
<li>Combs, brushes, curlers, and hair clips and bows should be washed in hot water.</li>
<li>Clothing worn by those with heavy body louse infestation may need the additional precaution of ironing seams as this is the attachment area for oviposits.</li>
<li>All bedding, towels, and worn clothing should be washed in hot water and dried in hot dryer.</li>
<li>Parents must be instructed about the necessity of thoroughly combing the hair with nit combs. Additionally, it must be reinforced that inspection should be carried out at regular intervals to reduce the possibility of reinfestation.</li>
<li>Pubic lice in young or adolescent children may indicate sexual activity.</li>
<li>All infested family members must be treated at the same time.</li>
<li>Hair conditioners should not be used prior to treatments for lice as the hair conditioner prohibits the treatments from adhering to the hair follicles.</li>
<li>Resistance to medications is being reported, but many instances of resistance are due to lack of adherence, incorrect treatment, lack of ovidical or killing properties of the</li>
</ul>
<p>medication, and reinfestation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Anderson, R. J., Campoli J., Johar, S. K., Schumacher, K. A., &amp; Allison, E. J. (2011). Suspected brown recluse envenomation: A case report and review of different treatment modalities. Journal of Emergency Medicine, 41(2), e31–e37.</p>
<p>Ayoub, N., Maatouk, I., Merhy, M., &amp; Tomb, R. (2012). Treatment of pediculosis capitis with topical albendazole. Journal of Dermatological Treatment, 23, 78–80.</p>
<p>Barnes, E. R. &amp; Murray, B. S. (2013). Bedbugs: What nurses need to know. American Journal of Nursing, 133(3), 58–62.</p>
<p>Bernardeschi, C., Le Cleach, L., Delaunay, P., &amp; Chosidow, O. (2013). Bedbug infestation. British Medical Journal, 346(f138), 1–8, doi: 10.1136/bmj</p>
<p>Biesiada, G. (2010). Lyme disease: Review. Archives of Medical Science, 8(6), 978–982.</p>
<p>Bouvresse D. R., Berdjane, Z., Izri, A., Chosidow, O., &amp; Clark, J. M. (2012). Insecticide resistance to head lice: Clinical, parasitological, and genetic aspects. Clinical Microbiology and Infection, 18, 338–344.</p>
<p>Burkhart, C. N., Burkhart, C. G. &amp; Morrell S. D. (2012). Infestations. In J. L. Bolognia, J. L. Jorrizzo &amp; J. O. Schaffer (Eds.), Dermatology (3rd ed., pp. 1423–1434). New York: Saunders Elsevier.</p>
<p>Burns, D. A. (2010). Diseases caused by arthropods and other noxious animals. In T. Burns, S. Breathnach, N. Cox, &amp; C. Griffiths (Eds.), <em>Rooks Textbook of Dermatology Online</em> (Chapter 38). (8th ed.). West Sussex, United Kingdom: Wiley-Blackburn.</p>
<p>Cole, S. W. &amp; Lundquist, L. M. (2011). Spinosad for treatment of head lice infestation. Annals of Pharmacology, 45, 954–958.</p>
<p>Dana, A. N. (2009). Diagnosis and treatment of tick infestation and tick-borne diseases with cutaneous manifestations. Dermatologic Therapy, 22, 293–326.</p>
<p>Drees, B. M., Calixto, A. P., &amp; Nester, P. R. (2013). Integrated pest management concepts for red imported fire ants Solenopsis invicta (Hymenoptera: Formicidae). Insect Science, 20, 429–438.</p>
<p>Elston, D. M. (2010). Tick bites and skin rashes Current Opinion in Infectious Diseases, 23, 132–138.</p>
<p>Elston, D. M. (2012). Bites and stings. In J. L. Bolognia, J. L. Jorrizzo &amp; J. O. Schaffer (Eds.), Dermatology (3rd ed., pp. 1435–1454). New York: Saunders Elsevier.</p>
<p>Elston, D. M. (2013). Systemic antiparisitic agents. In S. Wolverton (Ed.), Comprehensive Dermatology Drug Therapy (3rd ed., pp. 135–142). New York: Saunders/Elsevier.</p>
<p>Goddard, J. &amp; Edwards, K. T. (2013). Effects of bed bug saliva on human skin. Journal of the American Medical Association Dermatology, 149(3), 372–373.</p>
<p>Golden, D. B. K. (2013). Advances in diagnosis and management of insect sting allergy. Annals of Allergy, Asthma, and Immunology. 111, 84–89.</p>
<p>Goldust, M., Rezaee, E., Raghifar, R., &amp; Naghavi-Behzad, M. (2013). Ivermectin vs. lindane in the treatment of scabies. Annals of Parasitology, 59(1), 37–41.</p>
<p>Goldust, M., Rezaee, E., Raghifa, R., &amp; Hemayat, S. (2013). Treatment of scabies: The topical ivermectin vs. permethrin 2.5% cream. Annals of Parasitology, 59(2), 79–84.</p>
<p>Gullan, P. J. &amp; Cranston, P. (Eds). (2010). External anatomy. An outline of entomology (4th ed., pp. 23–52). Hoboken, New Jersey: Wiley.</p>
<p>Hahlholm, D. (2013). Stinging insect allergy. Advance for NP's and PA's. 4(4), 19–22.</p>
<p>Hubbard, J. J. &amp; James, L. P. (2011). Complications and outcomes of brown recluse spider bites in children. Clinical Pediatrics. 50(3), 252–258.</p>
<p>Juckett, G. (2013). Arthropod bites. American Family Physician, 88(12), 841–847.</p>
<p>Krishnan, S. S. &amp; Lockshen, B. N. (2013). Topical antiparasitic agents. In S. Wolverton (Ed.), Comprehensive Dermatologic Drug Therapy (3rd ed., pp. 481–486). New York: Elsevier Saunders.</p>
<p>Lane, L., McCoppin, H. H., &amp; Dyer, J. (2011). Acute generalized exanthematous pustulosis and comb-positive hemolytic anemia in a child following loxosceles reclusa envenomation. <em>Pediatric Dermatology</em>, 28(6), 685–688.</p>
<p>Losher, D. (2009). A brown recluse spider bite. Dermatology Nursing, 21(6), 360–361.</p>
<p>McDade, J., Aygun, B., &amp; Ware, R. E. (2010). Brown recluse spider (loxosceles reclusa) envenomation leading to acute hemolytic anemia in six adolescents. The Journal of Pediatrics, 156, 155–157.</p>
<p>Overstreet, M. L. (2013). Tick bites and Lyme disease: The need for timely treatment. Critical Care Nursing Clinics of North America, 25(2), 165–172.</p>
<p>Roupakias, S. Mitsakous, P., &amp; Al Nimer, A. (2011). Tick removal. Journal of Prevention Medicine and Hygiene, 52(1), 40–44.</p>
<p>Rudders, S. A., Clark, S., Wei, W., &amp; Camargo, C. A. (2013). Longitudinal study of 954 patients with stinging insect anaphylaxis. <em>Annals of Allergy, Asthma, and Immunology</em>, 111, 199–204.</p>
<p>Shimose, L., &amp; Munoz-Price, L. S. (2013). Diagnosis, prevention, and treatment of scabies. <em>Current Infectious Disease Reports</em>, 15, 426–431.</p>
<p>Stanek, G., Wormser, G. P., Gray, J., &amp; Strle, F. (2012). Lyme borreliosis. <em>The Lancet</em>, 349, 460–473.</p>
<p>Smith, G. N., Gemmill, I., &amp; Moore, K. M. (2012). Management of tick bites and Lyme disease during pregnancy. <em>Journal of Obstetrics and Gynecology Canada</em>, 34(11), 1087–1091.</p>
<p>Vinson, S. B. (2013). Impact of the invasion of the imported fire ant. <em>Insect Science</em>, 20, 439–455.</p>
<p>Walton, S. F. &amp; Oprescu, F. L. (2013). Immunology of scabies and translational outcomes: Identifying the missing links. <em>Current Opinion in Infectious Disease</em>, 26(2), 116–120.</p>
<p>Yavuz, S. T. (2013). Importance of serum basal tryptase levels in children with insect venom allergy. <em>Allergy</em>, 6, 386–391.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions-part-i">STUDY QUESTIONS: PART I<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions-part-i" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>The clinic triage nurse answers a call from a mother stating that her 4-year-old son has been stung by a bee. She asks what she should do to relieve the pain and itching. Appropriate advice to this parent regarding application of first aid includes which of the following?</li>
</ol>
<p>a. DEET to prevent further stings
b. Cold compresses on the sting area
c. Bacitracin ointment on the sting area
d. Mud compresses to "pull out the poison"</p>
<ol start="2">
<li>The vesicles caused by the imported fire ant contain:</li>
</ol>
<p>a. Coagulotoxin
b. Neurotoxin
c. Purulent material from an infection
d. Sterile material with many neutrophils</p>
<ol start="3">
<li>Mr. Barnard presents to a dermatology office reporting a new lesion. The lesion is located on his calf and resembles a 5-cm "bull's eye" with central clearing. You suspect this patient might have:</li>
</ol>
<p>a. Lyme disease
b. Rocky Mountain spotted fever
c. An isolated chigger bite, which has become infected
d. The bite of a mosquito carrying St. Louis encephalitis</p>
<ol start="4">
<li>One of the most critical questions to ask Mr. Barnard when obtaining his history is with regard to:</li>
</ol>
<p>a. Family history of similar lesions
b. Presence of pain in his extremity
c. Exposure to a possible tick bite
d. Recent history of nausea</p>
<ol start="5">
<li>Treatment of Mr. Barnard's condition should include:</li>
</ol>
<p>a. Local antibiotics and steroids for the skin lesion
b. Oral doxycycline for 21 days
c. Intravenous chloramphenicol
d. Symptomatic treatment only if fever occurs</p>
<ol start="6">
<li>A patient presents with a grayish-blue halo surrounding a central puncture on her right thigh. The area is slightly edematous and painful. She remembers feeling a mild stinging sensation on her thigh upon awakening the day prior to his visit. You suspect which of the following?</li>
</ol>
<p>a. Scorpion sting
b. Black widow spider bite
c. Brown recluse spider bite
d. Sting from a member of the Hymenoptera family</p>
<ol start="7">
<li>A patient presents to the emergency department reporting agonizing muscle spasms after a bite. You suspect which of the following?</li>
</ol>
<p>a. Scorpion sting
b. Black widow spider bite
c. Brown recluse spider bite
d. Yellow jacket sting</p>
<ol start="8">
<li>Appropriate treatment for the patient with the muscle spasms includes which of the following?</li>
</ol>
<p>a. High-volume infusion of normal saline
b. Intravenous benzodiazepines
c. Narcotics
d. Nitrates</p>
<ol start="9">
<li>Effective methods to remove an attached tick include which of the following?</li>
</ol>
<p>a. Burn it with a hot match.
b. Apply petroleum jelly over the tick.
c. Grasp the tick with tweezers close to the skin and pull upward.
d. All of the above.</p>
<ol start="10">
<li>The initial rash associated with Rocky Mountain spotted fever is a morbilliform pattern located on the:</li>
</ol>
<p>a. Palms and soles
b. Trunk
c. Neck
d. Face</p>
<ol start="11">
<li>The most reliable predictor of a severe allergic reaction to a future Hymenoptera sting is:</li>
</ol>
<p>a. Elevated IgG level</p>
<p>b. Elevated IgM level
c. Low serum tryptase level
d. History of reaction to a previous sting</p>
<ol start="12">
<li>Loxoscelism is a term used to describe the systemic effects caused by which of the following?</li>
</ol>
<p>a. Brown recluse spider bite
b. Rocky Mountain spotted fever
c. Sting from a Hymenoptera insect
d. Fire ant stings</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions-part-i">Answers to Study Questions Part I<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions-part-i" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.b
2.d
3.a
4.c
5.b
6.c
7.b
8.b
9.c
10.a
11.d
12.a</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions-part-ii">Study Questions: Part II<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions-part-ii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>
<p>Which one of the following patients would be most at risk for developing crusted Norwegian scabies?
a. A 4-year-old Carrie, who shares a bed with her 6-year-old sister who was just diagnosed with scabies
b. A 54-year-old Ben, who has poorly controlled type 1 diabetes
c. A 84-year-old Ed, who takes cyclosporine daily since undergoing renal transplantation
d. A 65-year-old Bonnie, who was recently diagnosed with a thyroid disorder</p>
</li>
<li>
<p>A mother calls the office stating that the permethrin given 4 days ago for her son is not working, as he is still miserable with itching. An appropriate reply to this parent includes which of the following?
a. Itching will persist up to 1 month past treating due to the allergic reaction from the scabies saliva.
b. Her son has probably been reinfected with the scabies mite.
c. Her son needs a different medication.
d. She probably did not clean all of the bedding properly.</p>
</li>
<li>
<p>Patient education after a diagnosis of scabies includes which of the following statements?
a. All household contacts should be treated simultaneously.
b. All bedding should be washed with hot soapy water and dried in a very hot dryer.
c. Topical medication should be applied from the neck down in adults, taking care to work the medication under the fingernails and skin crevices.
d. Keep fingernails cut short to avoid traumatizing the skin if scratching.
e. All of the above.</p>
</li>
<li>
<p>Sara presents to the dermatology office reporting that her eyes are irritated. Upon close examination, lice are noted on her eyelashes. Appropriate treatment for this condition will be which of the following?
a. Permethrin 5% lotion applied very carefully to the eyelashes to avoid accidental eye exposure
b. Petroleum jelly applied to the eyelashes three times daily for 7 to 14 days
c. Oral ivermectin
d. Over-the-counter pyrethrin lotion applied one time for 10 minutes and then rinsed</p>
</li>
<li>
<p>The drug that has been documented to cause seizure disorders in some children is:</p>
</li>
</ol>
<p>a. Pyrethrin.
b. Permethrin.
c. Lindane.
d. Ivermectin.</p>
<ol start="6">
<li>Which of the following statements to explain the rationale for repeated application of a topical antilouse agent is true?</li>
</ol>
<p>a. Some of the medications are not ovidical and will need the second treatment for nits that hatch after the first treatment.
b. Patients may not comb out all of the nits.
c. There is a high degree of resistance to the available medications.
d. All of the above.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions-part-ii">Answers to Study Questions Part II<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions-part-ii" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.c
2.a
3.e
4.b
5.c
6.d</p>
<p>CHAPTER 13</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="dermatologic-conditions-in-children">Dermatologic Conditions in Children<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatologic-conditions-in-children" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Emily Croce • Meghan O’Neill</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>Recognize the skin conditions commonly seen in the pediatric population, including a variety of transient cutaneous conditions in newborns, miliaria, oral candidiasis, ichthyosis, and hemangiomas.</li>
<li>Describe the factors that may precipitate or contribute to these pediatric skin disorders.</li>
<li>Discuss the therapeutic interventions frequently used in these pediatric dermatology conditions.</li>
<li>Identify the important patient teaching issues for these pediatric skin disorders.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Many skin conditions in newborns are transient, self-limiting problems that do not require intervention other than to provide reassurance to parents.</li>
<li>Genetic skin disorders may present lifelong problems for affected individuals.</li>
<li>Transient, self-limiting problems that generally do not require intervention other than to provide reassurance to parents include acne neonatorum, acropustulosis of infancy, erythema toxicum neonatorum, harlequin color change, cutis marmorata, sebaceous gland hyperplasia, subcutaneous fat necrosis (if small affected area), sucking blisters, and transient pustular melanosis.</li>
<li>Miliaria crystallina (self-limited), miliaria rubra (common prickly heat), and miliaria profunda (found in patients who have had several bouts of miliaria rubra) are all sweat-retention diseases related to heat exposure. Miliaria crystallina and rubra are the most common forms seen in the neonatal period. Oral candidiasis, also known as oral thrush, is an infection of the oropharyngeal cavity with Candida albicans, a yeast commonly seen in the infant period.</li>
<li>Ichthyosis, which means “fish scale,” is a broad category of dermatologic conditions involving varying presentations of excessive scaling of the skin. Major hereditary types,</li>
</ul>
<p>which have been described, include two autosomal recessive congenital ichthyoses (epidermal ichthyosis and lamellar ichthyosis types), ichthyosis vulgaris, and X-linked ichthyosis. Several other, rarer forms exist but are not covered in this chapter.</p>
<ul>
<li>Hemangiomas of infancy are common, benign, vascular tumors comprised of endothelial cells. They may be isolated, small, and uncomplicated or may lead to significant cosmetic and/or medical complications and require intervention.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="transient-cutaneous-conditions-in-the-newborn">TRANSIENT CUTANEOUS CONDITIONS IN THE NEWBORN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transient-cutaneous-conditions-in-the-newborn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: transient skin conditions that appear and disappear during the first few days to weeks or months of life.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-epidemiology">II. EPIDEMIOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-epidemiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Many infants will experience one or more of these conditions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-etiology-and-pathogenesis">III. ETIOLOGY AND PATHOGENESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-etiology-and-pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Infant skin differs from adult skin in that it seems to reflect bodily changes more readily.</p>
<p>B. These conditions are related to one or several of the following influences:</p>
<ol>
<li>Events occurring during birth</li>
<li>Immaturity of various physiologic systems</li>
<li>Influence of maternal hormones</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-assessment">IV. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>Acne neonatorum (neonatal acne or neonatal cephalic pustulosis) (Figure 13-1)</li>
</ol>
<p>a. Presents as multiple, discrete, inflammatory papules and/or pustules on the face, particularly on the cheeks. Occasionally, lesions are also present on the chest, back, and/or groin.</p>
<p>b. Not considered a true form of acne vulgaris, which also presents with comedones and larger, inflammatory papules</p>
<p>c. Appears at 2 to 4 weeks of age and may persist for up to 6 months of age. Present in 20% of infants</p>
<p>d. Thought to be the result of transient, benign increases of circulating androgens in the newborn. Also potentially related to an inflammatory reaction to <em>Pityrosporum</em> (Malassezia) species</p>
<p>e. A careful history must be obtained to determine whether other virilizing features are present, such as axillary/pubic hair and/or body odor. If present, the child must be referred to a pediatric endocrinologist for further workup.</p>
<ol start="2">
<li>Acropustulosis of infancy (Figure 13-2)</li>
</ol>
<p>a. Presents as pustules or vesicles on the palms and soles in recurrent crops and rapidly become pruritic
b. Pruritus in the neonate may present as an irritable, fretful child.
c. Lesions may recur every 2 to 4 weeks until 2 to 3 years of age.
d. Sometimes mistaken for scabies infestation
e. Etiology is unknown.</p>
<ol start="3">
<li>Erythema toxicum neonatorum (Figure 13-3)</li>
</ol>
<p>a. A central, 1 to 3 mm, yellowish papule or pustule with a 1 to 3 cm, irregular, macular flare.
b. Present at 24 to 72 hours of age in approximately half of term infants and typically clear in 4 to 7 days
c. Lesions are typically seen on the face, may spread to the torso and extremities, and can be seen anywhere except for the palms and soles.
d. Etiology is unknown.</p>
<ol start="4">
<li>Harlequin color change</li>
</ol>
<p>a. Occurs in approximately 10% of healthy infants when placed on one side. Also associated with low birth weight/preterm birth. The gravity-dependent skin develops an erythematous flush, with a simultaneous blanching of the upper side.
b. A distinct line of demarcation runs along the midline of the body.
c. Usually subsides within a few seconds of placing the baby in the supine position but may persist up to 30 minutes
d. Attributed to the immaturity of autonomic vasomotor control. May last up to approximately 3 weeks of age</p>
<ol start="5">
<li>Milia (Figure 13-4)</li>
</ol>
<p>a. Small retention cysts
b. One- to two-millimeter pearly white or yellow papules, most commonly on the nose, cheeks, chin, and forehead. Occasionally occur on the torso/extremities
c. May also occur on the oral mucosa, particularly the palate. These are called Epstein pearls.
d. Occurs in 40% to 50% of newborns
e. Usually resolve spontaneously in the first 3 to 4 weeks of life
f. Milia that are in a widespread or unusual distribution that persist may be associated with other genetic conditions.</p>
<ol start="6">
<li>Cutis marmorata (Figure 13-5)</li>
</ol>
<p>a. A physiologic reaction to cold in the newborn with the development of blanching, bluish, reticulated mottling of the skin on the trunk and extremities. Vasoconstriction may also lead to blue hands, feet, and lips, known as acrocyanosis.
b. Caused by constricted capillaries and venules. Disappears on rewarming
c. Thought to be caused by immaturity of the autonomic control of skin vascular plexus.</p>
<p>More common in preterm infants</p>
<p>d. Mottling that persists beyond the 6 months of life may be a sign of cutis marmorata telangiectatica congenita, a genetic skin condition that may have additional implications.</p>
<ol start="7">
<li>Sebaceous gland hyperplasia</li>
</ol>
<p>a. Follicular, evenly spaced, yellow-white papules where sebaceous gland density is greatest, typically around the nose and upper lip
b. Differs from milia, which are usually solitary, more discrete, and whiter
c. Occurs in 21% to 48% of infants.
d. Resolves by 4 to 6 months.
e. Hypertrophy of sebaceous glands thought to be the result of maternal and/or fetal stimulation of adrenal glands.</p>
<ol start="8">
<li>Subcutaneous fat necrosis (Figure 13-6)</li>
</ol>
<p>a. Sharply circumscribed, indurated, reddish or purple nodules and/or plaques in apparently healthy full-term newborns and young infants. Most commonly on cheeks, back, buttocks, arms, and thighs
b. Appears within the first 2 weeks of life and resolves over several weeks to months
c. May heal with atrophy, leaving a skin depression
d. Extensive subcutaneous fat necrosis can be associated with significant hypercalcemia.
e. Etiology is unknown. May be related to hypothermia, trauma, asphyxia, or hypercalcemia</p>
<ol start="9">
<li>Sucking blister (Figure 13-7)</li>
</ol>
<p>a. Solitary, intact blister or erosion on noninflamed skin of the fingers, dorsum of the dominant hand or wrist, or upper lip
b. Results from vigorous sucking in the prenatal period
c. Resolves within a few days</p>
<ol start="10">
<li>Transient pustular melanosis (Figure 13-8)</li>
</ol>
<p>a. Presents at birth as vesicles, pustules, or pigmented macules with a collarette of scale
b. Seen in less than 1% of newborns. More commonly seen in infants with darker pigment
c. Pustular lesions typically resolve within 23 to 48 hours, with resultant hyperpigmentation fading over several weeks to months.
d. Cause is unknown.</p>
<p>B. Diagnostic tests</p>
<ol>
<li>Diagnosis is generally made by the lesions' clinical features.</li>
<li>Occasionally, a gram stain or Tzanck preparation may be used to rule out infectious causes.</li>
<li>In general, due to the benign nature of these conditions, additional diagnostic studies usually are not required.</li>
<li>Extensive subcutaneous fat necrosis may warrant a biopsy and serum calcium levels.</li>
</ol>
<p><img src="assets/images/image-20251225-0d78cfe4.jpeg" alt="img-74.jpeg">
FIGURE 13-1. Neonatal acne (benign cephalic pustulosis) with multiple uniform red papules. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-7e2929d5.jpeg" alt="img-75.jpeg">
FIGURE 13-2. Scattered papules and pustules on the dorsum of the foot in acropustulosis of infancy. (From Lugo-Somolinos, A., et al. (2011). VisualDx: Essential dermatology in pigmented skin. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-cc0c7e42.jpeg" alt="img-76.jpeg">
FIGURE 13-3. Erythema toxicum neonatorum showing the usual pattern, with most of the lesions on the trunk and face and fewer on the extremities. (From Fletcher, M. A. (1998). Physical diagnosis in neonatology. Philadelphia, PA: Lippincott-Raven Publishers.)</p>
<p><img src="assets/images/image-20251225-f1fd9790.jpeg" alt="img-77.jpeg"></p>
<p>FIGURE 13-4. Milia. (From Jensen, S. (2010). Nursing health assessment. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-4af0b083.jpeg" alt="img-78.jpeg"></p>
<p>FIGURE 13-5. Cutis marmorata in a 2-month-old baby. (From Salimpour, R. R., Salimpour, P., &amp; Salimpour, P. (2013). Photographic atlas of pediatric disorders and diagnosis. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-0a650c2c.jpeg" alt="img-79.jpeg"></p>
<p><img src="assets/images/image-20251225-f1c4e91b.jpeg" alt="img-80.jpeg">
FIGURE 13-6. Subcutaneous fat necrosis of the newborn. (Image provided by Stedman's.)
FIGURE 13-7. Sucking blister. The lesion on the left hand of this newborn is the result of sucking that occurred in utero.(Courtesy of Denise A. Salerno, MD, FAAP.)</p>
<p><img src="assets/images/image-20251225-d380d543.jpeg" alt="img-81.jpeg">
FIGURE 13-8. Transient neonatal pustular melanosis. (Courtesy of Paul S. Matz, MD.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-nursing-considerations-table-13-1">V. NURSING CONSIDERATIONS (TABLE 13-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-nursing-considerations-table-13-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-interventions">A. Interventions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-interventions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Maintain an adequate fluid balance and nutrition in the infant.</li>
<li>Instruct and demonstrate appropriate skin care techniques that will keep the skin clean, moisturized, and protected.</li>
<li>The majority of these conditions resolve spontaneously and do not require treatment.</li>
</ol>
<p>a. In acne neonatorum, most cases require no treatment. For severe and persistent comedonal lesions, azelaic acid  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>  cream or the mildest topical retinoid preparations may be considered with close follow-up. Mild inflammatory lesions may be treated with ketoconazole cream. For inflammatory severe and persistent lesions,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span>  erythromycin,  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span>  clindamycin, or  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2.5\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2.5%</span></span></span></span></span>  benzoyl peroxide may be considered with close follow-up. Systemic therapy is avoided when possible, though scarring acne may warrant treatment with oral antibiotics, such as erythromycin.
b. If acropustulosis of infancy is symptomatic, oral sedating antihistamines (0.6 mg/kg/dose every 4 to 8 hours) may provide relief of itching and may be used in older infants. Potent topical steroids may also be used sparingly for severe cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-follow-up">B. Follow-up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Follow-up is only necessary if the condition worsens or parents have additional</li>
</ol>
<p>questions.</p>
<p>TABLE 13-1 Nursing Care of Children with Skin Disorders</p>
<table><thead><tr><th>Nursing Considerations</th><th>Goals</th><th>Expected Outcomes</th></tr></thead><tbody><tr><td>Impaired skin integrity related to: Environmental agents Somatic factors</td><td>Promote healing. Eradicate source of skin injury.</td><td>Affected area displays signs of healing. Avoids precipitating agents</td></tr><tr><td>Potential impaired skin integrity related to: Mechanical trauma Body secretions Infection susceptibility Allergenic factors</td><td>Maintain skin integrity. Prevent skin breakdown. Protect healthy skin. Prevent secondary infection. Promote general health.</td><td>Skin remains clean, dry, and intact. Infection remains confined to primary location. Complies with general hygienic measures</td></tr><tr><td>Pain related to skin lesions and/or pruritus</td><td>Relieve discomfort. Prevent or minimize scratching. Promote rest.</td><td>Displays no evidence of discomfort Affected areas remain free of excoriation. Child receives adequate rest.</td></tr><tr><td>Potential for infection related to presence of microorganisms</td><td>Prevent spread of infection to self and others.</td><td>Infection remains confined to primary location.</td></tr><tr><td>Body image disturbance related to perception of appearance</td><td>Promotion of a positive self-image Provide tactile contact. Support child. Encourage self-care. Educate child on home care.</td><td>Verbalizes concerns and feelings Displays signs of comfort Positive response to tactile stimulation Identifies ways to improve appearance Assumes responsibility for care when appropriate Maintains usual activities and relationships</td></tr><tr><td>Altered family process related to having a child with a skin condition: Child's discomfort Time intensive and lengthy therapy</td><td>Support family. Educate family on home care.</td><td>Family demonstrates necessary skills. Family demonstrates understanding of skin problem and supports child.</td></tr></tbody></table>
<p><img src="assets/images/image-20251225-ea542037.jpeg" alt="img-82.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="transient-skin-conditions">Transient Skin Conditions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transient-skin-conditions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Reassure parents regarding the benign nature of these conditions.</li>
<li>Assure that the child is kept adequately warm, but avoid overdressing or occlusive clothing.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miliaria">MILIARIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miliaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Eccrine sweat glands are not associated with hair follicles and are found everywhere on the body except for mucocutaneous junctions. Eccrine sweat glands function to help regulate the body's temperature. This is accomplished by the production of eccrine sweat that flows to the skin surface and cools by evaporation. Eccrine sweat is an odorless, colorless, hypotonic solution and is excreted during periods of stress and heat. Miliaria crystallina (self-limited),</p>
<p>miliaria rubra (prickly heat, most common in tropical climates), and miliaria profunda (found in patients who have had several bouts of miliaria rubra) are all sweat-retention diseases related to heat exposure. Miliaria crystallina and rubra are the most common forms seen in the neonatal period. Precipitating factors of these conditions include warming in incubators, fevers, occlusive clothing, dressings, or devices.</p>
<p>A. Definition: Miliaria is an itchy rash caused by inflammation following obstruction and rupture of eccrine sweat glands (Figure 13-9).</p>
<p><img src="assets/images/image-20251225-3e95b8a7.jpeg" alt="img-83.jpeg">
FIGURE 13-9. Miliaria in a 7-day-old infant. (From Salimpour, R. R., Salimpour, P., &amp; Salimpour, P. (2013). Photographic atlas of pediatric disorders and diagnosis. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-epidemiology">II. EPIDEMIOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-epidemiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Age: occurs predominantly in neonates, with a peak in those aged 1 week; but may occur in any age if febrile or recently moved to hot, humid climate
B. Sex: No sex predilection exists.
C. Race: in all races; Asian races produce less sweat and are thus less likely to have miliaria rubra.
D. Other factors</p>
<ol>
<li>
<p>Wearing synthetic clothing, which may irritate the skin</p>
</li>
<li>
<p>Swaddling too much in clothing or blankets</p>
</li>
<li>
<p>Lying for prolonged periods in bed or near heat sources (i.e., incubators, heaters, lights, etc.)</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-etiology-and-pathogenesis">III. ETIOLOGY AND PATHOGENESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-etiology-and-pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Known causes</p>
<ol>
<li>Conditions of high heat and humidity that lead to excessive sweating and occlusion of skin. For example, clothing and casts</li>
<li>Normal skin bacteria, such as <em>S. epidermidis</em> and <em>S. aureus</em>, thought to play role by producing sticky substance, which blocks sweat ducts</li>
<li>Leakage of sweat through walls of duct behind blocked duct responsible for production of miliaria and for further aggravation</li>
<li>Blockage of sweat ducts by dead skin</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-assessment">IV. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>Miliaria crystallina (asymptomatic and self-limited) (Figure 13-10)</li>
</ol>
<p>a. Clear, superficial vesicles that are 1 to 2 mm in diameter
b. Confluent crops without surrounding erythema
c. On head, neck, and upper part of trunk in infants
d. On trunk in bedridden, overheated individuals
e. Lesions rupture easily and resolve with superficial desquamation.
f. Older lesions will scale.</p>
<ol start="2">
<li>Miliaria rubra (prickly heat, heat rash) (Figure 13-11)</li>
</ol>
<p>a. Uniform, small, erythematous papules and vesiculopapules on a background of erythema
b. The most common of sweat-retention diseases
c. Nonfollicular distribution; do not become confluent
d. Can cause great discomfort; treatment is warranted.
e. On the neck, groin, and axillae in infants
f. On covered skin where friction occurs in adults</p>
<p>(1) Neck
(2) Scalp
(3) Upper part of trunk
(4) Flexures
(5) Face and volar areas spared</p>
<p>g. In late stages, anhidrosis may be observed in affected skin.</p>
<ol start="3">
<li>Miliaria profunda</li>
</ol>
<p>a. Firm, flesh-colored, nonfollicular papules that are 1 to 3 mm in diameter
b. Erythema is absent.
c. Primarily on trunk, but can also appear on the extremities</p>
<p>d. Transient episodes of sweating
e. Affected skin shows diminished or absent sweating.
f. May lead to heat exhaustion; treatment is warranted.
g. Hyperpyrexia and tachycardia are observed when there is heat exhaustion.</p>
<p>B. Diagnostic hallmarks</p>
<ol>
<li>Distribution: skin folds and on body in areas with friction from clothing.</li>
<li>Lesions: Minute red papules present in very large numbers.</li>
<li>Characteristic intense discomfort; not so much itching as an unbearable prickling sensation</li>
</ol>
<p>C. History and physical examination</p>
<ol>
<li>Duration of lesions: 5 to 6 weeks</li>
<li>Season: worse in hot, humid climate</li>
<li>Symptoms: characteristic prickling sensation</li>
</ol>
<p>D. Atypical findings</p>
<ol>
<li>Secondary infection appearing as impetigo or as multiple, discrete abscesses</li>
<li>Heat intolerance most likely to develop in miliaria profunda; recognized by anhidrosis or affected skin, weakness, fatigue, dizziness, and even collapse</li>
</ol>
<p>E. Differential diagnosis</p>
<ol>
<li>Cutaneous candidiasis</li>
<li>Varicella</li>
<li>Erythema toxicum neonatorum</li>
<li>Folliculitis</li>
<li>Herpes simplex</li>
<li>Pseudomonas folliculitis</li>
<li>Syphilis</li>
<li>Infantile acne</li>
<li>Viral exanthem</li>
</ol>
<p>F. Diagnostic tests</p>
<ol>
<li>Clinical diagnosis; laboratory tests not necessary</li>
</ol>
<p><img src="assets/images/image-20251225-f15c2dcd.jpeg" alt="img-84.jpeg">
FIGURE 13-10. Miliaria crystallina. Multiple tiny-walled, clear vesicles of varying sizes. (From Burkhart, C., Morrell, D., Goldsmith, L. A., Papier, A., Green, B., Dasher, D., &amp; Gomathy, S. (2009). VisualDx: Essential pediatric dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-f6f51fcf.jpeg" alt="img-85.jpeg">
FIGURE 13-11. Prickly heat in a 6-week-old infant. (From Hall, J. C. (2000). Sauer's manual of skin diseases (8th ed., p. 407). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-nursing-considerations-table-13-1">V. NURSING CONSIDERATIONS (TABLE 13-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-nursing-considerations-table-13-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Interventions</p>
<ol>
<li>Topical therapy</li>
</ol>
<p>a. Lotions containing calamine, boric acid, or menthol
b. Cool wet-to-dry compresses
c. Frequent showering with bland cleansers (although some discourage excessive use of soap)
d. Topical corticosteroids
e. Topical antibiotics if infection is present
f. Topical application of anhydrous lanolin in patients with miliaria profunda</p>
<ol start="2">
<li>Systemic therapy</li>
</ol>
<p>a. Prophylaxis of miliaria with oral antibiotics is reported.
b. Oral retinoids, vitamin A, and vitamin C have all been used with variable success.</p>
<p>B. Course and prognosis</p>
<ol>
<li>May last 5 to 6 weeks despite treatments because plugs formed in sweat duct openings only cast off by outward growth of sweat duct cells, which takes several weeks</li>
</ol>
<p><img src="assets/images/image-20251225-a18f26ab.jpeg" alt="img-86.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miliaria">Miliaria<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miliaria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Control heat and humidity so that sweating is not stimulated.</li>
<li>Treat febrile illness.</li>
<li>Remove occlusive clothing.</li>
<li>Avoid friction from clothing.</li>
<li>Wear clothing and blouses high in cotton and low in synthetics.</li>
<li>Limit activity.
Stay in air conditioning.</li>
<li>Avoid skin irritants.</li>
<li>Patients with miliaria profunda are at high risk for heat exhaustion during exertion in hot weather, because ability to dissipate heat by means of evaporation of sweat is impaired.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="oral-candidiasis">ORAL CANDIDIASIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#oral-candidiasis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: Oral candidiasis, also known as oral thrush or acute pseudomembranous candidiasis, is an infection of the oropharyngeal cavity with  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>C</mi></mrow><annotation encoding="application/x-tex">C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>  albicans, a yeast. It is commonly found in infants and also in immunocompromised adults (Figure 13-12).</p>
<p><img src="assets/images/image-20251225-24280f96.jpeg" alt="img-87.jpeg">
FIGURE 13-12. Thick white patches in the infant with oral candidiasis (thrush). (From Kyle, T., &amp; Carman, S. (2012). Essentials of pediatric nursing. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-epidemiology">II. EPIDEMIOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-epidemiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Most common in newborns
B. In adults, most common causes are local or systemic immunosuppression, steroid use, antibiotics, or poorly fitting dentures.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-assessment">III. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Physical examination</p>
<ol>
<li>Infected epithelium appears white, adherent, curd-like papules and plaques and may be able to be scraped off, leaving an inflamed base.</li>
<li>Tongue and buccal mucosa most often affected</li>
</ol>
<p>B. History</p>
<ol>
<li>White plaques in the mouth</li>
<li>May have coexisting candidal diaper rash</li>
<li>Mothers of infected newborns may have a history of vaginal candidiasis in late pregnancy.</li>
</ol>
<p>C. Diagnostic tests</p>
<ol>
<li>Biopsy</li>
</ol>
<p>a. Not recommended</p>
<ol start="2">
<li>Laboratory tests</li>
</ol>
<p>a. Positive KOH or fungal culture</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-nursing-considerations-table-13-1">IV. NURSING CONSIDERATIONS (Table 13-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-nursing-considerations-table-13-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Interventions</p>
<ol>
<li>Topical therapy—nystatin suspension 1 mL (100,000 units) to each side of the mouth QID or until symptom resolution</li>
<li>Systemic therapy—(full-term neonates) fluconazole 12 mg/kg × 1 day then 6 mg/kg/d for 14 days or until symptom resolution</li>
<li>Boil all bottle nipples and pacifiers. Breastfeeding mothers should consider treating their areolae.</li>
</ol>
<p>B. Course and prognosis</p>
<ol>
<li>In newborns, thrush may clear spontaneously but is more rapidly cleared with treatment.</li>
<li>Immunosuppressed patients can experience recurrent and chronic disease.</li>
<li>Complications are uncommon.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ichthyosis">ICHTHYOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ichthyosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: excessive scaling of the skin. The scale may be “fish scale-like.”</p>
<ol>
<li>Several major hereditary types have been described.</li>
</ol>
<p>a. Lamellar ichthyosis (LI) and congenital nonbullous ichthyosiform erythroderma (CNIE), both autosomal recessive congenital ichthyoses
b. Epidermolytic ichthyosis (EI), also known as bullous ichthyosis (BI) or bullous congenital ichthyosiform erythroderma
c. Ichthyosis vulgaris (IV)
d. X-linked ichthyosis (XLI)</p>
<ol start="2">
<li>There are several other, rare forms of ichthyosis that have associated abnormalities or are part of specific genetic syndromes such as Netherton syndrome, Sjogren–Larsson syndrome, KID syndrome, Darier disease, and others. They are not described in this chapter due to their rarity and involvement of other body systems beyond skin.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-epidemiology">II. EPIDEMIOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-epidemiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. IV is common, with 1:250 children having some variant of this disorder from mild to severe.
B. XLI is estimated to occur in 1 in 60,000 males.
C. LI and CNIE appear to occur in approximately 1 per 100,000 live births.</p>
<p>D. The incidence of EI is approximately 1 per 300,000 live births, with 50% of those being new mutations.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-etiology-and-pathogenesis">III. ETIOLOGY AND PATHOGENESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-etiology-and-pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. IV is inherited as an autosomal dominant disease.
B. XLI is inherited as an X-linked recessive trait that is due to a deficiency of the enzyme steroid sulfatase. Female carriers are asymptomatic.
C. LI and CNIE are inherited in an autosomal recessive trait pattern.
D. Epidermolytic ichthyosis (EI) is inherited as an autosomal dominant disorder.
E. Increased epidermal turnover with excessive production of stratum corneum cells has been demonstrated in LI and EI.
F. In XLI and IV, there appears to be normal epidermal turnover, and the accumulated scale is thought to be due to faulty shedding of the stratum corneum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-assessment">IV. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>
<p>Ichthyosis vulgaris (Figure 13-13)
a. The skin of the newborn with IV usually remains normal throughout the newborn period.
b. Manifestations are limited to the skin with fine scales predominately over the legs and buttocks that may be evident by 6 months to 2 years of age.
c. Dry, follicular, horny plugs (keratosis pilaris) are present on the extensor surface of extremities and may become widespread.
d. The entire surface of the skin is dry and may be associated with atopic dermatitis.</p>
</li>
<li>
<p>X-linked ichthyosis (Figure 13-14)
a. Presents in infancy with scales over the posterior neck, upper trunk, and extensor surfaces of the extremities.
b. Scaling is usually mild during the first 30 days of life, and the skin is a normal color.
c. As the child ages, the scales become thicker and dirty yellow/brown in color. Antecubital and popliteal areas are often spared as well as the palms and soles.
d. Corneal opacities are a clinical marker in XLI but are usually not present until adulthood.
e. Cryptorchidism may occur in as many as 25% of males with XLI, and there is an associated increased risk of testicular cancer.
f. There may be a history of a prolonged labor before affected individual was born due to the deficiency in steroid sulfatase.</p>
</li>
<li>
<p>LI and CNIE (Figure 13-15)
a. Large, plate-like, dark scales with or without erythematous skin are present in LI.
b. In CNIE, generalized fine scales on erythematous skin are present. The erythema may fade as the child ages.
c. With either condition, the affected infant may be born with a collodion membrane. This</p>
</li>
</ol>
<p>is when the infant is born in skin that is a tight, shiny membrane, often likened to plastic wrap or a sausage casing.</p>
<p>d. Facial tautness common may be accompanied by ectropion and eclabium that appear shortly after birth in children with LI.
e. The skin of the palms and soles is generally thickened.
f. Cicatricial alopecia may develop as well as thickening of the nails and inflammation of the nail folds.
g. Heat intolerance is common and due to obstruction of the eccrine glands.</p>
<ol start="4">
<li>Epidermolytic ichthyosis (Figure 13-16)
a. Presents at birth with extensive scaling, erythroderma, and recurrent episodes of bullae formation
b. The bullae frequently become infected with <em>Staphylococcus aureus</em> causing problems in all ages.
c. With age, the involvement may become more limited in extent, and by school age, thick, warty, malodorous, dirty yellow/brown scales will likely have developed on the palms, soles, elbows, and knees.
d. Flexural areas tend to have greater involvement and frequently become macerated and secondarily colonized with bacteria, producing a foul body odor.
e. Palmoplantar keratoderma affects 60% of patients.
f. After the neonatal period, the mechanobullous component becomes less prominent; however, focal blistering continues.
g. Facial involvement is common, but ectropion does not occur. Nails may become dystrophic due to nail fold inflammation.</li>
</ol>
<p>B. Diagnostic tests</p>
<ol>
<li>Skin biopsy helps to demonstrate the histologic changes in the epidermis and hyperkeratosis.</li>
<li>Measurement of steroid sulfatase activity in red blood cells may be useful in the diagnosis of X-linked ichthyosis.</li>
<li>Molecular genetic diagnosis is useful to distinguish the various forms of ichthyosis.</li>
</ol>
<p><img src="assets/images/image-20251225-26ca5f52.jpeg" alt="img-88.jpeg">
FIGURE 13-13. Ichthyosis vulgaris. This patient has atopic dermatitis and ichthyosis vulgaris lesions that resemble fish scales. Note the characteristic sparing of the popliteal fossa. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p><img src="assets/images/image-20251225-6107f3f5.jpeg" alt="img-89.jpeg">
FIGURE 13-14. X-linked ichthyosis typically has large discrete scales compared with ichthyosis vulgaris. (From Burkhart, C., Morrell, D., Goldsmith, L. A., Papier, A., Green, B., Dasher, D., &amp; Gomathy, S. (2009). VisualDx: Essential pediatric dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-cc889e92.jpeg" alt="img-90.jpeg">
FIGURE 13-15. Lamellar ichthyosis. (Image provided by Stedman's.)</p>
<p><img src="assets/images/image-20251225-981597b3.jpeg" alt="img-91.jpeg">
FIGURE 13-16. Epidermolytic ichthyosis with linear scaling reminiscent of "corrugated cardboard." (Image courtesy of CHOP Dermatology.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-nursing-considerations-table-13-1">V. NURSING CONSIDERATIONS (TABLE 13-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-nursing-considerations-table-13-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="a-interventions">A. Interventions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-interventions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Skin hydration at least two times daily</li>
<li>Daily use of emollients</li>
</ol>
<p>a. Bland emollients such as petrolatum or mineral oil. For example: Aquaphor, Eucerin, Vanicream, CeraVe, Cetaphil, Vaseline, and Aveeno product lines</p>
<ol start="3">
<li>Keratolytics</li>
</ol>
<p>a. Alpha hydroxy acid (lactic acid, urea, glycolic acid) in cream or ointment vehicles. Commercial preparations include Eucerin Plus, Lacticare, Lac-Hydrin, AmLactin, Aqua Glycolic, and Carmol
b. If available, compounding products of varying concentration is also an option.</p>
<ol start="4">
<li>Topical retinoids are helpful to some people to remove scaling. These include tretinoin and tazarotene.</li>
<li>Oral retinoids may be used to alleviate the hyperkeratosis. Due to their toxicity, the use is warranted only in patients with severe physical or emotional complications.</li>
<li>Treating active infection with cultures and appropriate antibiotics is of critical importance. Frequency of infection may be minimized by doing dilute bleach baths (1/8 cup per half tub of water) two to three times per week to reduce bacterial colonization of the skin.</li>
<li>Adequate provision of calories in diet, especially protein, and monitoring of child's iron status due to the metabolic drain of erythroderma on a growing child and substantial iron loss in hyperproliferative states</li>
<li>Infants with widespread blistering or collodion membrane are cared for in the NICU with precautions to avoid further trauma to the skin, regulate skin temperature and hydration, as well as prevent infection.</li>
<li>Psychosocial support to deal with issues related to body image, social relationships, and demanding complex therapy</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b-follow-up">B. Follow-up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>One week after discharge from the newborn nursery.</li>
<li>Routine visits for pediatric care and additional visits may be necessary, depending on the severity of the ichthyosis.</li>
</ol>
<p><img src="assets/images/image-20251225-869d0f11.jpeg" alt="img-92.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ichthyosis">Ichthyosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ichthyosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Prevent overheating, particularly during strenuous physical activity and/or warm temperatures.</p>
</li>
<li>
<p>Bathe with antibacterial soaps or dilute bleach solution to decrease bacterial colonization of skin.</p>
</li>
<li>
<p>Consider choice of clothing and shoe wear for children.</p>
</li>
<li>
<p>Alert that blistering after infancy often signifies a bacterial infection requiring treatment with an oral antibiotic effective against S. aureus.
Refer to the Ichthyosis Foundation for family support.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hemangiomas">HEMANGIOMAS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hemangiomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: benign, vascular tumor comprised of endothelial cells (Figure 13-17)</p>
<p><img src="assets/images/image-20251225-ff0d5000.jpeg" alt="img-93.jpeg">
FIGURE 13-17. Cutaneous hemangioma on the hand. (From Nelson, L. B., &amp; Olitsky, S. E. (2013). Harley's pediatric ophthalmology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-epidemiology">II. EPIDEMIOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-epidemiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Five to seven percent of newborns have hemangiomas.</p>
<p>B. Approximately 10% of hemangiomas have reached maximal regression with each year of life. For example, 50% of hemangiomas have reached maximal regression by 5 years of age, 90% by 9 years of age, and so on.</p>
<p>C. More common in girls, Caucasians, premature babies, multiple gestations, and in babies whose mothers had maternal hypertension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-etiology-and-pathogenesis">III. ETIOLOGY AND PATHOGENESIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-etiology-and-pathogenesis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. The underlying cause of hemangiomas is unknown. Different theories include lack of oxygen to the affected area, trauma to the affected area, and also a small portion of placenta attaching itself to the affected area.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-assessment">IV. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Clinical manifestations</p>
<ol>
<li>
<p>Only 20% of hemangiomas are present at birth. The remainder will appear during the first few weeks of life.</p>
</li>
<li>
<p>Classification of hemangiomas</p>
</li>
</ol>
<p>a. Superficial hemangiomas—bright red, papular or plaque-like hemangiomas (Figure 13-18)</p>
<p>b. Deep hemangiomas—blue, nodular hemangiomas (Figure 13-19)</p>
<p>c. Mixed hemangiomas—contain both a superficial and a deep component (Figure 13-20)</p>
<p>d. Hemangiomas may be plaque-like/segmental or more discrete.</p>
<p>e. Rapidly involuting congenital hemangioma (RICH)—fully expressed at birth and quickly involutes</p>
<p>f. Noninvoluting congenital hemangioma (NICH)—fully expressed at birth but does not resolve over time like typical hemangiomas behave</p>
<ol start="3">
<li>Characteristics of growth (Figure 13-21)</li>
</ol>
<p>a. Rapid growth phase—at 4 to 8 weeks of age, hemangiomas undergo rapid growth that typically continues until the infant is 6 months, with slower growth often continuing until 1 year of age. The rapid growth phase sees the hemangioma growing at a faster rate than the overall growth of the infant. The majority of rapid growth may be complete by 3 months of age.</p>
<p>b. Stabilization phase—the hemangioma growth slows and approximates the growth rate of the child.</p>
<p>c. Regression phase—this phase tends to begin sometime in the second year of life with color of the hemangioma fading, followed by flattening of the tumor. This phase slowly continues over a 1- to 10-year period.</p>
<ol start="4">
<li>Associated complications</li>
</ol>
<p>a. Obstruction of a vital function, such as vision, urination, breathing, eating, or defecation (Figure 13-22)</p>
<p>b. Cardiac, arterial, eye, and reproductive system abnormalities with associated syndromes</p>
<p>c. High-output cardiac failure and hepatic hemangiomas
d. Ulceration (Figure 13-23)
e. Infection
f. Bleeding
g. Pain
h. Undesirable, lasting cosmetic changes such as fibrofatty deposits, stretched skin, and scarring</p>
<p>B. Diagnostic tests</p>
<ol>
<li>Generally none. Diagnosed by clinical appearance</li>
<li>Occasionally, imaging may be required.
a. MRI is indicated with midline hemangiomas overlying other defects, such as capillary malformations, sacral dimple, asymmetric gluteal cleft, hair tuft, etc. (Figure 13-24).
b. Abdominal ultrasound should be performed in patients with 5 or more hemangiomas (hemangiomatosis) to rule out liver hemangiomas (Figure 13-25).
c. ENT referral with airway evaluation should be obtained for patients with hemangiomas in the "beard distribution" in order to rule out airway obstruction as this may be a medical emergency (Figure 13-26).
d. Patients with large, plaque-like hemangiomas on the face should be evaluated for PHACE syndrome (Figure 13-27).
e. Patients with large, plaque-like hemangiomas on the sacral/groin area likely require pelvic/abdominal U/S and/or MRI to rule out associated abnormalities.</li>
<li>Imaging and biopsy may occasionally be required to differentiate hemangiomas from other vascular malformations, lymphatic malformations, or subcutaneous sarcomas.</li>
</ol>
<p><img src="assets/images/image-20251225-f6844936.jpeg" alt="img-94.jpeg">
FIGURE 13-18. Superficial hemangioma. (From O'Doherty, N. (1979). Atlas of the newborn (pp. 342-345). Philadelphia, PA: JB Lippincott, with permission.)</p>
<p><img src="assets/images/image-20251225-e65d9c8e.jpeg" alt="img-95.jpeg">
FIGURE 13-19. Deep or subcutaneous hemangioma. Note the normal overlying skin. (Courtesy of Andrea L. Zaenglein, MD.)</p>
<p><img src="assets/images/image-20251225-1a9203f3.jpeg" alt="img-96.jpeg">
FIGURE 13-20. Mixed hemangioma on the back. These lesions contain both a superficial and a deep component.(Image provided by Stedman's.)</p>
<p><img src="assets/images/image-20251225-adbf100c.jpeg" alt="img-97.jpeg">
A</p>
<p><img src="assets/images/image-20251225-9a93d1ed.jpeg" alt="img-98.jpeg">
B</p>
<p><img src="assets/images/image-20251225-67e9a275.jpeg" alt="img-99.jpeg">
C
FIGURE 13-21. This girl with a right facial hemangioma demonstrates the three-stage life cycle consisting of rapid growth (A, age 3 months), stabilization (B, age 18 months), and regression (C, age 7 years). (From Thorne, C. H., Gurtner, G. C., Chung, K., Gosain, A., Mehrara, B., Rubin, P., &amp; Spear, S. L. (2013). Grabb and Smith's plastic surgery. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-93da63f3.jpeg" alt="img-100.jpeg">
FIGURE 13-22. Hemangioma of the medial upper eyelid. The lesion impairs the visual access and should be treated to prevent long-term vision problems. (From Mulholland, M. W., Lillemoe, K. D., Doherty, G. M., Maier, R. V., &amp; Upchurch, G. R., eds. (2005). Greenfield's surgery (4th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins, with permission.)</p>
<p><img src="assets/images/image-20251225-9eb00a0e.jpeg" alt="img-101.jpeg">
FIGURE 13-23. Ulcerated infantile hemangioma on the arm during the proliferative phase. (From Requena, L., &amp; Kutzner, H. (2014). Cutaneous soft tissue tumors. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-1b9f7dbb.jpeg" alt="img-102.jpeg">
FIGURE 13-24. Lumbar hemangioma. This midline lesion was associated with a dermal sinus and an underlying tethered cord. (Courtesy of Esther K. Chung, MD, MPH.)</p>
<p><img src="assets/images/image-20251225-8028dead.jpeg" alt="img-103.jpeg">
FIGURE 13-25. Diffuse neonatal hemangiomatosis: multiple infantile hemangiomas scattered all over the body surface. (From Requena, L., &amp; Kutzner, H. (2014). Cutaneous soft tissue tumors. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-06d14a1e.jpeg" alt="img-104.jpeg">
FIGURE 13-26. Segmental mandibular or "beard" hemangioma of infancy in association with hemangioma of infancy of the upper airway. (From McMillan, J. A., DeAngelis, R. D., &amp; Feigin, C. (2006). Oski's solution. Philadelphia, PA: Wolters Kluwer.)</p>
<p><img src="assets/images/image-20251225-82d2aff7.jpeg" alt="img-105.jpeg">
A</p>
<p>.</p>
<p><img src="assets/images/image-20251225-a48ae821.jpeg" alt="img-106.jpeg">
B</p>
<p><img src="assets/images/image-20251225-3c3e9e0e.jpeg" alt="img-107.jpeg">
C</p>
<p><img src="assets/images/image-20251225-d1b21246.jpeg" alt="img-108.jpeg">
D
FIGURE 13-27. PHACE syndrome with facial hemangioma.</p>
<p>A, B: A 6-month-old girl presenting with left facial hemangiomas with secondary ptosis of the left upper eyelid.</p>
<p>(Continued)</p>
<p>C, D: Magnetic resonance images demonstrating an intracranial aneurysm involving the left</p>
<p>internal carotid artery extending into the middle cranial fossa (arrows). (From Thorne, C. H., Gurtner, G. C., Chung, K., Gosain, A., Mehrara, B., Rubin, P., &amp; Spear, S. L. (2013). Grabb and Smith's plastic surgery. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="v-nursing-considerations-table-13-1">V. NURSING CONSIDERATIONS (TABLE 13-1)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#v-nursing-considerations-table-13-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-interventions">A. Interventions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-interventions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>In most uncomplicated hemangiomas, the lesions are observed and treated only if complications arise.</li>
<li>Measurement of the size of the hemangioma, along with photographs of the lesions at each visit, will document growth and regression.</li>
<li>Lesions on the face (particularly forehead, glabella, nose, lips), ears, areolae, and groin are often treated due to potential for disfigurement.</li>
<li>Propranolol has become the systemic therapy of choice for most patients requiring medical intervention. After obtaining a thorough cardiac history, auscultating the heart rate and rhythm, and obtaining a blood pressure, the patient is tapered up to a final dose of 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">3\mathrm{mg / kg / d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mg/kg/d</span></span></span></span></span></span> divided BID over a period of several days to a few weeks. The most common side effects are hypotension and decreased heart rate. Hypoglycemia has been reported, so it is recommended to give propranolol after a meal. Propranolol may also "unmask" or aggravate respiratory disease such as asthma and should be used with caution in these patients. It is generally started between 1 and 3 months of age and continued until approximately 1 year of age.</li>
</ol>
<p>a. Timolol gel-forming solution, a topical ophthalmic solution for the treatment of glaucoma, may be applied to superficial hemangiomas BID with good results. It does not help with deeper components of hemangiomas but has been shown to reduce the superficial color and some superficial volume.</p>
<ol start="5">
<li>Occasionally, oral or interlesional steroids may be used.</li>
<li>Pain management and infection prevention/treatment are often necessary for ulcerated hemangiomas.</li>
<li>Vascular-specific pulsed-dye laser is often an effective treatment for ulcerated hemangiomas and for residual erythema after involution of the hemangioma.</li>
<li>Hydrocolloid dressings may aid in the resolution of ulcerated hemangiomas.</li>
<li>Some hemangiomas that ulcerate and do not respond to other therapies may be removed surgically. Additionally, plastic surgery revision may be warranted after maximal involution has occurred if residual cosmetic defects remain.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-follow-up">B. Follow-up<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-follow-up" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ol>
<li>Follow closely during rapid growth phase, possibly may need to be seen every month.</li>
<li>Once growth is stabilized, time between visits can be lengthened.</li>
<li>Children with periorbital hemangiomas should be referred for ophthalmologic evaluation.</li>
<li>Children undergoing medical intervention with propranolol will require frequent follow-up visits to assess heart rate, blood pressure, response to therapy, and potential side effects/complications.</li>
</ol>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hemangiomas">Hemangiomas<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hemangiomas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Review the natural history of hemangiomas.</li>
<li>State the difficulty in predicting the eventual size, type, final outcome, and need for treatment during the rapid growth phase of the hemangioma.</li>
<li>Discuss potential complications, as appropriate.</li>
<li>Review side effects and dosage of any prescribed therapies.</li>
<li>Teach signs of infection or reaction to additional therapies.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-common-disorders-in-children-covered-in-this-textbook">Other Common Disorders in Children Covered in This Textbook<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-common-disorders-in-children-covered-in-this-textbook" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acne vulgaris—see Chapter 10.</li>
<li>Atopic dermatitis—see Chapter 9.</li>
<li>Diaper dermatitis—see Chapter 23.</li>
<li>Seborrheic dermatitis—see Chapter 9.</li>
<li>Psoriasis—see Chapter 8.</li>
<li>Infections—see Chapter 11.</li>
<li>Bites, stings, and infestations—see Chapter 12.</li>
<li>Disorders of pigmentation—see Chapter 17.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Burkes, S. A., Adams, D. M., Hammill, A. M., Chute, C., Eaton, K. P., Welge, J. A., Wickett, R. R., &amp; Visscher, M. O. (2015). Skin imaging modalities quantify progression and stage of infantile haemangiomas. <em>British Journal of Dermatology</em>, 173(3), 838–841.
Dixit, S., Jain, A., Datar, S., &amp; Kurhana, V. K. (2012). Congenital miliaria crystallina—A diagnostic dilemma. <em>Medical Journal Armed Forces India</em>, 68(4), 386–388.
Dyer, J. A., Spraker, M., &amp; Williams, M. (2013). Care of the newborn with ichthyosis. <em>Dermatologic Therapy</em>, 26, 1–15.
Eichenfield, L. F., Frieden, I. J., Mathes, E. F., &amp; Zaenglein, A. L. (2015). Neonatal and infant dermatology (3rd ed.). London, UK: Elsevier Saunders.
Enjolras, O. (1997). Management of hemangiomas. <em>Dermatology Nursing</em>, 9(1), 11–17.
Filippidi, A., Galanakis, E., Maraki, S., Galani, I., Drogari-Apiranthitou, M., Kalmanti, M., ..., Samonis, G. (2013). The effect of maternal flora on Candida colonisation in the neonate. <em>Mycoses</em>, 57, 43–48.
Fleckman, P., Newell, B. D., van Steensel, M. A., &amp; Yan, A. C. (2013). Topical treatment of ichthyoses. <em>Dermatologic Therapy</em>, 26, 16–25.</p>
<p>Ghosh, S. (2015). Neonatal pustular dermatosis: An overview. <em>Indian Journal of Dermatology</em>, 60(2), 211.
Gomes, M. P. C. L., Porro, A. M., Enokihara, M. M. S. S., &amp; Floriano, M. C. (2013). Subcutaneous fat necrosis of the newborn: Clinical manifestations in two cases. <em>Anais Brasileiros de Dermatologia</em>, 88(6, Suppl 1), 154–157.
Masatoshi, J. (2010). Recent progress in studies of infantile hemangioma. <em>Journal of Dermatology</em>, 37(4), 283–298.
Neri, I., Balestri, R., &amp; Patrizi, A. (2012). Hemangiomas: New insight and medical treatment. <em>Dermatologic Therapy</em>, 25, 322–334.
Paller, A. S., &amp; Manchini, A. J. (2011). <em>Hurwitz clinical pediatric dermatology</em> (4th ed.). Edinburgh, UK: Elsevier, Inc.
Paloni, G., Berti, I., &amp; Cutrone, M. (2013). Acropustulosis of infancy. <em>Archives of Diseases in Childhood. Fetal and Neonatal Edition</em>, 98, F334–F340.
Rudy, S. J. (1999). Superficial fungal infections in children and adolescents. <em>Nurse Practitioner Forum</em>, 10(2), 56–66.
Tawfik, A. A., &amp; Alsharnoubi, J. (2015). Topical timolol solution versus laser in treatment of infantile hemangioma: A comparative study. <em>Pediatric Dermatology</em>, 32, 369–376.
Van Praag, M., Van Rooij, R., Folkers, E., Spritzwer, R., Menke, H., &amp; Oranje, A. (1997). Diagnosis and treatment of pustular disorders in the neonate. <em>Pediatric Dermatology</em>, 14(2), 131–143.
Weston, W. L., Lane, A. T., &amp; Morelli, J. G. (2002). <em>Color textbook of pediatric dermatology</em> (2nd ed.). St. Louis, MO: Mosby Year Book, Inc.
Zuniga, R., &amp; Nguyen, T. (2013). Skin conditions: Common skin rashes in infants. <em>Family Practice Essentials</em>, 407, 31–41.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Which of the following findings, along with acne neonatorum, would signal the need for a more thorough evaluation and likely referral to an endocrinologist?</li>
</ol>
<p>a. Extensive comedonal acne (blackheads)
b. Early onset of pubic and/or axillary hair
c. Poor response to initial therapy
d. Family history of severe acne</p>
<ol start="2">
<li>Cutis marmorata will improve with which of the following interventions?</li>
</ol>
<p>a. Rest
b. Elevation of affected areas
c. Moving to a warmer environment
d. Removing excess layers of clothing</p>
<ol start="3">
<li>Which of the following physical findings is associated with harlequin color change?</li>
</ol>
<p>a. Bulging veins.
b. Eyes are two different colors.
c. Skin is darker on dependent areas.
d. A white patch on the hair on the scalp.</p>
<ol start="4">
<li>Which of the following subtypes describes miliaria that consists of tiny, clear, vesicular papules that easily, superficially desquamate?</li>
</ol>
<p>a. Miliaria crystallina
b. Miliaria profunda</p>
<p>c. Miliaria blanca
d. Miliaria rubra</p>
<ol start="5">
<li>To increase the likelihood of resolution, which of the following interventions should be included in the treatment in infantile oral candidiasis?</li>
</ol>
<p>a. Changing diapers frequently
b. Using BPA-free bottle nipples and pacifiers
c. Washing hands before feedings
d. Boiling bottle nipples and pacifiers</p>
<ol start="6">
<li>Which of the following forms of ichthyosis is only found in males?</li>
</ol>
<p>a. X-linked
b. Lamellar
c. Vulgaris
d. Bullous</p>
<ol start="7">
<li>Emollients are a hallmark of ichthyosis treatment. Which of the following topical therapies may help to remove some of the excess scale buildup on the skin?</li>
</ol>
<p>a. Clindamycin and benzoyl peroxide
b. Dial soap and bleach baths
c. Hydrocortisone and tacrolimus
d. Topical retinoids and keratolytics</p>
<ol start="8">
<li>In addition to asking about side effects and assessing the efficacy of the therapy, which of the following must also be checked prior to initiation and at all follow-up visits for propranolol used in the treatment of hemangiomas of infancy?</li>
</ol>
<p>a. Heart rate and blood pressure
b. Height and blood pressure
c. Complete blood count
d. Liver function</p>
<ol start="9">
<li>Which of the following additional tests should a patient with 5 or more hemangiomas undergo?</li>
</ol>
<p>a. Eye examination
b. Abdominal ultrasonography
c. Sacral magnetic resonance imaging
d. Electroencephalography</p>
<ol start="10">
<li>Which of the following is a topical therapy option for superficial, uncomplicated hemangioma?</li>
</ol>
<p>a. Ammonium lactate
b. Salicylic acid
c. Timolol gel
d. Lidocaine gel</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.b
2.c
3.c
4.a
5.d
6.a
7.d
8.a
9.b
10.c</p>
<p>CHAPTER 14</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="benign-neoplasms-hyperplasia">Benign Neoplasms/Hyperplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#benign-neoplasms-hyperplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Beth Haney</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="objectives">OBJECTIVES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#objectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>After studying this chapter, the reader will be able to:</p>
<ul>
<li>List the characteristics of benign neoplasms/hyperplasia.</li>
<li>Define benign neoplasms/hyperplasia.</li>
<li>Describe the signs and symptoms of benign neoplasms/hyperplasia.</li>
<li>Understand the various treatment options available to the patient with benign neoplasms/hyperplasia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="key-points">KEY POINTS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#key-points" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Benign neoplasms are noncancerous skin lesions or tumors.</li>
<li>Benign neoplasms are common skin growths.</li>
<li>Benign neoplasms have no malignant potential.</li>
<li>Some benign neoplasms require treatment for cosmetic purposes.</li>
<li>Some benign neoplasms require treatment to improve comfort.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acrochordons-skin-tags-papillomas-cutaneous-tags-soft-fibromas">ACROCHORDONS (SKIN TAGS, PAPILLOMAS, CUTANEOUS TAGS, SOFT FIBROMAS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acrochordons-skin-tags-papillomas-cutaneous-tags-soft-fibromas" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Acrochordons are benign neoplasms. Acrochordons are cosmetic disorders (Figure 14-1).</p>
<p><img src="assets/images/image-20251225-4ea7bf65.jpeg" alt="img-109.jpeg">
A</p>
<p><img src="assets/images/image-20251225-50942109.jpeg" alt="img-110.jpeg">
B
FIGURE 14-1. A: This soft, pedunculated skin tag, or acrochordon, is typical of a fibroepithelial polyp. Skin tags are most common in skinfolds such as the crural crease and axillae. B: Eyelid acrochordon. (From Edwards, L., &amp; Lynch, P. J. (2010). Genital dermatology atlas. Philadelphia, PA: Wolters Kluwer; Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>A. Definition: acrochordons are soft pedunculate, flesh-colored, tan, brown, or pigmented growths, commonly on the neck, shoulders, axillae, groin, inguinal folds, eyelids, upper chest, and trunk. These lesions are asymptomatic but may become irritated or inflamed if exposed to repeated trauma from jewelry, clothing, or opposing skin surfaces.
B. Etiology is not fully understood.
C. Pathophysiology</p>
<ol>
<li>Polyp-type lesion with mildly acanthotic epidermis, a loose, edematous fibrovascular core with mild chronic inflammation and a nerveless dermis</li>
<li>Varies in size from 1 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">5\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>  although tumors can grow up to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">1\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span></li>
<li>Single or multiple lesions</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Found in approximately  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span>  of males and females</li>
</ol>
<p>a. Increases during middle-aged and older adulthood, pregnancy, acromegaly, menopause, and family history</p>
<ol start="2">
<li>Equal in males and females</li>
<li>Associated with obesity</li>
<li>Frequently higher in diabetics</li>
<li>After the fifth decade, there is no further growth</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History and current health status
B. Diagnosis by clinical presentation: location, color, number, size, irritation, tenderness, and inflammation
C. Biopsy recommended if pigmented or erythematous</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Electrodesiccation
B. Scalpel or simple scissor excision at the base of the lesion
C. Cryosurgery</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-home-care-considerations">IV. Home Care Considerations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Wound care (Box 14-1)
B. Control bleeding.
C. Watch for signs of infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="box-14-1-wound-care">BOX 14-1. Wound Care<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#box-14-1-wound-care" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Keep dressing dry and in place for 24 to 48 hours as ordered.</li>
<li>Clean site with soap and water two to three times a day as ordered. Do not apply alcohol or peroxide. Pat site dry.</li>
<li>Apply antibiotic ointment to keep site moist, two times a day and cover with appropriate dressing.</li>
<li>If bleeding or oozing occurs at the site, gently apply pressure with a clean gauze for 20 minutes. The bleeding/oozing should stop within 25 minutes; if not, call the office.</li>
<li>Watch for signs of infection: redness, swelling, pain, heat, pus, and temp greater than 101. Take non-aspirin product for pain and discomfort—Tylenol, if not allergic. Avoid Aleve, Advil, Motrin, ibuprofen, and aspirin products.</li>
</ul>
<p>Adapted from: Butcher, M. (2013). Assessment, management, and prevention of infected wounds. Journal of Community Nursing, 27(4), 25–34.</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acrochordons">Acrochordons<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acrochordons" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acrochordons can become easily irritated or infected.</li>
<li>Patients may avoid complications if they:</li>
<li>Cover lesion(s) with bandage when clothing or jewelry irritates the lesion(s).</li>
<li>Lose weight if appropriate.</li>
<li>Keep skin folds clean and dry.</li>
<li>Monitor lesion(s) for changes in size, color, or pain.</li>
<li>See a health care provider for lesion removal options.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="calluses">CALLUSES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calluses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: a callus is an elevated superficial, diffusely thickened hyperkeratotic area, usually without a distinct border. Calluses are nontender, but pressure may produce dull pain (Figure 14-2).</p>
<p>B. Etiology</p>
<ol>
<li>Repeated friction or pressure</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Normal response to friction or pressure; increased activity of keratinocytes in superficial layer of skin leading to hyperkeratosis</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Frequently on palms and weight-bearing surfaces of the foot</li>
<li>Increases with age, women affected more often than men</li>
</ol>
<p><img src="assets/images/image-20251225-49b0aa38.jpeg" alt="img-111.jpeg">
FIGURE 14-2. Corn in a typical location over a metatarsal head. (From Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Physical examination
B. History of chronic pressure or friction
C. Examination of footwear may assist in assessment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Topical keratolytics (urea, ammonium lactate),  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40\%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span>  salicylic acid plaster, or ointment.</p>
<ol>
<li>Use OTC keratolytic preparations as directed. Forms include a patch, lotions, foam, gel, and cream. Apply keratolytic plaster, sticky medicated side to skin, making sure plaster covers the affected area. Cover the plaster with adhesive tape for 1 to 7 days.</li>
<li>Avoid normal skin to prevent irritation and skin damage.</li>
<li>Soak the area in warm water after removing the tape. Rub the soft macerated skin with a rough towel or pumice stone. Reapply the plaster and repeat the process until all hyperkeratotic skin is removed.</li>
</ol>
<p>B. Orthopedic shoes, braces, and support devices to redistribute weight.
C. Epsom salt soaks for 5 to 10 minutes several times a day.
D. Geriatric considerations: salicylic acid treatments can cause breakdown and/or ulceration of thin, atrophic skin, people with diabetes, and those with vascular compromise; use these products with caution. Use of protective padding. Avoid activities that contribute to painful lesion formation.
E. Patient education is similar to recommendations for corns in the next section.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="corns-clavi">CORNS (CLAVI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#corns-clavi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Corns are found over bony prominences such as the interphalangeal joints of toes (Figure 14-3).</p>
<p><img src="assets/images/image-20251225-14fc2c05.jpeg" alt="img-112.jpeg">
A</p>
<p><img src="assets/images/image-20251225-a93ca047.jpeg" alt="img-113.jpeg">
B
FIGURE 14-3. A: Corns and calluses. B: Corn with callus on lateral toe surface. (From Berg, D., &amp; Worzala, K. (2006). Atlas of adult physical diagnosis. Philadelphia, PA: Lippincott Williams &amp; Wilkins; and Craft, N., et al. (2010). VisualDx: Essential adult dermatology. Philadelphia, PA: Wolters Kluwer.)</p>
<p>A. Definition: circumscribed, hyperkeratotic, slightly elevated lesion with a central conical core of keratin resulting in a thickening of the stratum corneum. These lesions cause pain and inflammation. "Hard" corns are frequently over the interphalangeal toe joints, especially the fifth toe, and develop under the pressure site from footwear. "Hard" corns are usually painful: dull constant pain or sharp pain when pressure is applied. "Soft" corns appear as whitish thickening, usually in the interdigital spaces between the fourth and fifth toes.</p>
<p>B. Etiology</p>
<ol>
<li>Repeated external pressure creates localized accumulation of keratin.</li>
<li>Soft corns result from moisture leading to maceration of the skin and mechanical irritation.</li>
<li>Hard corns have a keratin-based core and are usually associated with bony prominences that cause skin to rub on shoe surfaces.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Localized pinpoint accumulation of keratin forms an elongated, hard plug in the horny</li>
</ol>
<p>layer of the epidermis. The plug presses downward on the dermal structure, causing inflammation and irritation of sensory nerves, resulting in marked tenderness.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Physical examination
B. History related to footwear, working conditions, foot surgery, previous similar lesions</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Surgical excision of superficial layer of corn and hard plug in the horny layer
B. Corticosteroids: triamcinolone injection (Kenalog, Aristocort) at base of the corn to relieve pain
C. Topical keratolytics
D. Epsom salt soaks every few hours for 5 to 10 minutes at a time</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-home-care-considerations">IV. HOME CARE CONSIDERATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Encourage proper-fitting shoes: extra wide for fifth metatarsal corns.
B. Debridement of corn and use of protective padding.
C. Avoidance of activities that cause pain or create lesions.</p>
<p><img src="assets/images/image-20251225-858fd684.jpeg" alt="img-114.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="calluses-and-corns">Calluses and Corns<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calluses-and-corns" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Activities with any repetitive friction, including walking, need to be evaluated and modified when corns or calluses are occurring.</li>
<li>Proper-fitting shoes are important (e.g., low heeled, wide toe, appropriate length and width).</li>
<li>Protection to affected areas is key such as use of gloves, padding, and special bandages to prevent additional formation.</li>
<li>Active treatment needs to be modified with excessive breakdown of skin.</li>
<li>Activities that cause pain should be avoided.</li>
<li>Health care provider should be consulted with any increased pain that occurs or signs of infection that develop, that is, redness, heat, swelling, and discharge.</li>
</ul>
<p>CYSTS</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A cyst is a benign, sac-like growth in the skin layers, which originates from the follicle orifice (Figure 14-4). Types of cysts may include epidermal, epidermal inclusion, epidermoid, keratinous, pilar, infundibular, sebaceous, and acne.</p>
<p><img src="assets/images/image-20251225-a446db31.jpeg" alt="img-115.jpeg">
A</p>
<p><img src="assets/images/image-20251225-09ba1a13.jpeg" alt="img-116.jpeg">
B</p>
<p><img src="assets/images/image-20251225-40f4b429.jpeg" alt="img-117.jpeg">
C
FIGURE 14-4. A: Pilar cyst on the scalp. B: Epidermoid cyst. These lesions often occur on the back. They appear as smooth, discrete, freely movable, dome-shaped ballotable masses. C: Epidermal inclusion cyst showing the typical characteristics of yellow color and telangiectasis. (From Stedman's; Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins; and Penne, R. B. (2011). Wills Eye Institute—Oculoplastics. Philadelphia, PA: Wolters Kluwer.)</p>
<p>A. Definition: a circumscribed lesion with a wall and a lumen that usually contains fluid or solid matter.
B. Etiology: spontaneous, trauma, or congenital.</p>
<ol>
<li>Cyst wall probably formed from occluded pilosebaceous follicles.</li>
<li>Result of cutaneous surface trauma and a portion of the epithelium is forced into the superficial dermis.</li>
</ol>
<p>C. Pathophysiology: cyst ruptures and keratin is released, causing an inflammatory foreign body response.</p>
<p>D. Incidence.</p>
<ol>
<li>Higher incidence in young and middle-aged males; increases with a family history</li>
<li>Multiple lesions (70%)</li>
<li>Solitary (30%)</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Diagnosis by clinical presentation and examination of expressed material confirmation by biopsy (Table 14-1)</p>
<p>TABLE 14-1 Characteristics of Cysts</p>
<table><thead><tr><th>Type</th><th>Common Names</th><th>Location</th></tr></thead><tbody><tr><td>Atheroma</td><td></td><td></td></tr><tr><td>Derived from the root sheath of the hair follicle. Globular, elastic, mobile tumor covered with atrophic thin skin, thick wall, filled with keratin, is not connected to the epidermis, and is without external opening. Tender if infected. Baldness over large cyst skin due to follicular pressure damage. No inflammation or proliferation from trauma. No malignant degeneration</td><td>Pilar cyst, trichilemmal cyst</td><td></td></tr><tr><td>Archaic names: Wen</td><td>&gt;90% Scalp, hair follicle epithelium</td><td></td></tr><tr><td>Retention cyst</td><td></td><td></td></tr><tr><td>Spherical, mobile, firm under tense skin. Ruptures easily by manipulation. Keratinous material can be pressed into the surrounding tissue and then acts as a foreign body and can cause granuloma abscess formation from bacterial infection.</td><td>Milia, acne cysts, and traumatic inclusion cysts</td><td>Face, trunk, hair follicles areas, scalp, neck, back, and cheeks</td></tr><tr><td>One millimeter to several centimeters in diameter</td><td></td><td></td></tr><tr><td>Cutaneous or subcutaneous—fluctuant, easily movable, tense, swelling</td><td></td><td></td></tr><tr><td>Expanded gland duct and foul-smelling rancid lipids and debris will reoccur if wall remains intact.</td><td></td><td></td></tr><tr><td>Sebocystomatosis</td><td></td><td></td></tr><tr><td>Central opening exudes a pasty, cheesy odoriferous material composed of keratin and lipid-rich debris</td><td>Sebaceous cysts (fat)</td><td>Young-middle-aged adults. Scalp, face, neck, upper trunk, scrotum, and vulva</td></tr><tr><td>Keratinous cyst</td><td></td><td></td></tr><tr><td>Firm, movable, globular, and nontender unless infected. Contents are soft and yellow-white, with a rancid odor</td><td>Epidermal and sebaceous</td><td>Face, neck, and upper trunk, almost any area of the body</td></tr><tr><td>Milium</td><td></td><td></td></tr><tr><td>Primary milia arise spontaneously and are keratin filled. Secondary milia arise in pilosebaceous glands or within damaged eccrine sweat gland ducts following subepidermal bulla formation (e.g., epidermolysis bullosa, porphyria cutanea tarda, bullous pemphigoid) or skin radiotherapy. Primary and secondary milia are identical histologically.</td><td>Subepidermal cyst</td><td>Eyelids, forehead, and cheeks</td></tr><tr><td>Young to middle-aged men and women and infants</td><td></td><td></td></tr><tr><td>Tiny (1–2 mm), superficial, white dome-shaped cysts</td><td></td><td></td></tr><tr><td>Dermoid cyst</td><td></td><td></td></tr><tr><td>Present at birth</td><td></td><td>Deep subcutaneous tissue</td></tr><tr><td>Walls composed of keratinizing epidermis containing hair follicles, sebaceous glands, and sweat glands</td><td></td><td></td></tr><tr><td>Epidermoid cyst</td><td></td><td></td></tr><tr><td>Occurs secondary to traumatic implantation of epidermal cells into the dermis. Contains accumulation of keratin and is encased by a well-formed granular layer of stratified squamous epithelium</td><td>Epidermal inclusion cyst</td><td>Most common on face, back, chest and base of ears although can occur on almost any skin surface.</td></tr></tbody></table>
<p>Adapted from Goldstein, B. G., &amp; Goldstein, A. O. (2014a). Overview of benign lesions of the skin. Retrieved 27 March, 2014 from <a href="http://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin</a>? source=search_result&amp;search=calluses&amp;selectedTitle=2%7E16#H1101420580; Goldstein, B. G., &amp; Goldstein, A. O. (2014b). Keloids. Retrieved 23 April, 2014 from <a href="http://www.uptodate.com/contents/keloids" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/keloids</a>? source=search_result&amp;search=keloid+scar&amp;selectedTitle=1%7E150; Wolff, K., Johnson, R. A., &amp; Saadvedra, A. P. (2013). Fitzpatrick's color atlas &amp; synopsis of clinical dermatology (5th ed.). New York, NY: McGraw-Hill; Habif, T. P. (2016). Clinical dermatology: A color guide to diagnosis and therapy Philadelphia, PA: Elsevier.</p>
<p>A. Location
B. Number
C. Size</p>
<p>D. Firmness
E. Mobility
F. Globular
G. Tenderness
H. Inflammation
I. Infection</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Cure by complete excision or punch biopsy for 1- to 2-cm uncomplicated lesions including wall to prevent recurrence
B. Incision and drainage of infected or severely inflamed cysts
C. Intralesional corticosteroid injections (triamcinolone, Aristocort, Kenalog) to decrease lesion size
D. Extraction: comedone extractor for small cysts or milia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-home-care-considerations">IV. HOME CARE CONSIDERATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Wound care (Box 14-1)</p>
<p><img src="assets/images/image-20251225-03ff63ea.jpeg" alt="img-118.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="cysts">Cysts<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cysts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Cyst changes, including growth, tenderness, or irritation, need to be monitored.</li>
<li>Surgical removal may be necessary with close follow-up of healing.</li>
<li>Health care provider should be consulted with any increased pain that occurs or signs of infection that develop, that is, redness, heat, swelling, and discharge.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="dermatofibroma-fibroma">DERMATOFIBROMA (FIBROMA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#dermatofibroma-fibroma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A. Definition: a benign lesion of fibrous connective tissue (Figure 14-5)
B. Etiology</p>
<ol>
<li>The exact cause is unknown.</li>
<li>Considered to be a late histiocytic reaction to trauma, viral infection, or insect bite.</li>
</ol>
<p>C. Pathophysiology</p>
<ol>
<li>Interwoven histiocytes and collagen mesh dermal nodule, with overlying epidermal hyperplasia</li>
</ol>
<p>D. Incidence</p>
<ol>
<li>Frequently occurs in middle age; dominant in females</li>
<li>Usually solitary but may be multiple, randomly scattered</li>
<li>Anterior surface of the lower extremities most commonly</li>
</ol>
<p><img src="assets/images/image-20251225-104a24a0.jpeg" alt="img-119.jpeg"></p>
<p><img src="assets/images/image-20251225-95909435.jpeg" alt="img-120.jpeg">
B
FIGURE 14-5. A: Dermatofibroma: "dimple" or "collar button" sign is elicited on compression of a lesion. B: Pigmented dermatofibroma. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins; and Stedman's.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Asymptomatic or may be pruritic, single or multiple, or papule or nodules.
B. Firm, hemispherical disc/dome-shaped borders are ill defined.
C. Color: skin colored, reddish, or tan to brown.
D. Texture of surface may be shiny, dull, scaling, or crusted secondary to trauma from shaving or excoriation.
E. Surrounding ring of pigmentation; 2 to  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">c</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3\mathrm{cm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">cm</span></span></span></span></span></span>  and less.
F. Can be found anywhere on trunk or extremities, but commonly on lower legs
G. "Dimples" when gently pinched between the thumb and forefinger (retraction or "dimple" sign)
H. Diagnosis by clinical presentation; confirmation biopsy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Excision for cosmetic reasons only
B. Cryosurgery every 3 to 4 weeks causes gradual involution and elimination of remaining pigment</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iv-home-care-considerations">IV. HOME CARE CONSIDERATIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iv-home-care-considerations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. The healing area may remain hard if a portion of the fibrous material remains after treatment.
B. Wound care (Box 14-1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hypertrophic-scars">HYPERTROPHIC SCARS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertrophic-scars" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Hypertrophic scars result from skin trauma in genetically predisposed individuals. Characterized by excess of collagen deposition during wound healing causing an inappropriately large scar usually within 4 weeks of injury. Histologically, hypertrophic scars differ from keloids in that they contain whorls of young, fibrous tissue and fibroblasts in uneven arrangements (Figure 14-6).</p>
<p><img src="assets/images/image-20251225-e6cb0d47.jpeg" alt="img-121.jpeg">
A</p>
<p><img src="assets/images/image-20251225-e00f88d3.jpeg" alt="img-122.jpeg">
B
FIGURE 14-6. A: Hypertrophic scars; characteristic of acne scars that occur on the trunk. B: Hypertrophic acne scars are seen on the shoulder of this patient. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Asymptomatic, pruritic or painful occasionally, and restricted to the area of injury
B. Commonly over the sternum, deltoid, mandible, or upper lip but can occur anywhere in predisposed people
C. Less exuberant than keloids
D. Diagnosis by clinical exam, biopsy not warranted unless there is clinical doubt because another procedure to the skin may include further hypertrophic scarring</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Involute spontaneously
B. Resolve, mostly or partially, becoming flatter and softer in time without treatment
C. Intralesional glucocorticoid injections
D. Prevention of additional injuries</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="keloids">KELOIDS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#keloids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Keloids are proliferations of connective tissues (collagen) that cause large collagen bundles at the site of a scar or traumatic injuries such as acne, vaccination sites, or thermal or chemical burns. Keloid scars extend in a claw-like fashion beyond the border of original injury and may also develop spontaneously, usually in the presternal area. Keloids may begin years after the original injury and may continue to expand in size for decades (Figure 14-7).</p>
<p><img src="assets/images/image-20251225-652c77b8.jpeg" alt="img-123.jpeg">
A</p>
<p><img src="assets/images/image-20251225-30effbfe.jpeg" alt="img-124.jpeg">
B</p>
<p><img src="assets/images/image-20251225-d127ea0d.jpeg" alt="img-125.jpeg">
C
FIGURE 14-7. A: Keloid: Developed as a reaction to having her earlobe pierced. B: Keloid beyond border of surgical scar. C: Keloid scarring, which grows like a tumor and flows over the scar boundary, occurs wherever the skin is breached. Its pathogenesis and treatment are different from those of hypertrophic scars. (From Rubin, E., &amp; Farber, J. L. (1999). Pathology (3rd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins; and Weber, J., &amp; Kelley, J. (2003). Health assessment in nursing (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<p>A. Description: nodular, nonencapsulated, highly hyperplastic mass of scar tissue beyond injury/trauma border resulting from overproduction of extracellular matrix and dermal fibroblasts.
B. Keloids begin as pink to red, firm, rubbery fibrous plaques with telangiectasias; 3 to 5 weeks to years after trauma. They are smooth, circumscribed, irregularly shaped, and hyperpigmented, sometimes bright red or bluish. May become tender and pruritic, particularly in the early stages of development. Enlargement and extension outside the original area of injury.
C. More prevalent among African Americans and people with blood type A.
D. Not present at birth and rare before puberty.
E. Increased prevalence in patients with severe acne and hidradenitis suppurativa.
F. Frequently affected areas are the earlobes (after piercing), face, neck, abdomen, chest, and upper back.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. History of burn, acne, injury, surgery, or other trauma to site
B. Physical exam: location, size, color, tenderness, pain, pruritus, and burning</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Prevention by avoiding accidental and intentional skin trauma if prone to keloid
B. Intralesional corticosteroid injections
C. Combination surgical excision and intralesional steroid injections
D. Pulsed dye laser treatment, multiple treatments may be necessary
E. Surgical excision with radiation therapy
F. Radiation therapy to keloids not appropriate for resection
G. Cryosurgery more effective on lesions less than 2 years old
H. Topical silicone gel sheeting may minimize scarring extent and promote gradual resolution</p>
<p><img src="assets/images/image-20251225-7bfcad7b.jpeg" alt="img-126.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="scars-and-keloids">Scars and Keloids<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#scars-and-keloids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Patients prone to scarring or keloid formation should avoid elective or unnecessary surgery or procedures whenever possible, that is, ear piercing, tattooing, or cosmetic mole removal.</li>
<li>The injured/scarred area must be protected from further trauma or irritation.</li>
<li>Wounds should be covered and remain moist to promote healing.</li>
<li>Avoid sun exposure during healing and posthealing to the area to avoid</li>
</ul>
<p>hyperpigmentation.</p>
<ul>
<li>The neck and leg areas should not be shaved while healing as this can irritate pimples or ingrown hairs and cause hypertrophic scar formation.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="lipoma">LIPOMA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lipoma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: subcutaneous fatty tissue with fine capsule (Figure 14-8). Most common of the benign soft tissue neoplasms
B. Etiology is not well understood.
C. Incidence</p>
<ol>
<li>Solitary or multiple; asymmetric irregular distribution</li>
<li>Equal sex</li>
</ol>
<p><img src="assets/images/image-20251225-363b8174.jpeg" alt="img-127.jpeg">
FIGURE 14-8. Lipomas. Multiple rubbery flesh-colored nodules are noted on this patient. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.).</p>
<p>Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Soft, rounded, without central pore
B. Freely moveable against overlying skin, slightly compressible
C. Usually small but can enlarge to over 6 cm
D. Frequently occurs on the neck, truck, and extremities most commonly but can occur anywhere</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. No therapy is necessary when diagnosis is confirmed
B. Surgical excision only if causes pain or is considered disfiguring</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sebaceous-hyperplasia">SEBACEOUS HYPERPLASIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sebaceous-hyperplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>These lesions involve hypertrophy of the sebaceous glands and are generally located on the central face of adults. Etiology unknown. Incidence: seen more often in fair-skinned individuals; these lesions occur after age 30 in 25% of the general population occurs in solid organ transplant recipients (Figure 14-9).</p>
<p><img src="assets/images/image-20251225-cc248ac4.jpeg" alt="img-128.jpeg">
A</p>
<p><img src="assets/images/image-20251225-dc2f9e7f.jpeg" alt="img-129.jpeg">
B</p>
<p>FIGURE 14-9. A: Sebaceous hyperplasia on the temporal area. B: Sebaceous hyperplasia on the forehead. Note yellowish papules with dells. (From Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Solitary lesion, umbilicated and cauliflower-like
B. Multiple soft yellowish and erythematous papules 1 to 3 mm in size, on the forehead and cheeks
C. Surface telangiectasis in the valleys between the small, yellow lobules
D. Asymptomatic; persist unless treated
E. Diagnosis by physical examination
F. Differentiated from basal cell carcinoma (BCC) which usually have recent history of changes and are not yellow in color</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. No treatment necessary except for patient's request for cosmetic improvement
B. Low-dose isotretinoin (Accutane)</p>
<ol>
<li>Normal liver function</li>
<li>Not currently pregnant or planning pregnancy for at least 1 month after therapy cessation</li>
<li>Lesions reappear weeks or months after discontinuation of treatment.</li>
</ol>
<p>C. Light electrocautery
D. Liquid nitrogen cryosurgery
E. Shave excision
F. Carbon dioxide laser
G. Trichloroacetic acid peels</p>
<p><img src="assets/images/image-20251225-ee8ecdd0.jpeg" alt="img-130.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="patient-education">PATIENT EDUCATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#patient-education" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="sebaceous-hyperplasia">Sebaceous Hyperplasia<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sebaceous-hyperplasia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ul>
<li>Lesions are benign, but if any changes, visit a health care provider.</li>
<li>In severe cases, a medication (isotretinoin) may be used to clear up the lesions but will require regular tests and ongoing treatment.</li>
<li>There are remedies such as peels and laser treatments that may help reduce the lesions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="seborrheic-keratosis">SEBORRHEIC KERATOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#seborrheic-keratosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A. Definition: benign, warty-appearing growths commonly seen on older adults. These lesions are superficial epithelial growths that are raised, well defined, scaly, and hyperpigmented that have a “stuck-on” appearance. Seborrheic keratosis (SK) is the most common benign cutaneous neoplasm (Figure 14-10). Types include seborrheic wart, senile wart, brown wart, and basal cell papilloma.</p>
<ol>
<li>Slow growing</li>
<li>Round—oval</li>
<li>“Greasy, stuck on the skin”</li>
<li>Hyperkeratotic lesions</li>
<li>Varied size from millimeters to centimeters</li>
<li>Color from flesh colored to brown to black</li>
<li>Common on the face, trunk, shoulders, scalp, and back, although they can appear on any hair-bearing surface</li>
<li>Develop in sun exposed as well as protected areas</li>
<li>Do not contain the human papillomaviruses</li>
</ol>
<p>B. Tendency to develop SK is an autosomal dominant trait and is extremely common; it has been found in 88% of people older than 65 years and is more prevalent in white-skinned individuals.</p>
<p>C. Pathophysiology: benign proliferations of immature epidermal keratinocytes; keratinization occurs, causing the lesions to become warty, dry, fissured, and at times crumbly appearing. Initially flat, coin-sized lesion with flesh-brown pigmentation that develops into papillomatous hemispherical raised tumors with dark brown to black pigmentation. A keratotic, conical protuberance (cutaneous horn) or open comedones may develop.</p>
<p>D. Incidence: hereditary, common in middle-aged and older adults with onset by age 30; equal sex; more numerous, smaller, and occur earlier in African Americans and Hispanics. A family history predispose to development, although it is not thought to be caused by chronic sun exposure.</p>
<p><img src="assets/images/image-20251225-83c6bc31.jpeg" alt="img-131.jpeg">
A</p>
<p><img src="assets/images/image-20251225-bf7c5926.jpeg" alt="img-132.jpeg">
B</p>
<p><img src="assets/images/image-20251225-7339c619.jpeg" alt="img-133.jpeg">
C
FIGURE 014-010. A: Seborrheic keratoses. These "stuck-on" appearing lesions are most often confused with malignant melanoma by nondermatologists. B: Seborrheic keratosis. This lesion has a warty, tortoise shell-like, "stuck-on" appearance. C: Seborrheic keratosis. (From Goodheart, H. P. (2003). Goodheart's photoguide of common skin disorders (2nd ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins; and Goodheart, H. P. (2010). Goodheart's same-site differential diagnosis: A rapid method of diagnosing and treating common skin disorders. Philadelphia, PA: Wolters Kluwer.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. History and current health status
B. Physical exam: location, size, number, appearance, color, borders, pruritus, changes, and irritation—erythema, tenderness, and increased pruritus
C. Diagnosis by clinical presentation and confirmation by biopsy</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. No treatment is necessary if small and asymptomatic
B. Snip or shave excision
C. Electrodesiccation and curettage
D. Cryosurgery
E. Carbon dioxide laser</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="seborrheic-keratoses">Seborrheic Keratoses<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#seborrheic-keratoses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Clothing, belts, and razors can easily irritate existing lesions.</li>
<li>Lesions frequently irritated need to be monitored for bleeding, redness, and changes.</li>
<li>Lesions can be easily removed with an office procedure when the number is limited.</li>
<li>Post-treatment area needs to be kept clean, moist, and covered until healed.</li>
<li>After lesion removal, the sites needs to be monitored for signs of infection.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cherry-angioma">Cherry Angioma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cherry-angioma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="i-overview">I. OVERVIEW<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-overview" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Definition: the most common vascular malformation is the benign cherry angioma. Histologically, the lesions are made up of numerous moderately dilated capillaries lined with flattened endothelial cells. The stroma is of homogenous collagen and edematous (Figure 14-11).</p>
<p><img src="assets/images/image-20251225-fcfd9288.jpeg" alt="img-134.jpeg">
FIGURE 14-11. Cherry angioma. (From Bickley, L. S., &amp; Szilagyi, P. (2013). Bates' guide to physical examination and history taking (11th ed.). Philadelphia, PA: Lippincott Williams &amp; Wilkins.)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ii-assessment">II. ASSESSMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-assessment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Bright red to violaceous or black
B. Dome shaped
C. Tiny to about  <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">3\mathrm{mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm">mm</span></span></span></span></span></span>
D. Usually appear around 30 years old
E. Occur most commonly on trunk
F. Virtually all elderly people will have a few lesions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="iii-common-therapeutic-modalities">III. COMMON THERAPEUTIC MODALITIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-common-therapeutic-modalities" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A. Electrocautery (cryotherapy is not effective)
B. Laser coagulation
C. Scissor excision
D. Treatment is only necessary if the condition is bothersome to the patient.</p>
<p>PATIENT EDUCATION</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cherry-angioma">Cherry Angioma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cherry-angioma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>As these lesions are vascular, the patient needs to avoid picking or irritating the lesions as they will bleed, sometimes profusely.</li>
<li>Patients should be advised that even after successful treatment, new lesions will likely develop.</li>
<li>There is no way to prevent lesions.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="bibliography">BIBLIOGRAPHY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#bibliography" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Burhan, J. K., &amp; Mak, B. M. (2013). Cyst, sebaceous. In F. J. Domino, R. A. Baldor, J. Golding, J. A. Grimes, &amp; J. A. Taylor (Eds.), The 5 minute clinical consult (21st ed., pp. 326–327). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Butcher, M. (2013). Assessment, management, and prevention of infected wounds. Journal of Community Nursing, 27(4), 25–34.</p>
<p>Dunphy, L. M., Winland-Brown, J. E., Porter, B. O., &amp; Thomas, D. J. (2011). Primary care: The art and science of advanced practice nursing (3rd ed.). Philadelphia, PA: F.A. Davis and Co.</p>
<p>Feldman, N. J. (2013). Corns and calluses. In F. Domino, R. Baldor, J. Golding, J. A Grimes, &amp; J. S. Taylor (Eds.), The 5 minute clinical consult 2013 (21st ed., pp. 304–305). Philadelphia, PA: Lippincott Williams &amp; Wilkins.</p>
<p>Goldstein, B. G., &amp; Goldstein, A. O. (2014a). Overview of benign lesions of the skin. Retrieved 27 March, 2014 from <a href="http://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin?source=search_result&amp;amp;search=calluses&amp;amp;selectedTitle=2%7E16#H1101420580" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/overview-of-benign-lesions-of-the-skin?source=search_result&amp;amp;search=calluses&amp;amp;selectedTitle=2%7E16#H1101420580</a></p>
<p>Goldstein, B. G., &amp; Goldstein, A. O. (2014b). Keloids. Retrieved 23 April, 2014 from <a href="http://www.uptodate.com/contents/keloids?source=search_result&amp;amp;search=keloid+scar&amp;amp;selectedTitle=1%7E150" target="_blank" rel="noopener noreferrer">http://www.uptodate.com/contents/keloids?source=search_result&amp;amp;search=keloid+scar&amp;amp;selectedTitle=1%7E150</a></p>
<p>Habif, T. P. (2016). Clinical dermatology: A color guide to diagnosis and therapy (6th ed.). Philadelphia, PA: Elsevier.</p>
<p>Safoury, O. S., &amp; Ibrahim, M. (2011). A clinical evaluation of skin tags in relation to obesity, type 2 diabetes mellitus, age, and sex. Indian Journal of Dermatology, 56(4), 393–397.</p>
<p>Wolff, K., Johnson, R. A., &amp; Saadvedra, A. P. (2013). Fitzpatrick’s color atlas &amp; synopsis of clinical dermatology (5th ed.). New York, NY: McGraw-Hill.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="study-questions">STUDY QUESTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ol>
<li>Acrochordons are benign neoplasms and cosmetic disorders with which of the following features?</li>
</ol>
<p>a. Soft pedunculate
b. Flesh colored, tan, or brown
c. Can evolve into precancerous lesions
d. A and B</p>
<p>e. All of the above</p>
<ol start="2">
<li>
<p>Calluses are caused by all of the above except:
a. Spontaneous development
b. External pressure
c. Repeated friction
d. All of the above</p>
</li>
<li>
<p>Appropriate treatment for corns includes which of the following?
a. Surgical excision of superficial layer of corn and hard plug in the horny layer
b. Corticosteroids: triamcinolone injection (Kenalog, Aristocort) at the base of the corn to relieve pain
c. Topical keratolytics
d. Epsom salt soaks every few hours for 5 to 10 minutes at a time
e. All of the above</p>
</li>
<li>
<p>All of the following are common therapeutic modalities for cysts except:
a. Complete excision and wall removal
b. Incision and drainage
c. Intralesional corticosteroid injections
d. All of the above</p>
</li>
<li>
<p>Dermatofibroma is:
a. Caused by spontaneous development of localized accumulation of fibroblasts or a reaction to an insect bite
b. A benign lesion composed of stratum corneum cells
c. Considered to be an early histiocytic reaction to an insult such as trauma or viral infection
d. A precancerous lesion that develops from accumulation of keratinocytes</p>
</li>
<li>
<p>Hypertrophic scars can involve spontaneously.
a. True
b. False</p>
</li>
<li>
<p>Keloid development can:
a. Continue in the same area of injury for decades
b. Never appear on the face
c. Be found in only the upper third of the chest
d. All of the above</p>
</li>
<li>
<p>Lipomas are the most common of the benign soft tissue neoplasms.
a. True
b. False</p>
</li>
<li>
<p>Characteristics of sebaceous hyperplasia include which of the following?
a. Small, solitary lesion, umbilicated, cauliflower-like
b. Multiple soft yellowish and erythematous papules 2 to 3 cm in size, on forehead and cheeks
c. Surface telangiectasis in the forehead
d. Painful unless treated
e. All of the above</p>
</li>
<li>
<p>Seborrheic keratosis is an autosomal dominant trait and is extremely common; it has been found in 88% of people older than 65 years and is more prevalent in white-skinned individuals.
a. True
b. False</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="answers-to-study-questions">Answers to Study Questions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#answers-to-study-questions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>1.d
2.a
3.e
4.d
5.a
6.a
7.a
8.a
9.a
10.a</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>